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Laboratory experiments were developed to incorporate pharmaceutical engineering 
concepts into Freshman-level engineering courses. The goal is to increase the interest of 
pharmaceutical engineering in students and provide the necessary background for more 
advanced courses in the field.  The experiments can be used on an individual basis, or to 
be grouped into themes for more focused learning objectives.  The laboratory 
experiments are available at the pharmaceutical knowledge and training website 
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Introduction and Background 
 
Pharmacy itself originates from the ancient art of apothecary.  The earliest evidence of 
apothecary can be found in ancient Mesopotamia, where medical texts were found on 
clay tablets.  These texts described symptoms of illnesses, instructions for making “drug" 
compounds, and even invocations to gods [1].  This practice can also be seen throughout 
all ancient cultures, including:  Egyptian, Indian, Chinese, Persian, Greek, and Roman 
[2].  This practice was observed in monasteries during the Middle Ages, and taken into 
private practice as apothecary shops in the 13
th
 century [1, 2].  Apothecary shops did not 
change significantly until the 19
th
 century, when the term pharmacy was used instead of 
the traditional apothecary [1].   
It was in 1821 when the first United States pharmaceutical board was created in 
Philadelphia.  The Philadelphia College of Medicine was formed on March 13, which 
encompassed not only a school of pharmacy, but a self-policing board of pharmacists to 
make sure that frauds and “snake-oil” salesmen were not inflicting damage on the public 
through improper pharmaceutical practices in Philadelphia [1].  The educational 
institution opened November 9 of the same year.  Pharmaceutical education soon spread 
throughout America, and the University of Michigan also opened a college of pharmacy 
in 1868.  What was novel about this program is that the course did not require 
pregraduation apprenticeship, which was convention at the time [1, 2].   
Pharmacy was again changed in the years of 1890 to 1930.  During this time, the 




companies, and then once again to large-scale manufacturing corporations that are 
prevalent today [3].  In this period of time, several aspects of culture and technology 
caused these changes in the pharmaceutical industry.  Four early instances include; 
innovations in the methods of drug preparation using machinery, the growth in popularity 
of standardized preparations, changes in therapeutic agents, and the influence of medical 
research [4].  This, in addition with the Federal Regulatory Act of 1906, paved the way 
for the large-scale manufacturers to dominate the pharmaceutical industry [3].   
Since then, the pharmaceutical industry has been steadily growing as one of the most 
profitable major manufacturing sectors [3].  This is not to say that the industry has not 
had drawbacks.  Since the 1950’s pharmaceutical corporations have been faced with 
several crises that have harmed their image.  Market manipulation, price fixing, dumping, 
and scores of unethical medical and business practices have destroyed certain firms [3].  
This has not stopped the industry from advancing, however, and the pharmaceutical 
sector continues to grow. 
The year of 2010 marked one of the highest points of the pharmaceutical industry, where 
it had the second largest earnings of all industries [5].  The pharmaceutical industry also 
increased its worldwide profit growth of 4.2% to approximately 800 billion USD that 
year [6]. This is substantial growth, considering that in the year 2007, the pharmaceutical 
industry amassed revenue of 315 billion USD [7]. These economic factors are coupled 
with shifting paradigms of the industry, such as a move towards shorter drug 
development times and an increased openness to change existing processes, which will 
increase the need for chemical engineers with pharmaceutical training [8]. In 2010, 5% of 




worked in pharmaceutical and medicinal manufacturing [9, 10].  One engineer reported 
that there was an observable increase in chemical engineering emphasis in active 
pharmaceutical ingredient process development within Pfizer from the years 1995 to 
2010 [11]. From 2004 to 2014, roughly 76 thousand jobs are to be created in the 
pharmaceutical and medicine manufacturing sector, while basic chemical manufacturing 
jobs are to decrease by roughly 46 thousand in that same time span [12]. 
As the demand for engineers has increased in the pharmaceutical industry, universities 
have found a need to provide engineers with education in the field of pharmaceutical 
engineering.  Pharmaceutical engineering is defined as the design of pharmaceutical and 
diagnostic products and the associated manufacturing processes [13].  Several 
universities have incorporated pharmaceutical engineering education into advanced 
degree studies.  Some examples of universities that have introduced pharmaceutical 
engineering programs on the graduate level are Rutgers University, the University of 
Michigan, and the New Jersey Institute of Technology.  All three of these universities 
offer a master’s degree program in pharmaceutical engineering, while Rutgers University 
also offers a pharmaceutical engineering option for Ph.D. students in chemical and 
biochemical engineering.  This pharmaceutical engineering option requires 5 courses 
which focus on the different aspects of pharmaceutical engineering [14].   
Stevens Institute of Technology offers a master’s degree program in pharmaceutical 
manufacturing.  The goal of this program is to provide students with a strong background 
in Good Manufacturing Practices, project management, and pharmaceutical facilities.  
This is considered an interdisciplinary program, administered by the mechanical 




from the Department of Education’s Graduate Assistance in Areas of National Need 
program for students to continue research in the field of pharmaceutical engineering.  The 
graduate student also has the ability to be a part of an international exchange program, 
gain industry experience through internship opportunities, and conduct supervised 
teaching to prepare them for a career in academia [16].   
Due to the expanding interest in pharmaceutical engineering training, the National 
Science Foundation funded an Engineering Virtual Organization to facilitate the creation 
and sharing of pharmaceutical engineering educational information [17]. The result was 
the website pharmaHUB.org.  The objective of this website was to facilitate 
collaborations with the Engineering Research Center for Structured Organic Particulate 
Systems (ERC SOPS) and the National Institute for Pharmaceutical Technology and 
Education (NIPTE) [17].  PharmaHUB.org is named based on the middleware that was 
used in its creation.  This middleware, known as HUBzero, has several features that were 
useful for the design of the website; including the ability for online simulation, making it 
possible to deliver simulation tools via the web; content management capabilities that 
make it possible for online presentations to combine voice and images; community-
building capabilities such as content uploading, a question/answer forum, and a user 
support area [17, 18].   
With this increased interest in pharmaceutical engineering at the graduate level, there has 
been some diffusion into undergraduate curricula.  A majority of the universities that 
have developed undergraduate pharmaceutical engineering programs are found in 
Europe.  In 2003, the University of Basel, in Switzerland, introduced a bachelor’s 




universities tend to offer pharmaceutical specializations within traditional bachelor’s 
degree programs.  This is especially true in the engineering colleges of the United 
Kingdom and Scandinavia.  In these countries, the pharmaceutical industry is a major 
contributor to the country’s economy.  For example, 40 percent of all exports from the 
Republic of Ireland are pharmaceuticals [20].  In the United States, the University of 
Iowa offers a pharmaceutical specialization for undergraduates.  This specialization can 
be obtained through higher-level electives that focus on different aspects of 
pharmaceutical sciences, such as drug delivery systems and basic pharmacology [21].  
Stevens Institute of Technology also offers a pharmaceutical manufacturing 
concentration for students of mechanical engineering.  This specialization is obtained 
through courses that incorporate pharmaceutical facility design, validation, and hands-on 
projects in the field of pharmaceutical manufacturing [22].   
Within these specializations, a majority of emphasis is on upper-level undergraduate 
courses, such as creating special topic courses that focus on pharmaceutical sciences.  At 
the New Jersey Institute of Technology, a class focusing on drug transport and 
pharmacokinetics was implemented as a specialty topic course for students wishing to 
obtain a specialization in pharmaceutical engineering [23].  The Georgia Institute of 
Technology has a course for senior and graduate level students in the field of 
pharmaceutical engineering; specifically drug design, development, and delivery [24].  
Rutgers University has a Pharmaceutical Engineering Training Program, which allows 
both graduates and undergraduates to work on projects based on realistic problems found 
in the pharmaceutical industry.  These projects deal mainly with product manufacturing 




Although new upper-level elective courses can be developed to include pharmaceutical 
engineering concepts with relative ease, there is a level of difficulty when trying to 
incorporate concepts into lower-level undergraduate courses.  In particular, the concepts 
have to be appropriate for students who are just beginning their undergraduate study.  In 
addition, these concepts might have to be presented in ways that can be applicable to 
different engineering majors.  There is also the complexity of adding new courses into an 
already saturated curriculum.  One approach is to modify pre-existing courses so that they 
have a focus in pharmaceutical engineering and at the same time, meet student learning 
outcomes.  For example, problem sets developed at Rowan University for the use in 
lower-level undergraduate courses contain material and energy balances that incorporate 
different aspects of pharmaceutical engineering [26, 27].  In addition to using problem 
sets, incorporating pharmaceutical concepts into laboratory experiments can be used to 
reinforce the course’s existing educational objectives.  One of the initial efforts in this 
was the development of a first-year laboratory experiment that focused on an 
investigation of the controlled release principles of drug delivery methods through the 









Experiments that have been developed for the use in a lower-level, laboratory-based 
course will be described.  Experimental methods as they pertain to the individual 
laboratory experiments will be described in the relevant sections.  These experiments 
were designed to not only introduce pharmaceutical concepts, but also to reinforce basic 
engineering educational objectives such as; understand and apply core science and 
mathematics principles; work individually and in teams to identify and solve engineering 
problems; design and conduct experiments as well as analyze and interpret data [29].  
Only the most novel of these works will be described.  The experiments to be discussed 
are the Tablet Statistical Analysis Lab, the Fluidization of Pharmaceutical Excipients 
Lab, the Asthma Drug Delivery Lab, the Degradation of Dissolvable Strips Lab, the 
Effervescence Reaction Lab, the Dextromethorphan Crystallization Lab, and the Creation 
of Dissolvable Strips Lab.  Other experimental write-ups are available on 
www.PharmaHUB.org, the resource described previously.   
The experiments were designed to meet the safety standards of a typical undergraduate 
laboratory and be performed by the students in approximately 2 hours.  The cost of these 
experiments was also considered so they did not rely on highly specialized equipment 
and the operating costs are reasonable.   Another point that was considered when 
developing these experiments was the ease of the setup.  
Two versions of these experiments are available; a student version and an instructor 




Teaching Materials section.  The pharmaceutical and engineering concepts that the 
experiment would incorporate are discussed in a brief introduction, which the students 
would read before beginning the experiment.  The instructor’s version includes a more 
detailed procedure, equipment and supplies list, additional pictures of correct setups for 
the laboratory experiments, concepts to reinforce, and a solutions section.  In order to 






Chapter 3  
 
Experiments Developed 
3.1 Tablet Statistical Analysis Lab 
Tablets have a long history in the pharmaceutical industry.  The earliest sign of pills 
being used can be seen in the 17th and 18th century, when apothecaries were used pill 
jars as their necessary equipment [2].  Tablets are often considered the best option for 
drug delivery by drug corporations, as they easy and inexpensive to manufacture and are 
relatively stable to package, ship, and store.  From a patient perspective, tablets are easy 
to swallow, have little issues with odor and taste, and are easy to administer [30].  
Tablets grew in popularity with the advances in pharmaceutical chemistry.  The 




 century caused pharmacists and apothecaries to 
shift from prescribing whole plants to offering powdered leaves and roots.  By the 19
th
 
century, several active pharmaceutical ingredients were being identified from plants and 
reproduced via chemical reactions [31].  To mask the often bitter tastes, additives were 
added to mask the flavor, which caused the invention of the tablet.   
Tablets can be considered one of the products that caused the change in the 
pharmaceutical sectors from small shops to large-scale manufacturing corporations.  In 
the late 19
th
 and early 20
th
 century, pharmaceutical companies gained reputations for their 
ability to standardize tablets and used this ability as a selling point.  In these terms, 
standardization means the process of making a drug or other pharmaceutical product so 
that it conforms to a standard, such as a certain amount of active ingredient within a 
certain range.  Since this laboratory experiment involves statistical analyses on tablets, a 




The H.K. Mulford Company was one of the companies that began the practice of 
standardization.  The H.K. Mulford Company began in 1891 as a small manufacturing 
pharmacy, but grew due to its reputation of high quality products [3, 32].  While the 
company specialized in lozenges, elixirs, antiseptics, syrups, and other preparations that 
were similar to its competitors, what set the Mulford Company apart were its efficient 
tableting machines [33, 34].  These patented tableting machines allowed the company to 
make tablets in a highly standardized fashion, ensuring that the tablets were relatively 
similar to each other [34].  This standardization was found to appeal highly to physicians, 
and became one of the selling points of the Mulford Company [3].  Indeed, this early 
standardization allowed the Mulford Company to survive the wave of standardization that 
would occur in later years. 
In the early ages of pharmacy, standards were published in pharmacopeias.  The earliest 
of these date back to the Medical Edict of 1240 by Frederick II of Sicily, which ordered 
that apothecaries prepare remedies always in a similar fashion [35].  Another known act 
of drug regulation occurred in 1540, when England enacted the Apothecaries Wares, 
Drugs, and Stuffs Act.  This act caused inspection and supervision of medicinal 
manufacturing of the common medicines of the time [35].   
The regulation of drug products via government and laws did not occur in the United 
States until the early 20
th
 century.  In 1902, the United States government passed a bill 
that controlled the production and sales of biologicals after an outbreak of tetanus 
occurred in Camden and St. Louis.  These outbreaks were thought to be linked to 
smallpox vaccines [3].  The act specified that manufacturers of vaccines had to be 




and gave the Treasury Department the rite to inspect company policies at any time [36].  
This was considered the first act in which pharmaceutical companies had to meet drug 
regulation in its modern form [3]. 
In 1906, another law was passed to regulate the adulteration of foods and drug 
manufacturing.  After the publication of Upton Sinclair’s The Jungle, in which the 
atrocities of the food industry were made public, outcry reached an apex, and the people 
demanded better regulation of their goods.  From this, the Pure Food and Drug Act was 
formed [3].  Through this law, main ingredients had to be identified in foods, drugs, 
medicines, and liquors.  Chemical examinations were required, and the Department of 
Agriculture was given authority over the examinations and regulations of the food and 
drug industries [37].   
These two acts helped shape the pharmaceutical industry into what it is today.  The 
regulatory sections of these two acts ensured that pharmaceutical providers had to have 
standardized products.  This proved to be a feat that was only capable of large-scale 
companies, who had the capital to spend on the necessary labs and technicians required 
for standardization [3].  The Mulford Corporation provides a great example of this.  In 
the first few years, the company did not have the equipment needed to test their 
diphtheria antitoxins, and so had to use the Laboratory of Hygiene at the University of 
Pennsylvania in order to ensure that their antitoxins met specifications [3].  Later, they 
managed to obtain their own standardization labs. 
Other large-scale manufacturers were hardly affected by the passing of these laws.  Parke 




techniques long before legislation [38].  Smith, Kline, and French also had analytical 
methods that they used to ensure that they met the standards of the Food and Drug Act.   
Indeed, company personnel such as Mahlon Kline were actually in full support of the law 
[3].  Wyeth Company was similarly affected, using advanced tableting machines to make 
sure they met the standards of the Food and Drug Act [3].    
Unfortunately, cataclysmic events once again occurred in 1937 when over 100 people 
died of diethylene glycol poisoning in the United States.  These victims were poisoned 
after taking a sulfanilamide elixir laced with diethylene glycol.  These elixirs were 
manufactured using diethylene glycol as a solvent, and were sent to the market without 
any safety testing.  This disaster was one of the catalysts behind the passing of the 
Federal Food, Drug, and Cosmetic Act of 1938 [35].  Other factors that caused the 
passing of the 1938 Act include Banbar, an ineffective cure for diabetes; Lash-Lure, an 
eyelash dye that caused eye injuries; Radithor, a radium containing tonic that caused 
painful deaths; and Wilhide Exhaler, a falsified tuberculosis medication [39].  This law 
required that drugs be labeled with directions for safe usage, and that approval of all new 
drugs be obtained by the Food and Drug Administration (FDA) before being put on the 
market.  The law also required factory inspections, and gave the FDA several 
enforcements tools to ensure compliance [39]. 
A second tragedy which influenced the development of pharmaceutical regulation 
occurred in Western Germany in 1956.  At this time, a sedative known as thalidomide 
went on sale.  Over the next few years, it was linked in over 10,000 birth defects from the 
years 1958 to 1960 [35].  Due to this, the United States Government passed the Drug 




allowed the FDA to set good manufacturing practices (GMP’s) and gave the FDA the 
authority to enforce these practices.  The FDA was also given control over drug 
advertising and the marketing of generic drugs [40]. 
GMP’s are manufacturing requirements that need to be met by corporations.  If they are 
not met, the product is considered adulterated, which can lead to regulatory actions [41].  
GMP’s cover many areas of pharmaceutical manufacturing, including personnel training 
and hygiene, building/ facility requirements, packaging, and process control [41, 42].  
Several of these GMP’s can be compared to the World Health Organization’s (WHO) 
quality assurance measures and the European Medicines Agency’s similar standards, 
which call for such things as an acceptable API variances and excipient quality testing 
[43, 44].   
Since GMP’s deal with acceptable variances and excipient quality testing, statistics play a 
vital role in the pharmaceutical industry.  This area is of such importance to the industry, 
that it has its own journal article, Pharmaceutical Statistics; in which discussions on the 
current statistical work done in the pharmaceutical industry is presented.  Discussions on 
higher-level statistics, such as how to design clinical trials, appropriate sample sizes, and 
ethical dilemmas for statisticians are common [45].  The changes in pharmaceutical 
statistical practices since the 1980’s have also been an important topic of discussion [46].  
In terms of novel approaches to statistics in the pharmaceutical industry is the use of 
Bayesian methods, statistical methods and calculations that uses databases of records to 
construct probability networks [47].  This has been extensively studied for use in product 




Engineers who will enter into the pharmaceutical industry should have knowledge of 
GMP’s and statistical work [43].  For this reason, engineers should receive a foundation 
in GMP’s and statistics if they are to enter into the pharmaceutical industry.  The Tablet 
Statistical Analysis Lab was designed with this in mind.  The objective of this experiment 
was to conduct a statistical analysis on the mass of analgesics; in this case, ibuprofen 
tablets.  From an educational perspective, the intended outcome of the experiment was 
that the students would gain experience interpreting data and using some basic statistical 
analysis methods.  Statistics is an important aspect of the pharmaceutical industry, used 
to determine the reliability and accuracy of data taken from drug samples, monitor and 
detect the adversities of a process, and assess the capability and reliability of a process 
[50]. 
For this experiment, students take mass measurement of two types of ibuprofen tablets; 
Advil
®
 brand and a generic brand.  Table 1 shows example raw data of these mass 
measurements.  Students are given ten samples of each brand, and then take mass 
measurements using an analytical scale.  The first calculations performed are mean ( ̅), 
standard deviation ( ), and variance ( ) of both brands.  Students then determine if the 
mass of the two brands are significantly different from each other through an F-test.  The 
equation for the F-test, along with the calculations used based on the raw data is shown as 
Equation 1. 
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For this experiment, the F-critical value was given as 3.18, based on the F-critical value 
table found in the Montgomery et al statistics text [51].  Since the experimental F-value is 
greater than the critical F-value, the two brands are considered statistically different.  A 
T-test is then used to compare the two sets of data to a known mass of an ibuprofen tablet 
(  ), obtained from the Handbook of Pharmaceutical Manufacturing Formulations [52].  
The T-test equation, along with a sample calculation of the t-test for the generic brand is 
shown in Equation 2. 
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The critical t-value, or t-critical, was determined to be 2.262 using a generic t-table in the 
Montgomery et al text [51].  Since the experimental t-value was larger than the t-critical 
value, it can be concluded that the generic brand is statistically different than the 
theoretical value.  When the T-test is conducted for the name brand, it was found that the 
experimental t-value was smaller than the critical t-value.  This leads to the conclusion 
that the name brand was not statistically different than the theoretical value.  The 
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From these calculations, students can see that there is a difference between the two 
brands.  In fact, the data shows that the standard deviation for the generic brand was 
lower than the name brand.  The reason is that the generic brand did not have a sugar 
coating or a polishing coat like the Advil
®
 brand.  These coatings are much less regulated 
than the active pharmaceutical ingredient (API) content of the tablet, and as such, adds 
more variance to the population.  The students also see that the generic brand does not 
correlate well with the literature value, which is also due to the lack of coatings.  As such, 
the values may change depending on the generic brand used for this experiment.  
Trial Number Advil
®
 Brand Mass (grams) Generic Brand Mass (grams) 
1 0.4784 0.3354 
2 0.4837 0.3300 
3 0.4715 0.3296 
4 0.5019 0.3280 
5 0.4840 0.3383 
6 0.4842 0.3284 
7 0.5050 0.3307 
8 0.4930 0.3365 
9 0.4804 0.3272 
10 0.4845 0.3362 
Average  0.4870  0.3320  
Std. Dev.  0.010  0.004  




Students also perform an outlier test, taking a portion of their data analysis for a Box-
Whisker plot to determine any outliers.  Students should not find any outliers in their 
experimental data, since the tablets are subjected to the high standards of pharmaceutical 
manufacturing [53].  Students also complete an exercise where they are given a table of 
mass measurements from a hypothetical batch of tablets, and must determine whether or 
















0.4665 0.4857 0.4481 
0.4786 0.4662 























Once the data has been sorted from highest to lowest, the students calculate the three 
quartiles (Q).  The first quartile (Q1) is the median of the lower half of the data, while the 
third quartile (Q3) is the median of the higher half of the data.  The second quartile (Q2) is 
the median of the entire data set.  Q1 and Q3 are then used to determine the low and high 
outlier cut-off points (OL and OH, respectively).  The equations for determining OL and 
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A box-and-whisker plot can then be used to show the outlier (Figure 1). 
 
 
Figure 1. The Box-and-Whisker plot for the exercise found in the Tablet Statistical 
Analysis Lab.  One outlier is clearly visible in this plot. 
 
As an introductory experiment, this lab presents important pharmaceutical terminology.  




different types of excipients (fillers, binders, glidants, etc.).  These technical terms were 
reinforced through an exercise where students determine the API and look up the first 
three inactive ingredients or excipients; and their functions.  In addition, students learn 
about batch manufacturing processes and receive an introduction to process flow 
diagrams through an exercise.  Students are given a manufacturing procedure from the 
Handbook of Pharmaceutical Manufacturing Formulations on how to make coated 
ibuprofen tablets, read it, and then convert their readings into a flow diagram of this 
process [52], shown in Figure 2.  The Student and Instructor’s Version of this laboratory 
experiment can be found in Appendix A.1 and B.1, respectively. 
 
 
Figure 2.  The solution to the flow diagram exercise found in the Tablet Statistical 
Analysis Lab.  Above, the powder is corn starch, and mix #1 is ibuprofen and corn starch. 
 
3.2 Fluidization of Pharmaceutical Excipients Lab 
Fluidization is defined as a technique or phenomenon where the internal frictional forces 
in a bed of solid particles are reduced so that the bed flows like a fluid.  Counter forces, 




began in the late 1940’s with Richard H. Wilhelm and Mooson Kwauk, who investigated 
the different phases of fluidization [55].  Fluidization then began a period of extensive 
research through the 1950’s and well into the 1970’s, when Kunii and Levenspiel 
published their book entitled ‘Fluidization Engineering’ [54].  The book laid out 
extensive details on the previous research done; including equations, heuristics, and 
graphs of fluidization data [56].  After the 1970’s, fluidization research began to 
decrease, only to grow again in the late 90’s.  One example is a group of researchers from 
Beijing that began an in-depth study on how to fluidize fine particles in 1998 [57]. 
The pharmaceutical industry has used fluidization technology for several years.  Early 
investigations of fluidization in the pharmaceutical industry can be seen in a three-part 
series of articles by Davies and Gloor [58, 59, 60].  Pharmaceutical manufacturers can 
use fluidized beds for granulation, and has been used for this purpose for several decades.  
Granulation is defined as a process where small powder particles are gathered and turned 
into larger particles [61].  This is done to improve the powder properties for downstream 
processing [62].  A two-phase process is usually used for granulation, which includes 
spraying, drying, and the addition of a binding liquid [62, 63].   In cases where there are 
heat- or moisture-sensitive drugs, granulation can occur with compaction. 
In the early days of this unit process, granulation was considered more of an art than a 
science.  After extensive investigations by a few researchers, models were developed for 
granulation phenomenon, and can be seen in several review articles [64, 65].  A highlight 
of some of these theoretical developments include:  Determining the drop penetration 
time based on capillary pressure; determining deformation through a Stokes deformation 




and liquid content [66, 67, 68, 69].  From a manufacturing perspective, there have been 
several studies on granulation.  Controls and scale-up work that has been done has been 
compiled by Faure, York, and Rowe [70].  This compilation includes an extensive list of 
process parameters that affect wet granulation.  Techniques used for controlling the 
distribution and shape of granules were also discussed.  Some of these techniques include 
fuzzy logic, neural networks, and image processing [71, 72, 73]. 
Fluidization can also be used for coating operations.  The appeal of using a fluidized bed 
apparatus for coating processes is due to high energy and mass transfer rates that are 
available through the system [74].  Coating is often used for taste masking and drug 
release control in pharmaceutical products [75].  A patent was filed in 2014 by the New 
Jersey Institute of Technology that used fluidized bed coating for drug release control 
[76].  Coating can also be used to improve product flowability [77].  One study 
investigated the improvement in flow properties of ibuprofen after a thin-coating with a 
fluidized bed apparatus [78].   
Coating in fluidized beds is mostly used for dry solid particles, powders, or pellets.  In 
this setup, particles are fluidized by hot air, and then the coating solution is sprayed over 
top of the particles.  The hot air causes solvents to evaporate, leaving a coating on the 
surface of the fluidized particles [79].  In most of the cases in the pharmaceutical 
industry, the Wurster process is used.  The Wurster process was patented in 1966, and 
uses a spray coater that sprays up from the bottom, which allows for higher coating 
quality and homogeneity [80, 81].  This process has been shown to be the most useful 




Fluidized beds are also used for drying.  Due to its rapid heat and mass transfer abilities, 
large capabilities, and relatively low capital cost, fluidized beds are often utilized for the 
drying of wet granules [83, 84, 85].  This type of drying can be done either in batch or 
continuous processes.  Usually, batch operation is used in small-scale productions and 
continuous operation is used in large scale productions.  Batch operations may also be 
used for heat-sensitive materials [86].   
There has been extensive research on drying using fluidized beds.  Chandran, Subba Rao, 
and Varma published their work on developing a kinetic model for this phenomenon in 
1990 [87]. Thomas and Varma investigated several factors on fluidized bed drying, 
including temperatures, flow rates of the heating medium, and the mass of solids in the 
fluidized bed [88].  Circulating fluidized beds are used for drying, and have been 
investigated by Balasubramanian and Srinivasakannan [86].  A model has also been 
developed for fluidized bed drying of granular material [89].  Mixtures of solids have 
also been investigated for their drying behavior in fluidized bed systems [90].    
From the literature review, it is obvious that fluidization is now an important unit 
operation in the pharmaceutical industry.  The Fluidization of Pharmaceutical Ingredients 
Lab was designed so that students would be introduced to the fluidization equipment and 
the phenomenon of fluidization.  This experiment is based on a polymer coating lab for 
freshmen developed by Rowan engineering faculty [91].  The objectives of the lab are to 
analyze the fluidization of a pharmaceutical ingredient, such as an excipient, and measure 
basic fluid/particle properties.  In order to do this, students first determine three 
properties; bulk density, particle density, and bed porosity.  This is done through a 




the bulk and particle densities, and then calculate the porosity of the substance using 
these two parameters.  Students compare these to literature values and learn how to use 
particulate data bases.  The second part of the experiment focuses on fluidization 
phenomena.  The objective of this part is to determine fluidization regimes and the effect 
of process parameters related to fluidization.  The setup of the fluidized bed is shown in 
Figure 3, in which the excipient is fluidized in air.      
 
 
Figure 3.  The fluidized bed apparatus used in the Fluidization of Excipients Lab. 
 
Students conduct an experiment to measure the bed height as a function of air flow rate.  
They notice through this exercise that as bed height starts to increase, fluidization has 




Through graphs of these variables, as seen in Figure 4, students observe where the slope 
of the lines change, denoting transformation from packed bed to fluidized bed behavior.   
In addition, students receive an exercise in using online reference tools.  This exercise 
asks the students to find an article through library electronic search tools that discusses 
fluidized beds in the pharmaceutical manufacturing.  The students are to print out the 









Figure 4.  Sample data from the Fluidization of Pharmaceutical Ingredients Lab.  a) Air 
flow rate versus bed height is shown.  b) Air flow rate versus pressure drop.  Studies used 
Avicel® Ph200 at 20 °C. 
 
The pharmaceutical objective of this experiment is to show equipment used in 
transportation, granulation, coating, and drying of solids [58].  Since the solid particles 
act like a fluid, they become much easier to transport through conventional conveying 
equipment.  Students also see how excipient properties affect the fluidization process.  


































































Reynolds Number at minimum fluidization, Remf, of two different substances; Avicel
®
 
(microcrystalline cellulose powder) and kaolin (white clay powder).  The main difference 
between these two studies is the average particle size (1.4 µm for kaolin and 180 µm for 
Avicel
®
), which is the primary reason the Reynolds Number calculations at minimum 
fluidization are different.  The Reynolds Number (Re) calculation gives students 
experience in units and conversions, requiring them to convert to one system of units and 
prove that Re is dimensionless.  Students are also introduced to fluid flow in calculations 
and conversion of volumetric flow rates to a fluid velocity in the bed.  Finally, they use a 
design equation to predict what the Remf should be and compare that to their 
experimentally determined value [92].  This equation, along with supplemental governing 
equations, is shown in Equations 6 through 9.   
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Where     is the void fraction at minimum fluidization;    is the diameter of the 
particle;    is the density of the fluid;    is the particle density of the solid; and   is the 




Reynolds number of 19.36, while experimental data determined a Reynolds number of 
19.10, which is within 1.4% difference. The Student and Instructor’s version of this lab 
can be found in Appendix A.2 and B.2, respectively. 
3.3 Asthma Drug Delivery Lab 
Asthma is one of the most chronic illnesses diagnosed in children.  The illness has been 
reported throughout most of human history, being recorded in ancient Chinese, Indian, 
Egyptian, and Greek writings [93].  Cures from these writings include special teas, 
vapors, honey, mustard oil, turmeric, and garlic.  Asthma’s current definition wasn’t 
established until 1698 by John Floyer, an English physician.  Floyer defined asthma as 
“laborious respiration with lifting of the shoulders and wheezing” and also understood 
that the illness was intermittent and episodic, which requires rescue and controller 
therapy [94]. 
It wasn’t until 1896 that the approach to asthma treatment took on its current form of 
acute rescue treatment, controller treatment, and prevention of long-term complications 
[95].  Sir Thomas Granger Stewart and George Alexander Gibson noted that 
environmental allergens can affect asthma at this time, and offered some advice for 
removing offending allergens from the environment [96].  From then on, asthma was 
treated pharmacologically.  The first treatment prescribed for asthma treatment was 
anticholinergic belladonna-related alkaloids [95].  It was Stewart and Gibson who 
suggested smoking stramonium, a dried leaf and flower of the plant Datura stramonium, 
with tobacco (or preferably pure stramonium) to reduce the symptoms of asthma [96].  In 




Pilocarpus, were noted to be effective, and added to the common treatments for asthma 
[97]. 
In 1940, theophylline, a non-anti-cholinergic bronchodilator, was reported for the first 
time as a method for treating asthma [98].  This sparked the use of non-anti-cholinergic 
bronchodilators for asthma treatments, leading the way to the prescription of ephedrine, 
adrenaline, salbutamol, remiterol, and fenoterol [99].  Unfortunately, these drugs did not 
go through specific safety regulations, and were unrestrictedly supplied in over-the-
counter medications.  It was this that caused an epidemic of asthma related deaths in the 
United States, Australia, United Kingdom and New Zealand from the 1960’s to 1980’s 
[100].  These epidemics lead to the prescribing and careful regulation of asthma 
medications.   
While cigarettes and injections were used early in asthma treatments, inhalers were used 
in the first third of the twentieth century [95].  Atomizers and inhalers can be seen in 
early 1900’s and through the 1950’s [93].  In the year 1956, the metering valve was first 
invented, and so, the first pressurized meter dose inhaler (pMDI) came into being [101].  
A pMDI delivers a dose of pharmaceutical medication that has been suspended through a 
chlorofluorocarbon (CFC) [102].  A pMDI consists of three major components:  A 
reservoir, in which the raw drug is suspended; a metering valve, which delivers a 
specified amount of the medication when depressed; and a spray actuator, which delivers 
the drug to the body.   
The pMDI is arguably the most famous version of an asthma inhaler, with most 




drug delivery method are that it is efficient when used correctly, they are portable, and 
they are relatively easy to use.  In most cases, pMDI’s have a deposition efficiency of 
6.5% to 24%, which is better than previous methods of drug delivery [103].  However, 
there are some drawbacks to this method.  The major problem with MDI’s is that if not 
used correctly, the drug will deposit itself on the tongue, causing fungal infections in the 
mouth [104].  Also, the use of CFC’s has become under fire, since they lead to ozone 
depletion.  As such, new excipients are used, which cause a decrease in efficiency.  These 
new propellants also have to be rigorously tested for any possible toxicological effects 
[102].  
Another form of asthma medication delivery is known as the dry powder inhaler (DPI).  
Although DPI’s are not as widely known as pMDI’s, this method of delivery has been 
investigated since the 1930’s.  The first patent to be given for a powder inhalation method 
was awarded in 1940 for the inhalation of aluminum powder [105].  The first 
pharmaceutical dry powder inhaler can be seen in a patent from 1949 [106].  These dry 
powder inhalers do not use a propellant agent in order to deliver the medication.  Rather, 
the mechanism of delivery is solely based on the size of the particles and their inhalation 
from the device [102, 107]. 
 This lack of needing a propellant is considered a great advantage, since one does not 
have to worry about using ozone depleting propellants.  Some other advantages for using 
a DPI are that it is easy to use and causes less irritation in patients [108].  In addition, the 
DPI is just as portable and compact as a pMDI.  Thus, several companies have produced 




DPI’s are not without their setbacks, however.  One of the main problems with DPI’s is 
paradoxically caused by their greatest asset; they do not use propellants.  As such, 
patients who use DPI’s must inhale at a suitable flow rate in order to obtain the correct 
dosage of the drug [109].  This is a problem specifically for young children [110].  Some 
of the lesser DPI disadvantages include that they are more expensive than MDI’s and also 
need to be stored in cool and dry areas [111].   
As asthma medications have several different modes of drug delivery, this was thought to 
be an opportune moment for introducing differences in drug delivery mechanisms.  The 
Asthma Drug Delivery Lab compares three different drug delivery systems for asthma 
medicines.  The first objective of the experiment is to have the students reverse engineer 
the three systems; a dry powder inhaler, a metered dose “rescue” inhaler, and a nasal 
spray.  Secondly, the students determine the quality control measures of the inhalers and 
how they deliver a specific dosage each time used.   
The dry powder inhaler, an ADVAIR Diskus®, is also known as a diskhaler.  The 
students compare the production design of the Diskus® with a metered dose “rescue” 
inhaler and a nasal spray through a reverse engineering exercise.  Only the ADVAIR 
Diskus® reverse engineering process is described in this paper, as it was the most 
technically complex device.  First, the students brainstorm the drug delivery mechanism 
of the diskhaler, using the patient insert as the source of information.  Most students will 
guess that there is some sort of puncture device that allows the medicine to enter the main 
chamber of the diskhaler, as it is described in the pamphlet as blisters being punctured 
open.  Seeing the inner mechanisms gives the student insight into how the inhaler 




utilizes blisters, the device ensures that only a certain amount of active pharmaceutical 
substance is released for each use, keeping the rest of the powder fresh inside the 
individual blisters for subsequent doses, as shown in Figure 5.  Students also have to 
discuss the ergonomics and aesthetics of each of the products, so that they also 
understand the importance of these two factors on product design in drug delivery. 
 
 
Figure 5.  The inner mechanisms of an ADVAIR Diskus®. 
 
The second half of this experiment has the students review the quality control aspect of 
the three devices by taking mass measurements of the doses being delivered and 
calculating the mean and standard deviation (Table 3).  From this data, the students 
compare the standard deviations, and what that implies about the function of the devices.  
Students observe that the diskhaler has the lowest standard deviation of the three devices, 
which is due to the design of the device.  Similar results are not obtained with the 
metered dose inhaler and the nasal spray because the metered dose inhaler involves a 
fluid that easily evaporates and the precision of the nasal spray depends on how well the 




deviations for those two designs have an order of magnitude difference from that of the 
diskhaler.  Students are also tasked with looking up typical standard deviations for 
therapeutic dosage delivery. The Student and Instructor’s version of this lab can be found 
in Appendix A.3 and B.3, respectively. 
 
Table 3.  Sample data and results from the Asthma Drug Delivery Lab. 
Trial 
Number 
Mass of Diskhaler 
Powder(g) 
Mass of Metered Dose 
Inhaler (g) 
Mass of Nasal Spray 
(g) 
1 0.0130 0.0130 0.0867 
2 0.0130 0.0128 0.0979 
3 0.0127 0.0088 0.0989 
4 0.0132 0.0107 0.0854 
5 0.0126 0.0130 0.1004 
6 0.0123 0.0140 0.0983 
7 0.0130 0.0140 0.1022 
8 0.0129 0.0148 0.1000 
9 0.0124 0.0120 0.0991 
10 0.0130 0.0121 0.0986 
    










3.4 Degradation of Dissolvable Strips Lab 
Drug delivery has become a widely popular area of study for chemical engineers.  Indeed, 
this topic is also of great importance to the pharmaceutical industry as well.  From a 
pharmaceutical perspective, the purpose of developing novel methods of drug delivery 
systems is to improve patient compliance and optimize dosage regiment while not 




delivery systems also cost less and take about half the time as it does for a pharmaceutical 
company to develop as opposed to new drug discovery [113]. 
Although tablets are the most common form of drug delivery, other methods exist.  
Transdermal patches, inserts, and implants are all examples of these other methods.  
Implants were first discovered as possible methods for drug delivery in the 1960’s 
through the experimentation of Judah Folkman of the National Naval Medical Center.  
His experiments found that sealed segments of silicon tubing containing drugs could be 
planted within the body as a constant rate drug delivery device [114].  An early form of 
insert was offered by the Alza Corporation in the 1970’s, which would deliver glaucoma 
medication to the eye through an ocular insert [115].  This insert was found to be more 
effective than the commonly prescribed ophthalmic solutions that were available at the 
time [116].  Inserts are now becoming popular as modes of contraception.  The Alza 
Corporation was again early providers of this kind of insert, which was inserted vaginally 
to release a contraceptive drug [115].  These rings, and other versions of vaginal inserts, 
are still popular forms of contraception. 
Another innovation that occurred in the 1970’s was the transdermal skin patch.  Once 
again, the Alza Corporation was a pioneer in this form of drug delivery, being one of the 
first corporations to obtain a patent for transdermal skin patches [117].  This type of 
transdermal patch was advertised as a bandage that would administer anti-motion 
sickness medication [115].  In the early to middle 1980’s transdermal delivery systems 
began to be a popular area of research [118].  Transdermal patches are currently popular 
for nicotine delivery for use as smoking cessation aids [119].  More recent research has 




While the 1970’s drug delivery research was focused on the macroscopic level, the 
middle to late 1980’s was the moment when investigations began to focus on the 
microscopic level.  This is not to say that investigations in the microscopic level did not 
occur previously.  The earliest patent based on microparticles was dated in 1973 [122].  
Microparticles were prioritized during this middle to late 1980’s period [115].  A 
revolution of microparticle research occurred in the early 1990’s, when a group of 
researchers invented a process for fabricating uniform sized microparticles [123]. This 
area of research still continues in this century.   
In the late 1970’s, the concept of nano-therapeutics were beginning to form and rise in 
interest.  Three key technologies developed in the 1980’s stimulated and ensured the 
success of the field:  Polyethylene glycol drugs and drug carriers; active targeting of the 
drug conjugate via cell membrane receptor antibodies; and discovering the enhanced 
permeation and retention (EPR) effect.  The conjugation of polyethylene glycol was the 
first of these technological jumps, and was first reported by researchers at Rutgers 
University in the 1960’s [124].  It was effectively used to deliver cancer fighting proteins 
[115].  In 1975, the first example of drug conjugate targeting was published [125].  This 
research led to another cancer fighting breakthrough, in which drug conjugates were 
actively targeted by ligands which were imperative for liver cancer treatment [115, 126].  
The EPR effect was the last of the developments to be discovered.  This discovery was 
made in 1984 by Hiroshi Maeda of Kumamoto University after carrying out animal 
studies with a novel drug conjugate [115].  Further investigation lead to a publication on 




Surface-controlled drug release has been a clinically successful area of research since the 
1960’s, and can be one of, or a combination of, macroscopic, microscopic, and 
nanoscopic technologies [115].  One of the first successful investigations into surface 
controlled drug delivery began with the polysaccharide heparin, which was used to coat 
surfaces of polymers to prevent coagulation of blood on polymers.  This area of research 
was heavily investigated since the 1960’s [128].  More recent investigations look at using 
drug eluting stents, which have been investigated by Johnson & Johnson and Boston 
Scientific [129].  There have also been insights into surface coatings for enhanced drug 
delivery for mucosal tissues.  Gastric retention formulations have been one of the key 
areas of study for mucoadhesive systems [130].    
While the drug delivery development of the past century might seem impressive, 
scientists and engineers conclude that development has been quite poor for this time 
period.  One worker of SmithKline Beecham Pharmaceuticals stated in 1999 that the 
developments of the century would score no more than a 2 or 3 on a 1-10 scale [131]. 
There is speculation, however, that development will increase in this current century.  
More emphasis will be placed on creating “smart tablets” that can be used for both 
immediate and controlled release [131].  These smart tablets are to be more beneficial to 
patients by maximizing drug efficacy by using a smarter drug delivery selection system.  
With this in mind, regulatory requirements are also hypothesized to change [131].  With 
this in mind, it is imperative that those seeking employment in the pharmaceutical 
industry be well-versed in the drug delivery process. 
Drug delivery education is not always a difficult concept to incorporate into engineering 




engineering topics.  Drug delivery itself relies heavily on transport phenomenon, a staple 
in the chemical engineering curriculum [118].  Others have already made significant 
progress integrating drug delivery into engineering education.  Farrell and Hesketh of 
Rowan University developed an introduction to drug delivery for chemical engineers in 
2002 [28].  A drug delivery experiment was also developed that could be used for the 
Freshman Engineering Clinic class offered at Rowan University by Farrell and Vernengo 
[132].  At the National University of Singapore, a group of educators used a design 
project to discuss controlled-release drug delivery devices [133].  Simon, Kanneganti, 
and Kim of the New Jersey Institute of Technology introduced a laboratory on drug 
transport and pharmacokinetics, as mentioned previously [23].  As also mentioned in a 
previous section, the Georgia Institute of Technology offers an interdisciplinary course 
on drug design, development, and delivery [24].  The Georgia Institute of Technology 
developed a laboratory module around the same time focusing on skin diffusion, an 
important aspect of transdermal drug delivery [134].   
Following this trend, the Degradation of Dissolvable Strips Lab is an investigation into 
the drug delivery aspects of dissolvable strips.  In this experiment, students are tasked 
with investigating the dissolution rate of ingredients in dissolvable strips.  Strip films 
have become an area of interest in the past few years as an alternative to conventional 
tablets and capsules, especially for patients suffering from dysphagia [135].  Some 
examples of consumer products formulated into orally administered strips include breath 
fresheners, energy supplements, and analgesics for flu and sinus symptoms [136].  In this 
lab, students work with Sheets™ brand energy strips, containing caffeine and blue food 




ingredient.  The students are to investigate the effect of temperature on the dissolution 
rate by placing one strip in water kept at room temperature (~ 22 °C), and placing another 
in water at body temperature (~ 37 °C).  To simulate the mouth, a shallow petri dish is 
filled with 25 mL of water, in which a strip is placed; absorbance measurements are taken 
at regular intervals, generating graphs as seen in Figure 6.  The absorbance values are 
related to the concentration of the ingredients released by using a standardization curved 
developed at the beginning of the experiment. 
 
 
Figure 6. Sample data from the Dissolvable Strip Lab, using one strip film for each. 
 
The experiment introduces the students to spectrophotometry, and the principles related 
to the methodology used to measure solution concentration.  This is done by having the 
students apply the Beer-Lambert law to determine the molar absorptivity coefficient of 





























point where the strip has fully dissolved in the water.  The equation and a sample 
calculation are shown in Equation 10. 
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Where A is the absorbance (unitless), ℓ is the measurement cell width, and c is the molar 
concentration of the sample. The students should notice that the coefficients are identical 






), which determines that for the 
ranges used in this experiment, the temperature does not significantly affect the molar 
absorptivity coefficient.  The students are then charged with determining how the Beer-
Lambert law and molar absorptivity coefficients can be applied in other engineering 
applications.  Some of the common answers will be waste water treatment, product 
synthesis, and algae growth.  
The pharmaceutical relevance of this experiment is that students are introduced to a novel 
drug delivery system.  The students also see how the strip film quickly dissolves in water, 
indicating that the polymer used in the strips breaks down when it comes in contact with 
water.  The concept of higher temperatures affecting the dissolution rate of the strip is 
also reinforced through an example involving rate laws.  In this example, the students use 
absorbance readings and determine the rate law coefficient, k, for both experimental 
conditions.  Upon calculating, the students see that the rate coefficient is higher for the 




Some additional parts of this experiment have been developed based on advanced 
instrumentation and the available time.  If a broader range spectrophotometer is available, 
absorbance data can be taken for caffeine at a wavelength of 273 nm.  An agitated system 
can also be used to examine the convective effects on dissolution rate of the strip. The 
Student and Instructor’s version of this lab can be found in Appendix A.4 and B.4, 
respectively. 
3.5 Effervescence Reaction Lab 
An effervescence reaction is one in which an organic acid and a carbonate substance 
which will release carbon dioxide upon reaction with the organic acid [137].  
Effervescent reactions can be seen in several different areas of chemical research.  
Recently, investigations have been made in using effervescent reactions for the extraction 
of solids.  The effervescence reactions help to improve the extraction yield, with absolute 
recoveries in the range of 61 to 85 % [138].  Another study also looked at using 
effervescent reactions and nanoparticles to increase the extraction yields in dispersive 
liquid-liquid microextraction [139]. 
Effervescence reactions are also important in the food industries, specifically the 
champagne and sparkling wine industry.  Carbon dioxide plays an important role in the 
champagne and sparkling wine; as it affects the frequency of bubbles, the growth rate of 
bubbles, the oral feelings, and the aromatic perception [140].  Carbonation is also an 
important aspect in beer, seltzers, and sodas.  In beer production, carbonation helps to 
release aroma compounds, improving the smell of beers [141].  This process is also used 




Effervescence itself has been used for over 250 years in the pharmaceutical industry 





 was developed in 1930’s as a cure for a hangover [144].  Since 
then, the tablets have been used as cures for heartburn, headaches, seasickness, and 
flu/cold-like symptoms.  Due to the success of Alka-Seltzer
®
, other manufacturers began 
to produce their own form of effervescent tablets.  This has led to several patents being 
awarded for the production of effervescent tablets, including a novel process for making 
tablets in 1978, granules in 1986, and a modification of the effervescent compositions in 
1987 [137, 145, 146].  
Currently, effervescent tablets are still an area of research.  Ranitidine, an API often used 
for ulcers, acid reflux, and Zollinger-Ellison syndrome, is currently being investigated for 
possible inclusion in effervescent tablets [147].  Prochlorperazine maleate, an API for 
nausea treatment, is also investigated for use in effervescent tablets for improved patient 
compliance [148].  In the field of prostate cancer research, the API flutamide was 
incorporated into effervescent tablets in order to increase its bioavailability with 
considerable success [149].  The effervescent powders themselves are also an area of 
study.  Effervescent powders are currently being investigated for their use in respiratory 
drug delivery to incorporate an active release mechanism, increasing the release 
efficiency [150].   
Since effervescence is an interesting and innovative area of the pharmaceutical industry, 
it was decided that an experiment should be developed to introduce this type of reaction.  
This experiment, the Effervescence Reaction Lab, evaluates the effect of tablet 




effervescent reaction of a whole tablet of Alka-Seltzer
®
 to the initial raw ingredients.  
These are allowed to react with water, while students take residual mass measurements as 
time progresses.  Students must determine why the whole tablet reacts faster.  Upon a 
review of the manufacturing procedure, it is determined that there is a milling step to 
reduce the active ingredient particle size.  Therefore, with greater surface area and a more 
uniform composition, the reaction proceeds faster than the un-milled raw materials. 
By having students measure the amount of mass that left the system, they determine the 
amount of carbon dioxide (CO2) gas produced via the effervescence reaction.  Using 
stoichiometry, the students also determine the amount of CO2 they should have 
theoretically generated during the reaction.  The stoichiometric equation is shown in 
Equation 14. 
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Using these two values, the students determine the percent difference between their 
theoretical and experimentally observed values, as shown in Figure 7.  They see that the 
longer the reaction continues the difference between theoretical values and experimental 
values starts to decrease.  Students use this information in an exercise to obtain an 
equilibrium constant for the effervescent reaction.  The Student and Instructor’s version 







Figure 7.  The differences from stoichiometry between the tablet and the pure 
components, students see that as the time increases, the percent error decreases. 
 
3.6 Dextromethorphan Crystallization Laboratory 
Crystallization is an important aspect of several different industries.  In chemical 
engineering, crystallization is an important process for solid-liquid separation, and is 
often incorporated into separation texts [151, 152, 153].  Crystallization is a process in 
which solid particles are formed from a homogenous mixture.  In crystallization, a 
mixture is concentrated, usually to saturation, and is then cooled until the solute 
concentration becomes greater than the solubility of the mixture at that temperature.  This 
causes the solute to form crystals and precipitate out of solution [153].  Crystallization is 
often employed as a separation process for two reasons.  Crystallization has a large 
separation factor, and as such, creates crystals of high purities; crystallization also 
produces crystals of uniform sizes and shapes [152].  The latter characteristic is a highly 
regarded aspect for the pharmaceutical and food industry. 
In crystallization theory, there are four important parameters of the crystal; saturation, 







































concentration of a solute which is thermodynamically stable [151].  In several cases, 
however, a solution can contain more solute than the saturation limit.  In this case, the 
system is considered supersaturated, and is often metastable, meaning that the solution, 
while unstable, can remain unaltered for long periods of time [151].  Purity is the relative 
purity of crystals created, which is important if several different substances can be 
formed from one reaction.  Factors such as crystal size and shape can affect the purity of 
the solids precipitating out [154].   
Nucleation rate concerns the rate of crystal production, and occurs in four specific 
mechanisms; homogeneous, heterogeneous, secondary, and attritive [151]. Homogeneous 
nucleation is the formation of crystals due to supersaturation only, while heterogeneous 
results from the presence of other insoluble materials.  Secondary nucleation is somewhat 
of a catch-all, and includes nucleation caused by the contact between different crystals.  
Attrition is the breakup of existing crystals that then grow into larger crystalline 
structures [151].  Single crystal growth defines the rate at which existing crystals grow in 
size.  Factors such as agitation of the system, crystal size, and geometry of crystal all 
affect single crystal growth [151]. 
The solubility of a solute, and its dependence on temperature, is an important aspect of 
the designing of crystallization equipment.  To visualize this dependence, solubility 
curves are often employed.  Solubility curves, or solubility diagrams, can also be used 
with Miers diagrams, which graph the metastable, stable, and unstable regions of 
solutions [152].  Through these diagrams, calculation of yields for crystallizers can be 





Crystallization, as stated before, is an important unit operation in the pharmaceutical 
industry.  API’s often are synthesized and purified using crystallization processes [155].  
The areas of crystallization; including theory, empirical formulas, appendices of data, and 
scale-up considerations have been well documented [156, 157, 158].  Crystallization is 
also an important aspect of pharmaceutical research and development, with numerous 
papers being published on novel approaches in this field.     
Crystallization is being investigated for possible uses in changing crystal characteristics.  
For example, acetaminophen can have its thermodynamic stability and other properties 
change by adding other molecules before the crystallization process [159].  Indeed, 
cocrystallization is often used to change the properties of one or two molecules so that 
they may be optimized for use in a pharmaceutical product [160].  This has recently been 
investigated to increase the solubility of nitrofurantoin, an API used in treating urinary 
tract infections [161].  The melting point of a crystal can be changed in this manner as 
well.  Researchers found that using cocrystals of hexamethylenebisacetamide A, an 
anticancer drug, helped increase the solubility and melting point of the API [162].    
Compressibility and flowability can also be improved by using cocrystals, as was 
discussed in an article on carbamazepine cocrystals published in 2007 [163]. 
One of the unit operations that have been researched for crystal engineering and 
cocrystallization is supercritical fluid processes.  Several studies have been completed 
that focus on supercritical fluids and their use in crystal engineering.  Researchers have 
found that using supercritical fluids not only reduces solvent waste, but also reduces the 
necessary volumes for API crystal formation [164].  Others have found that using 




particle dispersion of the final product [165].  Feasibility studies are included, such as an 
investigation into the feasibility of creating indomethacin-saccharin cocrystals to use in 
anti-inflammatory medications via supercritical fluid technology [166].  Another study 
found that cocrystals of indomethacin, theophylline, caffeine, sulfamethazine, aspirin, 
and carbamazepine could all be produced viably using supercritical CO2 [167].   
In addition to using supercritical fluids, others are looking at developing other methods, 
such as high-throughput crystallization technologies.  These technologies combine design 
of experiments, experimental protocols, and data analysis, and consist of both hardware 
and software components [168].  This technology can be used to determine a selection for 
specific salts.  For example, a study used several salt forms of the antibacterial 
sulfathiozole to determine the use of high-throughput systems.  The results of this found 
that the high-throughput machine rapidly identified 10 salt forms and could characterize 
them based on melting point ranges [169].  Another study found that high-throughput was 
effective in determining which cocrystals of caffeine-oxalic acid and theophylline-oxalic 
acid had proper solubilities and solid/solution stability properties [170].  Others have 
looked at including Raman microscopy in the high-throughput process to gain even more 
information, such as equilibrium of cocrystal formation and polymorphic transformation 
[171].     
While crystallization is a relevant topic in pharmaceutical manufacturing, many engineers 
in the industry find that the unit operation is de-emphasized in most engineering 
curriculums.  Most newly employed engineers learn what they do about crystallization 
from on the job training [155].  The Dextromethorphan Crystallization Lab is designed 




this experiment are to develop a solubility curve for dextromethorphan hydrobromide 
(DXM), and to also learn the underlying theory of crystallization, such as the thermal 
energy transfer that occurs in the crystallization process.  Students are tasked with 
determining the temperature at which saturation occurs for several concentrations of 
DXM in water.  Students complete this by heating up solutions of DXM and water and 
recording the point of recrystallization.  The experiment involves the students taking a 
specific mass of DXM and adding it to 5 mL of water in a test tube.  DXM is known for 
being an insoluble molecule in water [172].  As such, students will observe that the 
particles simply sink to the bottom of the test tube.  To obtain solubility data, the students 
are to heat this mixture in a hot water bath, kept at around 90 °C, which can be seen in 
Figure 8.   
 
 
Figure 8.  The hot water bath setup used for the Dextromethorphan Crystallization Lab.  
Two thermocouples are used to regulate the temperature of the hot water bath and the 




The mixture is heated until the students see all the crystals dissolve in the water.  Using a 
thermocouple, the students will record the point at which crystals start to reform in the 
test tube. A sample of what this looks like can be seen in Figure 9.  This is considered the 
temperature of saturation for that concentration.  This is done for several concentrations, 
including one which is chosen by the students.  A sample solubility curve that would 
have been produced can be seen in Figure 10.    
 
 
Figure 9. The DXM and water solution once recrystallization has begun.  Notice the 







Figure 10.  An example of a solubility curve developed for the Dextromethorphan 
Crystallization Lab. 
 
By recording the saturation temperatures, students are given the task of creating a 
solubility curve for DXM in water.  The random concentration that the students chose is 
used for two purposes; to allow students to determine the reliability of their solubility 
curve; and to gain experience using interpolation.  Interpolation is an important tool for 
engineers, as it can be used to determine new values that lay inside existing data points.  
Students are to determine the saturation temperature that corresponds to their chosen 
concentration. Calculating the percent difference from their interpolated value to that 
which they found experimentally will determine how well their solubility curve can 
predict the point of saturation for a given temperature. For example, for a random 
concentration of 150 grams per liter, the temperature was determined via interpolation to 
be 53 °C.  This is 0.95% different than the 52.5 °C temperature found via 
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Interpolation is also reinforced through exercises.  In these exercises, a solubility curve 
adapted from Dalman is given to the students [173].  Students are given a scenario in 
which they need to determine a temperature for a solution in which a specific mass of 
crystals will precipitate out.  The interpolation necessary for this solution is shown in 
Figure 11.  Another exercise is also given that uses interpolation; this time using the 
DXM solubility curve that the students generated.  This exercise has them determine a 
saturation concentration at a certain temperature.  The interpolation necessary in this 






Figure 11.  The interpolation used for the citric acid exercise.  Here, the dark line is the 






Figure 12.  The interpolation necessary for the DXM exercise.  Once again, the dark line 
represents the solubility curve (provided by sample data), while the lighter line represents 
the interpolation steps. 
 
This was used as part of an exercise that introduced some topics that would be in a 































































problem found in the Felder and Rousseau text [174].  In this problem, a simplified 
crystallization process is described using a cooler/crystallizer, a filter, and a dryer.  A box 
diagram of this process is shown in Figure 13.  The interpolation shown in Figure 12 is 
used to determine the solids produced in the crystallizer.  Once this is done, the mass of 
liquid that leaves with the filter cake can be determined, given that the filter is 100% 
effective at removing crystals and that the cake is 80% crystals by mass.  The mass % 
equation is used for this calculation, which can be seen in Equation 17.  Lastly, the yield 
is determined by finding the mass of crystals removed via the process and comparing it to 
the mass of crystals in the starting solution.  The mass of crystals and yield were 
calculated using Equations 18 and 19, respectively. 
 
 
Figure 13.  The box diagram for the industrial crystallization exercise given in the 
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The solubility curves are the focus of this experiment, as they are a useful tool for 
engineers when designing crystallization equipment [152, 153].  Another focus of this 
experiment is to discuss a separate aspect of crystallization; thermal energy transfer.  The 
flow of heat is an important concept for crystallization theory, since heat will need to be 
transferred to or from the solution in the process.  And with this flow of heat there is also 
the transfer of energy.  For transferring energy, a scenario is given to students in which 
they determine the energy required to heat the water bath used in the experiment, and also 
a theoretical 200 gallon tank of water.  The equation they use, and a sample calculation 
for the 200 gallon tank of water, is shown Equation 20. 
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Where Q is the energy in the form of heat added to the system, m is the mass of the water,  
   is the specific heat of water, and ΔT is the temperature change for the water.  This 
introduces the students to the differences in values from lab-bench to industrial scale.  In 
terms of heat transfer, two exercises are given.  The first example has students determine 
the thermal diffusivity ( ) of a substance.  The thermal diffusivity of a substance is the 
ratio of a substance’s ability to conduct thermal energy in relation to its ability to store 
thermal energy [175]. Students are tasked with calculating the thermal diffusivity for 
aluminum and water. They are also tasked with determining the temperature dependence 
of the thermal diffusivity of aluminum by calculating this ratio for several temperatures. 
The theoretical equation and a sample calculation for the thermal diffusivity of water at 
25 °C are shown in Equation 21. 
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Where   is the thermal conductivity,   is the density, and    is the specific heat of the 






, showing that water has a higher thermal diffusivity, and thus a higher 
conduction to storage of thermal energy ratio than aluminum at this temperature.  When 
comparing α values for aluminum at different temperatures, students see that the thermal 




Table 4.  This reinforces the notion that pure metals show a decrease in thermal 
conductivity and thermal diffusivity with increasing temperature [175].   
 
Table 4.  Sample thermal diffusivity values of aluminum at varying temperatures.  As 
shown, thermal diffusivity values decrease as temperature increases. 
Temperature (K) α (m
2
/s) 
200 1.09 · 10
-4 
400 9.43 · 10
-5 




The second exercise has the students model the rate of heat transfer for a test tube.  
Students are to model the flow of heat from the center of the water in the test tube to the 
top of the water in the test tube (Figure 14).  In this exercise, a simplistic model is given 
to the students in which three assumptions are made: That heat flows at a steady state; 
that all the sides, except for the open end of the tube are perfectly insulated; that free 
convection on the top surface of the water is negligible.  While these assumptions are 







Figure 14.  A representation of the one-dimensional, steady-state conduction model for 
the test tube in the Dextromethorphan Crystallization Lab. 
 
With these assumptions, a heat flow equation that models heat flow in one direction can 
be used (Equation 22).  
 
     
 







With    being the heat transfer rate,    the length at which the heat transfer is taking 
place (     ),   the surface area of the heat transfer,   the thermal conductivity of the 
substance, and    the difference in temperature from the end point to the start point 
(      ).  This exercise has the students use different values for  ; one assuming the 
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With   being the thermal conductivity,   being the concentration of the salt in the 
solution, and   being the temperature of the system.  In both instances, the students use 
their test tube #1 data to determine the heat flow.  The percent difference between the two 
heat transfer rates is then calculated. Since the solution is dilute, percent difference will 
be minimal between the two.  The Student and Instructor’s version of this lab can be 
found in Appendix A.6 and B.6, respectively. 
3.7 Creation of Dissolvable Strips Laboratory 
In the field of drug delivery, there has been a focus on finding different sites of 
administration for therapeutics.  While the oral route remains the most popular, it does 
have its drawbacks.  These include hepatic first pass metabolism or first pass effect, and 
degradation of the drug in the gastrointestinal tract [177].  In addition, tablets are known 
to be problematic for patients that suffer from dysphagia, the medical term for difficulty 
swallowing [135].  As a consequence, researchers have investigated transmucosal drug 
delivery methods.  One of the promising subsets of these methods is oral transmucosal 




buccal region of the mouth.  The buccal region is the area of the mouth that corresponds 
to the inner cheeks.  The rough texture of the buccal mucosa (mucous membrane) makes 
it suitable for drug delivery [178].  Buccal drug delivery offers three advantages; direct 
entry into systematic circulation, ease of administration, and the ability to terminate 
delivery when required [179].   
This buccal region is becoming especially popular for pediatrics and pediatric 
medications.  Oral transmucosal delivery has been investigated for pediatric medications 
in order to increase patient compliance in this subset [180, 181].  There has been a new 
focus on pediatrics in the pharmaceutical industry, especially in Europe.  The European 
Union began a tighter regulation of pediatric medicines beginning in 2007, after the 
concern of unlicensed and off-label medicines for pediatric use reached an apex [182].  
Since then, there have been several studies on the challenges faced by the pharmaceutical 
industry to provide effective products for child patients [181, 183, 184].   Investigations 
from this have led to several systems that have been developed for oral transmucosal drug 
delivery; including liquids, solids, semisolids, and even sprays [177].  
Of all the delivery systems that have been developed, one of the most recent is orally 
dissolving thin films, or strips [185].  Thin films, or buccal patches, improve patient 
compliance in those with difficulty swallowing due to their small size and thickness 
[186].  Thin films have an area similar to a postage stamp and a thickness between 50 and 
200 millimeters [135, 187].  In addition, thin films are usually designed so that they 
dissolve without the patient needing to administer water [187].  Fast dissolving films 
were first developed for the confection and oral care markets, used as breath strips and/or 




that thin films have been used to deliver API’s found in several over the counter 
products; including dextromethorphan HBr, found in cold medications; simethicone, an 
anti-foaming agent found in anti-gas medications; and benzocaine, an anesthetic used in 
oral pain relief [189].  This delivery method is currently being investigated for 
prescription drugs [187]. 
While thin films do have great advantages, there are some drawbacks to the delivery 
method.  For example, due to the instability of the films, specifically their hygroscopic 
nature, they need to be packaged and stored in dry areas [188].  To combat degradation, 
film products are often stored individually in flexible plastics that act as moisture barriers 
[189].  This can lead to some additional costs in manufacturing, but there are methods to 
reduce these costs.  A recent invention has been developed to form a pharmaceutical 
product directly onto packaging surfaces, reducing wasted material and the associated 
costs [190].  In addition, dosage uniformity can be a technical challenge for these films 
[188, 191].  The last setback for thin films is that high dosages cannot be incorporated 
into them [135, 188].  These limitations of thin films also put constraints on the drugs that 
can be incorporated into them.  API’s and drug formulations that can be delivered via this 
method must meet certain criteria:  They must have a dosage lower than 20 mg; they 
must be of a small to moderate molecular weight; they must have good stability in water 
and saliva; they must be able to diffuse and partition into the epithelium of the upper 
gastrointestinal tract; they must be able to permeate oral mucosal tissue.  When used for 
pediatric medicine, it is also beneficial to use a drug with no bitter tastes [188].  Of 





These setbacks have not stifled investigations of this method.  One of the earliest research 
investigations into thin films was in using patches of miconazole nitrate, an anti-fungal 
agent.  Researchers found that the patches were able to deliver a potent dosage over a 
longer period of time than the commonly used gel delivery method [192].  Another early 
study looked at optimizing mucoadhesive patches that contained cetylpyridinium 
chloride, a common antiseptic used to kill bacteria in the mouth [193].  Immunization 
was also investigated early in thin film research.  The idea that vaccination could be 
conducted without needles provided advantages in both cost and safety.  Animal research 
studies have been conducted to show that immunization via mucosal thin films is 
achievable [194].  Contraception is also an area of study for dissolvable strips.  Jain, Jain, 
Gupta, and Kharya investigated polyvinylpyrrolidone (PVP) films for the buccal 
administration of the contraceptive drug progesterone [195].   
Others have explored using other types of plastics for making dissolvable strips, such as 
hydroxypropylmethylcellulose and pullulan, and their qualities when made into thin films 
dissolvable strips [196, 197].  Maltodextrins, a polymer that is formulated from natural 
sugars is also under investigation as a possible polymer for making dissolvable strips.  
Maltodextrins have several characteristics that make them good candidates for thin film; 
such as solubility in water, an inherent sweetness, and favorable hygrscopicity [198].  
One research team investigated the effect dextrose equivalents have on the physical 
characteristics of the maltodextrin films [199].  Another study used nicotine to further test 
the sweetness of the maltodextrin films, since nicotine is known for having a bitter taste 




This has been studied for enhancing the dissolution rate of poorly water soluble drugs 
[200]. 
Dissolvable strips are also being considered for use in cancer therapies.  In this case, 
dissolvable strips are loaded with antiemetic drugs to cancer patients, to reduce the 
effects of nausea and vomiting that can occur when they are given potent opioid 
analgesics [201].  The use of thin films in this type of therapy is regarded for reducing the 
time it takes for the drug to take effect.  This was first seen in 2009, when a group of 
researchers published their work on using disintegrating films containing 
prochlorperazine and found the films to deliver the drug in rats within 2 minutes [202].  
This was soon followed by a study that focused on using thin films loaded with 
dexamethasone for reducing nausea in chemotherapy patients [203].  This latter work was 
soon tested in a clinical trial, which produced favorable results.  This led the researchers 
to conclude that these oral thin films are effective at reducing nausea and vomiting in 
chemotherapy patients [204]. 
With the advances in thin film research, and with several dissolvable strip products on the 
market, the need for engineers to have an understanding of this drug delivery technique, 
from its manufacture to end use is important.  The Creation of Dissolvable Strips Lab is 
designed to introduce students to the manufacturing and quality testing of dissolvable 
strips.  In this lab, students are introduced to the different ingredients that make up 
dissolvable strips; these being polymers, plasticizers, sweeteners, and other flavoring 
agents [135].  The students are then tasked with creating these thin films and conducting 




To create these films, students are given a “recipe” for making these strips which was 
developed based on literature [135, 188].  This includes the polymer 
carboxymethylcellulose (CMC), the plasticizer glycerol, citric acid for saliva stimulation, 
sucrose as a sweetening agent, and sodium lauryl sulfate as a surfactant.  Included for 
flavor and color were peppermint oil and blue food dye, respectively.  All of these items 
are added to water kept just below the boiling point (approximately 80 to 90 °C) and at a 
vigorous stir.  Since this process is open to the atmosphere, air bubbles do form in 
solution.  To remove these, students create an apparatus involving two Buchner flasks 
and some tubing.  The mixture is placed in this apparatus, seen in Figure 15, and allowed 







Figure 15.  The vacuum apparatus used for removing air bubbles from the thin film 
mixture. 
 
Once this is complete, the students place their mixture in a petri dish and also a special 
casting tray developed for this lab (Figure 16).  Students pour 400 mL of their thin film 




added to the petri dish using a bench scale.  The thin films solutions are allowed to sit for 
1 to 4 days, allowing the solution to dry and form dissolvable strips.  
 
 
Figure 16.  The casting tray used to create dissolvable strips.  The surface is a Teflon
®
 
baking sheet, and the guides are aluminum strips.  The guides are reinforced using 
silicone caulk. 
 
Once the films are dried, students perform different analyses on their strips.  Using the 
dried solution in the cast, students cut 4 samples with dimension of 1 in. by 1.5 in.  These 
samples are then used for quality analysis.  The tests used in this section of the lab were 
chosen from literature based on their ease of setup and lack of specialty or expensive 
equipment [135, 188].  The three tests chosen were thickness measurements, folding 
endurance, and surface pH.  Thickness measurements are taken using a caliper and 
measuring the thickness of each side of the samples.  The folding endurance is calculated 
by folding a strip in half repeatedly until the strip breaks in two.  Surface pH is found by 
placing one drop of water unto the surface of a sample.  Litmus paper is then placed on 




each of these quality tests.  Students are then asked to comment on their findings; such as 
if the surface pH was acceptable for human ingestion, how the folding endurance 
compares to a commercial brand strip, and what dangers there are for large variances in 
strip thickness.  Quality measurements can be seen in Figure 17.  Sample data can be seen 
in Table 5. 
 
 
Figure 17.  Sample quality measurements for the Creation of Dissolvable Strips Lab.  a) 
Creation of sample strips for quality testing. b) Measuring the thickness using a caliper. 











1 0.08 32 5.0 
2 0.10 28 5.5 
3 0.12 39 5.5 
4 0.07 23 6.0 





Using the petri dish sample, students conduct a moisture content analysis.  By weighing 
the sample before and after drying, and assuming the mass that evaporated was strictly 
water, students can determine the mass of water that left the sample. The moisture 
content equation, and a sample calculation, is shown in Equation 24. In this equation,   
is the final mass of the sample and   is the initial mass of the sample. Using this, 
students can also determine the amount of energy that was needed to evaporate the water.  
This calculation is seen in Equation 25, with   being the energy required to dry the 
sample,     being the mass of the water vaporized, and     
    being the latent heat of 
vaporization for water.  Lastly, students determine where this energy came from.  Since 
the sample was allowed to sit in an open area, the energy was transferred from natural 
convection in the air.  In addition, students might cite solar energy if they left their 
sample in a sunny area of the lab. 
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The manufacturing aspects of thin films are also discussed throughout the lab.  Students 
are first given an introduction to the two processes that are usually used in industry to 




given a comparison of the two processes, including the unit operations used and when it 
is preferred to use one process over the other.  To reinforce this, students are given a 
scenario in which the specifications of a thin film product are given and are tasked with 
determining which unit operation would best suit their product. Students also research 
different API’s that are placed in thin films, and what kinds of treatments they are used 
in.  Students are then tasked with determining what kind of thin film polymer, 
hydrophilic or hydrophobic, would be best to use for these API’s.  The Student and 









Initial assessment efforts show that the experiments convey both desired pharmaceutical 
concepts and core engineering objectives.  Preliminary assessment of the laboratory 
experiments was completed and assessment of broader pharmaceutical engineering 
educational activities in underway.  Some of the results relevant to the experiments 
developed will be shown.  Other results from course development, problem sets, and 
laboratory activities are planned for later.  Representative results using the Tablet 
Statistical Analysis Lab are provided, which involved three student groups.  The students 
were individually given a pre-lab test to measure their knowledge of several 
pharmaceutical and statistical aspects that were covered in the laboratory experiment.  
Multiple choice questions included several pharmaceutical concepts such as definition of 
an API and function of excipients, along with questions about appropriate use of F- and 
T-tests.  A representative question about excipients would be “The substance used in a 
tablet to take up space in a pharmaceutical product is…” and a representative question 
about the F-test would be:  “The purpose of an F-test is to …”.  The correct answer to the 
excipient question and the F-test question is “filler” and “to compare two sets of data to 
one another”, respectively.  After the experiment was completed, a post-lab test was 
performed and the average of the correct responses of the students is shown in Figure 18.  
This indicates that the students have a better understanding of pharmaceutical concepts 
and the purpose of statistical tests after conducting the experiment.  The test can be seen 





Figure 18.  Pre-lab and post-lab concept test results for the assessment of the Tablet 
Statistical Analysis Lab. 
 
Students were given a post-lab survey to determine if the experiment helped to advance 
the broader educational objectives of increasing pharmaceutical interest and experimental 
methods.  The survey asked the students to agree or disagree with a statement about their 
experience with the laboratory using a Likert scale (1 being a strong disagreement and 5 
being a strong agreement with the statement).  The statements used in the survey relate to 
the student’s interest in pharmaceutical engineering (I wish to pursue more studies in the 
field of pharmaceutical engineering), the pharmaceutical aspect of the laboratory (The 
experiment introduced a concept of pharmaceutical engineering), the utility of the 
statistical tests (I can apply the statistical principles I learned in this lab to other 
engineering problems), and the educational objectives of the experiment (I had to 
appropriately use laboratory equipment (scales, etc.) for data collection).  The survey in 



































students gave a response of 4 for all categories of statements (Figure 19).  We have also 
solicited input from current employers about the industrial relevance of the experiments.  
Representative feedback from one of our pharmaceutical professionals indicates, “These 
experiments are valuable in exposing engineering students to principles of 










































With the current laboratory experiments, it is possible that a course could be adapted to 
include these experiments for a semester.  With this, a more thorough assessment plan 
should be implemented.  While some assessment has been shown, this was only for a 
small population and for one laboratory experiment.  The goal would be to gain a 
population of a whole class (approximately 24 students) and receive input for more 
experiments.  The implementation would be similar to the assessment shown previously, 
where students are given a pre- and post-lab quiz and a post-lab survey.  These will be 
developed to target specific goals of the intended laboratory experiments. 
In addition, more experiments should be developed.  This will not only give more options 
to faculty as far as which experiments they will have the students conduct for one 
semester,  but may also rise to a second semester of experiments.  Experiments could also 
be developed for other classes, such as a thermodynamics or mass transfer course.  These 
experiments would be more complex than the experiments shown in this work, and would 
be more targeted to the specific field of engineering. 
For future laboratory experiments on the freshman level, emphasis will be placed on 
taking existing experiments and expanding on those concepts. An example would be an 
expansion of the Tablet Statistical Analysis and the Creation of Dissolvable Strips Labs.  
For the Tablet Statistical Analysis Lab, an expansion would be on using different tablets 
or other forms of drug delivery.  With these different forms of drug delivery, different 




and design of experiment techniques, students could gain an in-depth assessment of 
statistics and experimental design.  Emphasis could also be put on Bayesian 
methodology.   
The Creation of Dissolvable Strips Lab could be expanded to using advanced 
mathematical equations to model certain parameters of the thin film.  For example, 
students may use advanced heat transfer equations to determine drying times for different 
polymer matrices.  This could be used for the students to design different dryers.   In 
addition, a semester long project could be developed specifically with dissolvable strips.   
The semester long project would investigate starting volumes versus final volumes using 
a fixed volume cast.  The students could then develop a mathematical model to determine 
the final volume of a thin film when it is cast in a certain initial volume.  In addition, 
design of experiments could be implemented to investigate this.  Students would start 
with a simple 2
2











The experiments developed can be easily integrated into Freshman-level engineering 
courses.  These experiments illustrate basic engineering and science principles, while 
acquainting students with fundamentals of pharmaceutical engineering.  The experiments 
convey concepts in pharmaceutical fundamentals, drug manufacture, drug 
formulation/delivery, and pharmacokinetics/pharmacodynamics.  Experiments developed 
to date include: Tablet Statistical Analysis Lab; Asthma Drug Delivery Lab; Antacid 
Comparison Lab; Effervescence Reaction Lab; Fluidization of Pharmaceutical 
Substances Lab; Degradation of Dissolvable Strips Lab; Bandage Comparison Lab; 
Dextromethorphan Crystallization Lab; and Creation of Dissolvable Strips Lab.  The 
experiments can be used individually to meet specific educational objectives, such as 
applying statistical methods to manufacturing quality control, or grouped into a theme for 
more in-depth learning.  The experiments have multiple parts that allow faculty to add 
more complexity or accomplish other learning objectives.  These experiments can peak 
student interest in pharmaceutical engineering and provide background needed for 
advanced courses or laboratories.  Complete laboratory procedures, both students and 
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Appendix A   
 
Student Versions of Laboratory Experiments 
A.1 Tablet Statistical Analysis Lab 
Tablet Statistical Analysis Lab  
Developed by:  Alex Jannini, David Krause, Heather Malino and Kevin Sweeney, 
Rowan University, Department of Chemical Engineering 
Edited by:  C. Stewart Slater and Mariano Savelski, Rowan University, 
Department of Chemical Engineering 
Date of Experiment: 
 
OBJECTIVES 
 Students will perform a basic statistical analysis applied to an over-the-
counter drug 
 Students will learn about pharmaceutical engineering, including key terms 
and concepts 
INTRODUCTION 
In the pharmaceutical industry, drugs are manufactured, produced, and marketed 
for therapeutic use.  The industry has been one of the highest earning industries 
of the last decade, with 791 billion dollars in worldwide sales in 2010.  The 
majority of these sales were in North American companies, totaling 335 billion 
dollars1. 
A pharmaceutical product is not just one specific chemical, but many chemicals 
combined together to make a final product.  Tablets, which the students will be 
working with in this lab, are composed of a few chemicals mixed together and 
then compressed.  The therapeutic ingredient is known as the active 
pharmaceutical ingredient (API).  The API is what causes the desired effect of 
the drug.  The rest of the ingredients that remain inert are known as the 
excipients.   
Excipients can have different functions, which is why there are sub-categories of 
excipients found in pharmaceuticals.  For example, a filler is a type of excipient 
used to make up the volume of a medicine so that it can be taken in the form of a 
pill. In some cases, excipients known as binders are used to act as glue and 
make sure the ingredients stick together.  Lubricants and glidants are used in 
combination since they reduce wall friction and interparticle friction, respectively.  




may also be flavors or colors, which will mask any unpleasant tastes that the 
other ingredients have and improve the appearance of the product.   
In any engineering field, statistical analysis is an important tool.  In the 
pharmaceutical industry, statistics can be used in various ways.  For example, 
statisticians use statistics to create trials for experimental drugs.  A chemical 
engineer might use statistics in order to figure out a new process that creates 
more product for less.  In these cases, statistics play an important role in 
analyzing data in order to come to a conclusion. 
In this lab, the students will be looking at two different over the counter 
medications that contain the API ibuprofen, a known pain reliever and fever 
reducer.  The rest of the inactive ingredients in the tablets are binders, fillers, or 
any other kind of excipient.  This lab will consist of a statistical analysis on the 
difference in mass between the ibuprofen tablets, and also the difference in the 
mass of a generic brand and the trademarked brand Advil®.  An introduction to 
creating a flow diagram will also be incorporated into this experiment. 
MATERIALS NEEDED  
 Container of Advil® tablets (minimum of 10 tablets)  
 Container of generic ibuprofen tablets (minimum of 10 tablets) 
 Weigh boat 
 Tweezers 
 Bench scale (accurate up to 1/1,000 g). 
SAFETY CONSIDERATIONS  
Always wear laboratory safety glasses when working in the lab. 
PROCEDURE 
1. Make sure that the bench scale is turned on, and that the scale is set to 








Figure 1.  Where to find the active and inactive ingredients 
2. Take the Advil package and note where they list the active and inactive 





3. Place the weigh boat on the bench scale.  Record the weight, and then 
tare the instrument.  The bench scale should now read 0 grams. 
4. Open the box of Advil®, and with tweezers, place one tablet in the weigh 
boat.  You may use the table provided below, but you should also record 
your findings in your lab notebook.  
5. Once the mass has been recorded, tare the scale again. 
6. Repeat the two previous steps until you have weighed ten Advil tablets.  
Empty your weigh boat, place it back on the bench scale, and tare the 
instrument.  You should now have the Advil® portion of the data table filled 
out. 
7. Now, look at your generic brand.  Record all the non-active ingredients. 
8. Open the container, and using the tweezers, place one tablet in the weigh 
boat.  Once again, tare the instrument after recording the mass. 
9. Repeat until you have collected ten measurements of the generic brand.  
You should now have the generic brand portion of the data table filled out. 
10. Once all measurements have been completed, dispose of the measured 














You will need your calculator to do the following calculations.  You must show all 
work to receive credit. 
1. First, take the average of each set of data.  Use the equation below, with i 
being the trial number (given in the data table), n being the total number of 
trials (10), and x being the mass recorded for the specific trial number.  
Record this in your lab notebook and include in your results. 
 ̅   
∑   
  
   
 
 (1)  
 
Trial Number Name Brand Mass (grams) Generic Brand Mass (grams) 
1   
2   
3   
4   
5   
6   
7   
8   
9   
10   





2. Standard deviation is defined as the variation from the average.  In other 
words, it is the average of the difference between each value obtained and 
the average value obtained.  So, in this case, it would be important to 
know the standard deviation of the mass of the tablets for the trademarked 
brand and also the generic brand.  To calculate the standard deviation, 
use the equation below, with i once again being the trial number, n being 
the total number of trials, and x being the mass recorded. 
   √
∑ (|     ̅| )
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3. Now, we will look for any outliers in our data.  An outlier can be defined as 
a data point significantly different than the mean of the data.  In other 
words, an outlier is a datum point that significantly distant from other 
points.  To do this, find the median data point in both sets of data.  To find 
the median, list the data in order from lowest value to highest value, and 
find the point that resides in the middle.  If you have an even number of 
data points, the median is found by averaging the two middle data points.  
From now on, this median (the median of the entire data set) is known as 
overall median.  From here, find the first and third quartiles.  These 
values are found by splitting the list of data in half.  In this case, we now 
have two sets of five data points; one with the lower data points, and the 
other with the higher data points.  The first quartile can be found by 
taking the median of the lower data points.  The third quartile is the 
median of the higher data points.  Lastly, we state that the overall median 
is the second quartile.  Using the equations below, calculate if any of 
your data points are outliers.   
 
          (     ) (3)  
 
 
Where, OL is the low-value outlier cutoff, Q1 is the first quartile, and Q3 is 
the third quartile. 
 
          (     ) 
 
(4)  
Where, OH is the high-value outlier cutoff, Q3 is the third quartile, and Q1 is 




Are any weights you measured above OH or below OL?  If so, they are 
outliers.  Arrange your findings in a box-and-whisker plot as described in 












 Be sure to record all findings for this lab.  Answer any questions that might 
have been asked in the procedure section of the lab. 
QUESTIONS 
1. During the statistical analysis section, you were asked to find the standard 
deviation of the trademarked and the generic brand. Explain what this 
value tells you.  Compare the two standard deviations you calculated, and 
determine what this means. 
 
2. Now, you will determine whether or not these two brands are different 
from each other.  To do this, you will use a statistical analysis technique 
known as an F-test.  An F-test is used to compare two samples.  This test 
can become difficult if the samples are not done in a similar manner.  In 
this case, the number of measurements taken in each sample is similar, 
so this makes the F-test much simpler.  To conduct an F-test, do the 
following: 
 




a. Find the variance of the two samples.  The variance of a sample is 
defined as the average of the squared difference of the means.  An 
equation of what this would look like is shown below: 
 
 
           
 
                                                     




     






Another way of looking at the variance is it’s relation to the standard 
deviation of a sample.  The relation of the variance of a sample to 
the standard deviation of a sample is shown below: 
 
       (7) 
 
If you compare the equation of variance to the equation of standard 
deviation, you can see how this is true.  Use the relation between 
standard deviation and variance to find a value of variance for the 
two samples. 
 
b. Now, find the F-value for your experiment.  To find your F-value, 
use the following equation: 
 









For this equation, the variance in the numerator “s1” has to be the 
larger of the two variances.   
 
c. Now, compare this value to a critical value.  This is known as the F-
critical value.  The F-critical value is dependent on the number of 
measurements taken in each sample, and the percent confidence 
that is desired.  The percent confidence is another way of saying 
how accurate one wishes to be in their experiments.  The higher 
the percent confidence, the more certain one is in their 
experiments.  In this case, you will use a standard percent 
confidence of 95%.  So, you will need an F-critical value which 
corresponds to a 95% percent confidence, a variance based on 10 




measurements in the denominator.  Usually, these would be looked 
up in tables, as seen in appendix A Figure 1.  However, below you 
will find an critical F value for your calculations3: 
 
           
 
If the F value you calculated in part b of this problem is larger than 
the critical value given, then the two samples are significantly 
different.  If the F value you calculated in part c of this problem is 
smaller than the critical value given, then the two samples are not 
significantly different.  State whether or not there is significant 
difference between the two samples . 
 
3. Research suggests that one ibuprofen tablet should have a mass of 480 
mg.2 Do you think there is significant difference between the values you 
obtained and this literature value for a typical formulation?  To answer this, 
you will use another statistical test known as the t-test.  There are several 
different types of t-tests used in statistics.  In this case, you will be using a 
one-sample t-test, which compares a single mean to a fixed value.  So for 
this test, the fixed value will be the 480 mg.  You will conduct a t-test on 
both samples.  In order to conduct this analysis, do the following: 
 
a. For a t-test, you will need to find a t-value.  The t-value for an 
experiment relates the average, standard deviation, and number of 
measurements to a given value.  Using the symbols found 
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  In this case, μo will be the mass found in research (480 mg). 
 
b. You will now compare this value to a critical value.  This is known 
as the critical t-value.  Like the F-critical value, the critical t-value is 
dependent on the percent confidence that is desired and the 
number of measurements taken in the sample.  Again, you will use 
a percent confidence of 95%.  The critical t-value you will be using 





             
 
Just like with the F-test, if the critical t-value is higher than the value 
obtained earlier, then there is no difference between your sample 
and the value from literature.  If the t-value calculated earlier is 
higher than the critical t-value, then there is a significant difference 
between the sample and the value obtained from literature.  State 
whether or not there is significant difference between the value 
obtained from experiments and the value obtained from literature. 
 
c. Repeat this process for whichever sample you did not already 
conduct the analysis on. 
 
4. It has been estimated that the world production of ibuprofen is in the 
vicinity of 15,000 tons per year.4 It has also been estimated that the 
average price for one ibuprofen tablet is roughly 0.12 USD.5  Using this 
information, calculate the total price of ibuprofen production for a year.  
 
5. Remember that you listed the inactive ingredients from each of the 
brands.  Research the first three ingredients from both brands and state 
what type of excipient you believe them to be (i.e. filler, preservative, 
lubricant, etc.). 
 
6. It is your first day on the job working for Pfizer and you are told to do an 
experiment on the Advil production line.  A new tablet press has been 
installed and your boss wants to know if it is producing tablets with 
consistent weight.  To start your experiment, you pull a sample of 20 
tablets off of the line and weigh them.  The data is arranged in a table 
below.  Your boss tells you that each pill must be 90% to 110% of the 
mean tablet size, which is 0.485 g.  Do any pills in your sample fall outside 
of these bounds?  Furthermore, did you find any outliers in your sample?  
What does this say about the consistency of the new pill press?   
 
Advil Sample - 20 Tablet weights (g) 
0.4850 0.5435 0.4686 0.4837 
0.5198 0.4448 0.5211 0.5895 
0.5048 0.4668 0.4863 0.5227 
0.4857 0.4465 0.4217 0.4662 
0.4786 0.4835 0.4481 0.5101 
 
 




7. You will now have an introduction to creating process flow diagrams.  
These diagrams are an important part of engineering, as they are used in 
most plants.  A process flow diagram indicates the major equipment used 
in a process.  In this case, a box with a label will be acceptable as a piece 
of equipment.  An example is shown below: 
 





If you have more than one stream entering or exiting a process, multiple 
lines can be drawn.  For example, if a mixer blends water and titanium 




a. Make a process flow diagram for the creation of the ibuprofen 
tablets as described by the steps below: 
i. Mix the powder (maize starch) for 15 minutes at high speed.  
Add 10.67 g of cold water and check weight (theoretical 
weight, 58.00g).  If required adjust with hot water.  Record 
the quantity of extra water added. 
ii. Mix this binding solution with Mixture 1 (Ibuprofen and maize 
starch). 
iii. Collect and spread the granules onto the trays, one third the 
thickness of the tray. 
iv. Load the trolley into the oven and dry the granules in the 
trays and change the position of the trays for uniform drying. 
v. Mix stearic acid and corn starch separately and add to the 
granules before sending them to a compressor.  Compress 
into 330-mg tablets, using 10-mm convex punches at 4 to 9 
kPa. 
vi. Put the tablets into the coating and rolling pan. 
b. Make another process flow diagram that shows the coating of the 
ibuprofen tablets as described by the steps below: 









1. Heat 72.0 g of item 6 (purified water) in mixer to 
boiling. 
2. Dissolve 168.0g of item 4 (sucrose) and then cool to 
25°C. 
3. Filter the syrup through a 180-µm stainless steel 
sieve. 
4. Dispense item 5 (titanium dioxide) into the sugar 
syrup from the previous step and homogenize. 
5. Check for evenness of the dispersion. 
ii. Apply Sugar Coating to tablets in coating pan by rolling 
tablets and slowly adding the sugar solution over 30 
minutes.   
iii. Make gloss solution  
1. Melt items 1 - 3 (bee’s wax, polyethylene glycol, 
carnauba wax) in a steam-heated vessel by gentle 
heating to 70°C or in a stainless steel container on a 
hotplate heater. 
2. Mix thoroughly. 
3. Pass the mixture through a homogenizer. 
4. Store the polishing emulsion in a closed container at 
room temperature. 
iv. Apply gloss solution to tablets in coating pan by rolling 
tablets. Once the desired polish appears, stop rolling the 
pan. 
v. Dry the tablets in the pan at 30°C for 30 minutes.  Final 
tablet weight should be 480 mg. 
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 Students will fluidize a pharmaceutical excipient, and learn about the 
variables affecting fluid-particle transport 
 Students will construct and interpret fluidization graphs using experimental 
data 




A fluidized bed occurs when solid 
particulate matter is put under specific 
conditions that allow it to behave as a 
fluid.  This is usually performed in some 
sort of vessel and achieved through the 
use of a pressurized fluid, such as air.  
Some of the properties that the 
particulate matter has in its fluidized 
state include the ability to be transported 
in a manner that is similar to other fluids.  
This phenomenon is called fluidization.  
Fluidization and fluidized beds are used 
in several different industries for several 
different purposes. 
 
In fluidization, there are many different 
variables that need to be considered.  If 
one was to design a fluidized bed, 
equipment parameters such as the 
pressure of the incoming fluid, the flow 
rate of the incoming fluid, and the temperature of the system would need to be 
part of the design process.  In addition, the material that is to be fluidized will also 
need to be investigated.  Material properties such as particle size, density, and 
porosity (also known as the void fraction, or the fraction of empty space in a 
packed vessel) are important when designing a fluidized bed. 
 
As the solids are fluidized, they behave as common fluids.  As such, flow 







called pressure drop.  Pressure drop is the difference in pressure between two 
points along the path of fluid movement in the process.  Pressure drop is caused 
by frictional forces, resistances to the flow, as the fluid flows through the vessel. 
 
In the pharmaceutical industry, fluidized beds have many different applications.  
Initially, fluidized beds were mainly used for the drying and coating of solids1. 
Granulation, the act of forming or crystallizing substances into grains or granules 
in fluidized beds, was later investigated for pharmaceutical purposes.1 
Fluidization can also be used for the transportation of solids, as the fluidized 
solids can be transported via pipes rather than conveyer belts or in discrete 
amounts1. 
 
In this experiment, you will be investigating four different variables of a fluidized 
bed; air flowrate, air pressure, pressure drop, and bed height.  You will then use 
the data you collected to perform some fluidized bed calculations.  By the end of 
this experiment, you should have a better understanding on how fluidization 
occurs, and why it is an important aspect of pharmaceutical manufacturing.   
 
MATERIALS NEEDED 
 PART I 
 250 mL plastic graduated cylinder 
 1000 mL plastic graduated cylinder 
 Bench scale capable of reading at least 1 kg 
 Avicel® PH 200 
 Kaolin powder 
 DI water 
 Stirrer 
PARTS II & III 





Laboratory goggles must be worn at all times when in the laboratory.  Laboratory 
gloves and a dust mask must be worn if handling pharmaceutical powders.  
Obtain and read the MSDS on Avicel® PH 200 and kaolin. 
 
PROCEDURE 
PART I – DETERMINING BULK AND PARTICLE DENSITIES 
1. Begin by placing the empty 250 mL graduated cylinder on the bench 
scale.  Tare the instrument. 
2. Place approximately 50 to 60 grams worth of one of the powders into the 
graduated cylinder.  If you are a little over or under, that is fine, as long as 
the powder does not surpass a measureable level on the graduated 




3. Record both the mass of the powder you added to the cylinder, and how 
much volume it takes up.  Use these values to calculate the bulk density 
by dividing the mass added by the volume it takes up.  Set aside this 
graduated cylinder. 
4. Now, fill the 1000 mL graduated cylinder with DI water to around the 700 
to 800 mL mark.  Again, this does not need to be precise.  Record the 
volume of water you added. 
5. Place the graduated cylinder filled with water on the bench scale, and 
once again tare the instrument. 
6. Slowly, add the powder from the small graduated cylinder into the large 
one.  You may need to stir the solution at intervals of the pouring process 
so that all the particles are suspended.  Remember that you do not want 
to surpass the readable levels of the graduated cylinder. 
7. Once the particles have been poured in, stir the mixture thoroughly, but 
carefully.  You do not want to lose any of the water.  Once stirred, place 
back on the scale bench and record the mass of the powder you added to 
the water.  Also, record the new volume of the water and powder mixture. 
8. Now, find the particle density.  The particle density is the mass of the 
powder added to the water and the volume taken up by the particles.  You 
can determine the volume taken up by the particles by subtracting the 
volume of water from the volume of the mixture. 
9. Do this for the other powder.  Make sure that you clean and dry the 
graduated cylinders thoroughly, and use new cylinders before starting to 
work with the new powder.  You may use the following table to record your 
findings, but you should copy this table into your lab notebook. 
 
 
Table1. Empty table for recording data during the fluidization lab. 
Measurement Kaolin Avicel PH 200 
Mass of substance (g)   
Volume of substance (mL)   
Bulk density (g/cm3)   
Volume of water (mL)   
Volume of mixture (mL)   
Volume of particles (mL)   
Mass of substance (g)   
Particle density (g/cm3)   
 
 
PART II – THE FLUIDIZED BED 
1. The first step in running these experiments is to become acquainted with 
the equipment.  First, briefly look over the equipment and the station in 
front of you.  Note where your pressurized air is coming from. 
2. After investigating your system, measure the inner diameter of the 




Figure 2.  Laboratory scale fluidized bed. 
Figures 3 and 4.  From left to right; the inlet air 







PART III – SUBSTANCE INVESTIGATIONS 
1. After becoming familiarized with your equipment, you may begin testing.  
Begin by measuring the height of the fixed bed.  
2. Set the incoming air at a pressure of 60 pounds per square inch (psi).  
Make sure that the flowmeter is closed, but the air valve is open (make 
sure you know which is which!).  
3. With the inlet air pressure at 60 psi, open the 
flowmeter and 
slowly raise the flow 
rate of the incoming 
air to 5 gallons per 
minute (gpm).  At 
this reading, take a 
pressure drop 
measurement and a 
bed height 
measurement.   
4. Once the 
measurements have 
been recorded, 
increase the air flow 
rate by 5 gpm.  Again, 




Figure 5.  Plug flow occurring in 
the fluidized bed. 
5. Repeat this until you reach 30 gpm.  Now, increase the intervals to 10 
gpm.  If you notice plug flow, bubbling, or channeling in the fluidized bed, 
record the flow rate and pressure drop, but make a note of the 
phenomenon that occurred.  Also, it might be necessary to check on the 
air pressure periodically during the experiment.  You should make sure 
this is done before taking any measurements. 
6. Once you have taken the pressure drop and bed height at the maximum 
flow rate of air, bring the flow rate back down to zero.  
7. Complete the same steps as above, but now using an air pressure of 100 
psi.  You may use the tables below to record your data, but you should 












Table 2. Empty data table for recording pressure drop at an air pressure of 60 psi and bed 
expansion in the fluidization lab  
Air Pressure of 60 psi 
Flow Meter Reading 
(gpm) 
Pressure Drop (in H2O) 
Bed Expansion 
(inches) 
0   
5   
10   
15   
20   
25   
30   
40   
50   
60   
70   
80   
90   
100   
 
Table 3. Empty data table for recording pressure drop at an air pressure of 60 psi and bed 
expansion in the fluidization lab 
Air Pressure of 100 psi 
Flow Meter Reading 
(gpm) 
Pressure Drop (in H2O) 
Bed Expansion 
(inches) 
0   
5   
10   
15   
20   
25   
30   
40   
50   
60   
70   
80   
90   









1. Based on your results, what was the point of minimum fluidization (the 
point where fluidization was first noticed) for both of the data sets?  What 
does this tell you about air pressure when it comes to minimum 
fluidization?  Does this mean that air pressure is a negligible variable 
when it comes to fluidization?  Why or why not? 
 
2. You will make a graph of the air flow rate versus the bed height (this 
means that the air flow rate is on the x-axis and the bed height is on the y-
axis) for both of the air pressures.  Using the graph, determine when the 
bed goes from behaving as a packed bed to a fluidized bed.   
 
3. Prepare a fluidization graph.  A fluidization graph is obtained by plotting 
the air flow rate versus the pressure drop.  When you make these graphs, 
there will be a change in the slope at a certain point.  This point is known 
as the point of minimum fluidization.  At this point, the bed of solids 
changes from behaving like a packed bed to behaving like a fluidized bed.  
Label where you believe this point is on the graphs you made.  Also label 
what sections of the graph model the packed bed behavior and fluidized 
bed behavior. 
 
4. For this experiment, we have delved into some of the properties of fluid 
mechanics, a branch of science that deals with the properties of fluids and 
some of the phenomenon that occurs when they are placed under certain 
conditions.  One of the first variables you will learn in fluid mechanics is 
known as the Reynolds Number, a dimensionless quantity that is used to 
determine a flow regime.  Today you will determine the Reynolds number 
of the system at minimum fluidization.  To do this, you will use the 
following formula: 
 
    
       
 
 (1)  
a. The Reynolds Number is considered a dimensionless quantity.  








   = Average diameter of the particle (m) 
    = Velocity of minimum fluidization (m/s) 
   = Density of the gas (kg/m
3) 




Figure 6.  A few fluid regimes of fluidized beds.  





b. Find the Reynolds number for the minimum fluidization point for 
both of your experimental runs. To help you in the calculation of this 
number, use the following values2,3,4: 
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In addition, determine which of the fluidization regimes the fluidized 







5. The following fluidization data was collected using kaolin powder with the 









Table 4. Fluidization data using kaolin powder at an air pressure of 60 psi 
GPM Bed Height (in.) ΔP (psi) 
0 5.00 0.0 
5 5.00 0.5 
10 5.00 1.8 
15 5.50 1.8 
20 5.75 2.4 
25 5.75 2.4 
30 6.00 2.5 
40 6.00 2.8 
50 6.50 3.2 
60 6.50 3.6 
70 6.50 3.8 
80 6.75 4.1 
90 6.75 4.2 
100 6.50 4.6 
 
 
a. Create a flow rate versus bed height graph and a flow rate versus 
pressure drop graph. 
b. Determine if there is a point of minimum fluidization using the 
graphs. 
c. If you could determine a point of minimum fluidization, determine 
the Reynolds number at that point.  If not, find the Reynolds 
number at the same point you used for Question 4.  Use an 
average particle diameter of 1.4 µm for this problem.6  
 
6. Now, we will go over another important tool for engineers; design 
equations.  Design equations are used by engineers to determine 
information about a process without having to do extensive 
experimentation.  These equations are usually based on data obtained by 
research.  For example, the following equation can be used to determine 
the Reynolds number at minimum fluidization7: 
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Where Ar (Archimedes Number), C1, C2, are shown below: 
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 (5) 
Where: 
   = Average diameter of the particle (m) 
   = Density of the gas (kg/m
3) 
   = Particle density of the excipient (kg/m
3) 
  = Acceleration due to gravity (9.81 m/s2) 
  = Dynamic viscosity of the gas (Pa*s) 
 
In order to use the equations above, you will need to determine the 
porosity at minimum fluidization (εmf).  This can be a difficult characteristic 
to determine, which is why many researchers have come up with different 
constants to approximate the porosity.8 However, we have enough 
information to determine εmf, so we will solve for C1 and C2. 
To determine εmf, we first need to know the normal porosity, ε.  This can 
be determined by using the bulk density (ρb) and the particle density (ρs): 




We also have to determine the total volume (Vtot).  For this, use the bed 
height at the 0 gpm air flowrate, and multiply by the cross-sectional area of 
the bed.  Now, we can determine the void volume (Vv) using the following 
equation: 
    
  
    
 (7) 
Now, to determine the volume occupied by the particles (Vp): 
             (8) 
From here, we now need to use the point of minimum fluidization to 
determine the volume (Vmf).  This can be done by using the bed height at 
the point of minimum fluidization and the cross-sectional area.  Using Vmf, 
you can determine the void volume at minimum fluidization (Vvmf): 






Finally, determine εmf: 
      
    




a) Determine εmf for the Avicel
® trial at the air pressure of 60 psi. 
b) Determine the Remf using Equation (2) for the same conditions as part 
a). 
c) Calculate the percent difference between your answer for part b) and 
the answer you obtained in Question 4. 
 
           
  
|       |
(
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      (11) 
 
d) You should notice a considerable (>10%) difference in part c).  This is 
because you are using superficial velocity, as opposed to interstitial 
velocity.  Superficial velocity is defined as the theoretical flow through 
the bed based on the flow rate of the liquid divided by the cross 
sectional area of the tube.  Interstitial velocity takes into account how 
the flow is affected by the volume occupied by particles.  Interstitial 
velocity is the flow velocity post a particle, and is the “correct” velocity 
to use in the Remf equation.  To determine the interstitial velocity (vi): 
     
   
      
 (12) 
Where: 
    = volumetric flow rate at minimum fluidization (m
3) 
   = cross sectional area (m
2) 
    = porosity at minimum fluidization (dimensionless) 
 
Determine vi, calculate a new Re as in Question 4, and then compare 
as in part c). 
 
7. It is important to learn how to use the online library tools that you have 
available.  These online tools have thousands of scientific papers and 
articles in databases that you have free access to.  Using one of the 
scientific online resources (i.e. Science Direct, SciFinder, etc.) available, 
you and your lab partners will find an article online about pharmaceutical 
manufacturing practices.  Try to find an article that also discusses either 




prepared to discuss the article in class.  NOTE:  It is all right if you do not 
understand all of the technical details of the paper, but you should have a 
good understanding of the overall concept being discussed. 
In addition, use the MSDS’s that you obtained as part of your pre-lab and 
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OBJECTIVES 
 Students will learn about 
intrusive laboratory 
experiments 
 Students will gain experience 
in reverse engineering 
strategies and project designs 
 Students will conduct a basic 




ADVAIR® is a dry powder inhaler prescribed to patients with asthma and chronic 
obstructive pulmonary disease that uses two active pharmaceutical 
ingredients.  Fluticasone propionate, one of the two, is a corticosteroid, which is 
used to reduce the inflammation of the lungs.  Salmeterol xinofoate, the second, 
is a bronchodilator, which relaxes the muscles in the airways to help improve 
breathing.1  
 
ADVAIR® is not only used as an option for people with asthma, but also can be 
used as a maintenance treatment for chronic obstructive pulmonary disease.¹ 
Chronic obstructive pulmonary disease (COPD) is a disease that makes it difficult 
to breathe.  It also takes the form of chronic bronchitis, causing a long-term 
cough with mucus, and emphysema, which destroys the lungs over time.  Most 
sufferers of COPD have a combination of the two symptoms.² Asthma occurs 
when the airways of the lungs tighten and narrow, which leads to wheezing, 
shortness of breath, coughing, and a tightening in the chest.³ 
 
ADVAIR® comes in three varieties: ADVAIR DISKUS® 100/50; ADVAIR DISKUS® 
250/50; ADVAIR DISKUS® 500/50.  The three varieties of ADVAIR® have 
different amounts of fluticasone propionate in the powder.  For example, in an 
ADVAIR DISKUS® 100/50, there will be 100 μg (micrograms) of fluticasone 




propionate and 50 μg of salmeterol.  The 250/50 prescription of ADVAIR® is used 
for COPD treatment.¹ 
 
In this lab, the teams will be examining an ADVAIR DISKUS®, and conduct an 
invasive reverse engineering experiment on the diskus.  They will then compare 
the dry powder inhaler to two other types of inhaled medication transport 
systems; a nasal spray and a traditional metered dose inhaler.  The goal is to see 
the difference in the transport process that each system uses, and to also see if 
there is any way to improve the design of the diskus.  A quality control study on 
the packaging of powder in the ADVAIR DISKUS® is also provided.  This will 
include an average and a standard deviation of the powder packages. 
 
MATERIALS NEEDED 
● ADVAIR DISKUS® 
● Small flathead screwdriver 
● Analytical scale (able to read at least 1/10,000g) 
● Albuterol metered dose inhaler (or suitable substitute) 
● Fluticasone propionate nasal spray (or suitable substitute) 
● Narrow-headed spatula 
● KimWipes 
● Weigh boats 
 
SAFETY CONSIDERATIONS 
All students should know that laboratory 
gloves and eyewear must be worn at all 




PART I - REVERSE ENGINEERING 
1. Open up the diskus box and 
remove the information packets.  
Make general observations on the 
diagrams and information included. 
2. Remove the inhaler from the 
tinfoil package.  Based on its outside 
appearance, how do you think it 
works?  Sketch the diskus.  
3. With the flathead screwdriver, 
proceed to remove the outer shell of Figure 3: Proper removal of mouthpiece 




the inhaler.  Be careful to not break or shatter any plastic. 
4. Insert the screwdriver under the mouthpiece and use it as a lever to 
dislodge the mouthpiece. 
5. Along the outside 
circumference of the diskus you 
will notice several slots and tabs 
that hold each half of the inhaler 
together.  One by one, carefully 
depress each tab and pry the 
inhaler open.   
6. This should expose the 
inside of the inhaler.  Make 
observations on its appearance 
and the gears.  Sketch the 
inside of the diskus. 
7. Pull the lever down and reset it a few 
times.  Discard the powder inside the 
blisters.  Note how the gears move.  Based 
on this, do you have any other ideas as to 
how the inhaler works?    
8. Remove the foil strip.  It will be stuck 
at one part after the foil has been split in 
half.  Cut this section away to fully remove 
the rest of the foil strip.  
9. The large white plastic mold that the 
foil fits into can be removed.  Look for white 
tabs interlocking with the purple exterior 
shell by the mouthpiece.  Push these tabs 
in to remove the white mold. 
10. At this point, the gears should be 
fully exposed.  Move the lever up and 
down.  Was your hypothesis as to how the 
diskus worked correct?  If not, what is 
actually happening? 
11. Set the diskus aside and look at the aerosol inhaler and nasal 
spray.  Compare and contrast these methods of asthma drug delivery to 




Figure 5: Inside the Diskus 
















PART II - QUALITY CONTROL/MEASUREMENT 
You may wish to place your findings in the table found in the RESULTS section 
of this experiment, but you should also record them in your laboratory notebook. 
 
ADVAIR® Quality Control 
1. Take the foil strip that was previously removed over to a weighing 
station that has a precise analytical scale. 
2. Place a weigh boat on the scale and tare the instrument.   
3. Remove the boat and pull back the foil strip exposing the powdered 
drug in one blister.  Carefully empty its contents into the weigh boat using 
a spatula to scrape off any remaining powder. 
4. Place the boat back on the scale and record the result.  Tare the 
scale once again so the powder does not have to constantly be thrown out 
in between measurements.  Repeat this nine more times so that the 
weights of ten blister packs have been recorded. 
5. After all measurements have been taken, dispose of the boat and 
powder in the trash. 
6. Reassemble the diskus and place it back in the box along with 
included pamphlets.     
 




Figure 8: Proper removal of medicine from blister pack  
 
Metered Dose Inhaler Quality Control (See Figure 9 for proper techniques for this 
section) 
1. First, take a weight boat, and place it on the analytical scale. 
2. Now, take a KimWipe and fold it until you have a small rectangle that will 
fit over the end of the metered dose inhaler.  Place this folded KimWipe in 
the weigh boat, and then zero the analytical scale. 
3. Take the metered dose inhaler, and shake well.  Remove the KimWipe 
from the weigh boat, and place on the end of the inhaler where the 
propellant will exit. 
4. With the KimWipe on the end of the inhaler, press down on the canister 
section of the inhaler, allowing the propellant to exit the inhaler and the 
KimWipe to capture it. 
5. Quickly place the Kimwipe back on the weigh boat and take a mass 
measurement. (This may be difficult as the excipient, which acts as a 
propellant, will evaporate.)  Take the measurement once the scale stays 
on the same value for at least a second. 
6. Dispose of the KimWipe.  Repeat steps 2 to 5 with fresh KimWipes until 
you have ten mass measurements. 
Nasal Spray Quality Control (See Figure 9 for proper techniques for this section) 
1. Once again, take a weight boat, and place it on the analytical scale. 
2. Now, take a KimWipe and fold it.  Place this folded KimWipe in the weigh 
boat so that it covers the bottom and most of the sides of the weigh boat. 





3. Take another KimWipe or a paper towel and fold several times.  Take the 
nasal spray and shake.  Prime the device by spraying it a few times into 
this second wipe. 
4. With the spray primed, take the weigh boat off the scale, and place on a 
slightly downward angle. Spray the propellant into the weigh boat once. 
5. Place the weigh boat back on the scale and take a mass measurement.  
6. Dispose of the KimWipe.  Repeat steps 2 to 5 until you have ten mass 
measurements. (Step 3 may not need to be repeated every time, but once 
every 2 to 3 measurements.) 
 
 
Figure 9:  Different examples of the correct technique for metered dose inhaler (MDI) and 
nasal spray quality control measurements.  a) The folding of the KimWipe before taking a 
mass sample of the MDI.  b) The MDI cartridge being pushed down so that the medicine 
will be ejected into the KimWipe, and a mass measurement taken.  c) The lining of a 
KimWipe on the bottom of a weigh boat far nasal spray mass measurements.  d) Priming 
the nasal spray apparatus before taking a mass measurement.  e) Taking a mass 
measurement using the nasal spray. 
 
RESULTS 
Make sure that the students record all results in a lab notebook, and that all 
members of the teams receive the data.  These results can be placed in the table 
below and turned in along with solutions to the questions below.  Questions were 




Table 1.  Empty data table for collecting data in the Asthma Drug Delivery laboratory 
experiment 
Diskhaler Trial Mass (g) MDI Trial Mass (g) Nasal Spray Trial Mass (g) 
1  1  1  
2  2  2  
3  3  3  
4  4  4  
5  5  5  
6  6  6  
7  7  7  
8  8  8  
9  9  9  




















1. Compare and contrast the different styles of drug delivery that you 
examined in part I.  Which of these systems did you think had the most 
appeal?  Which do you think will work the best? 
 
2. When comparing the MDI and the nasal spray, which of the two has a 
higher standard deviation?  Compare all three standard deviations.  
Determine the highest and the lowest standard deviation.  Explain what 
these results imply about the quality control measures of the three 
devices. 
 
3. What were some sources of error in part II?  How do you think you could 
fix some of these problems? 
 
4. Based on the average weight of the blisters, what percentage of the 
powder are active pharmaceutical ingredients (API’s) and what 
percentage is inactive?  Assume that the amount of active ingredient from 
each sample is equal to the amount stated in the prescription dosage. 
The formula for finding the percentage of inactive ingredients is as 
follows: 
          (
      
   
  ∑    
      
   )        
(1)  





From this, find the percentage of active ingredients. 
5. Do you think that the assumption made for problem 4 was a valid 
assumption to make?  Why or why not? 
 
6. The Advair dry powder inhaler, as described in the introduction section, 
contains two active ingredients, fluticasone propionate and salmeterol 
powder.  There is one other ingredient listed on the label, lactose. 
a. What is lactose? Where else is lactose commonly found? 
b. Why would lactose be used in the inhaler?  What type of excipient 
should it be considered? 
c. What are some negatives of using lactose? 
Be sure to site all references. 
 
7. All metered dose inhalers (MDIs) need a propellant.  A propellant makes 
up almost 99% of the dose of an inhaler.  The propellant must have 
specific properties.  Some of these include the boiling point, solubility of 
the API, toxicity and others.  The API is suspended in the propellant and 
when the medication is dispensed the propellant creates an aerosol cloud, 
that the medication can be inhaled by the patient.4 
a. What is a CFC? 
b. Why are CFCs no longer used as propellants in inhalers? 
c. What type of propellant is used in the Ventolin inhaler?  Which type 
of propellant did it replace? 
d. Compare the two propellants.  Why do you think they replaced the 
propellant? 
Be sure to cite all references. 
REFERENCES 
1. GlaxoSmithKline.  “Highlights and Full Prescribing Information for ADVAIR 
DISKUS.”  January 2011. http://us.gsk.com/products/assets/us_advair.pdf 
2. United States National Library of Medicine. "Chronic Obstructive 
Pulmonary Disease."  May 
2011.  http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001153/ 
3. United States National Library of Medicine.  “Asthma.”  July 
2012.  http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001196/ 
4. Noakes, T. Medical aerosol propellants. The Journal of Fluorine 




Figure 1.  The energy strips you 
will be using in class. 
A.4 Degradation of Dissolvable Strips Lab 
Degradation of Dissolvable Strips 
Developed by:  Alex Jannini, David Krause, Heather Malino and Kevin Sweeney, 
Rowan University, Department of Chemical Engineering 
Edited by:  C. Stewart Slater and Mariano Savelski, Rowan University, 
Department of Chemical Engineering 
Date of Experiment: 
 
OBJECTIVES 
 Students will learn about mass transfer and degradation rates of drug 
delivery films 
 Students will learn how to properly operate a spectrophotometer 
 Students will determine the effect of temperature on this process 
INTRODUCTION 
In 2000, the pharmaceutical company Pfizer 
introduced a new over-the-counter product for 
the treatment of bad breath.  This product 
came in a novel form that was not seen before; 
a small, orally dissolvable strip.  This product 
revolutionized the industry, generating roughly 
250 million dollars in sales.  By 2002, many 
other brands of dissolvable strips were also on 
the shelves.1 In 2011, the energy supplement 
industry also saw the potential profits of 
sheets.  One company, known as Sheets, 
introduced a caffeine based strip which they 
claim has zero calories, zero sugar, and has 
the same caffeine as one cup of coffee, shown 
in Figure 1.  The brand also states that 
negative side effects, such as a “crash,” are not common when taking the 
product.  Although the company has faced controversy, especially with the 
endorsement of LeBron James, Sheets continues to make energy supplement 
strips.2 
While the use of dissolvable strips is a relatively new delivery method, it has 
become a popular method of drug delivery.  In fact, many other fields of over-the-
counter pharmaceutical products have introduced dissolvable strip products.  
Dissolvable strips that contain medicines for flu and sinus infection symptoms 




With dissolvable strips, the delivery vehicle is a thin, flexible sheet of polymer.  
The active pharmaceutical ingredient (API) is incorporated into this polymer to 
form the final product.  Depending on the nature of the medicine, the API can be 
incorporated in one of two ways; either through liquid dissolution or solid 
suspension in the polymer.  The size and thickness of these strips is dependent 
on the dosage of API that needs to be delivered.3 
In this experiment, you will investigate the dissolution and degradation rate of a 
dissolvable strip that contains menthol.  You will be using a spectrophotometer to 
take absorbance readings.  These absorbance readings will then be used to find 
the amount of menthol that was released from the strips.  You will also be 
comparing these rates for two different temperatures; ambient, otherwise known 
as room (roughly 20°C), and body (37°C). 
MATERIALS NEEDED 
 2 Sheets™ brand Mint Boost dissolvable strips 
 2 petri dishes 
 2 timers 
 Incubator or oven capable of reaching and maintaining 37°C 
 Pair of tweezers 
 Deionized water 
 500 µL to 5000 µL pipette 





Laboratory gloves and eyewear must be worn at all times inside the lab.  Be sure 
to keep water away from the spectrophotometer. 
PROCEDURE 
1. Start by turning on the spectrophotometer and setting it to take 
absorbance readings at 630 nm. 
2. While the spectrophotometer warms up, place 2.5 mL of deionized water 
into each of the petri dishes. 
3. Place one of the petri dishes into the oven/incubator that is set at 37°C. 
4. Allow 20 minutes to pass so that the water may reach 37°C and the 




Figures 2 and 3.  From left to right, the proper (l) and 
improper (r) way to take a sample. 
5. After the 20 minutes 
have passed, fill a 
cuvette with 
deionized water and 
zero the 
spectrophotometer. 
6. Now that the 
spectrophotometer 
has been zeroed, use 
the tweezers to place 
a strip into one of the 
petri dishes.  Once 
the strip has been 
placed in the petri 
dish, cover and start 
the timer. 
7. Place the other strip in the other petri dish using the tweezers.  Once 
placed, close the petri dish and start a secondary timer. NOTE: It is a 
good idea to stagger the starting times so that you do not find yourself 
rushing to take two measurements.  It may also be a good idea if you are 
working in teams to split the team so that one section of the group is in 
charge of one specific temperature study. 
8. After five minutes have elapsed, take a sample of your water into a 
cuvette.  Make sure that this sample is relatively far from the dissolvable 
strip so that you do not accidentally pick up any large portions of the 
dissolvable strip, as in Figures 2 and 3. 
9. Take an absorbance reading then return the sample to the corresponding 
petri dish. 
10.  Take absorbance readings every five minutes for the first thirty minutes.  
After that, take absorbance readings every ten minutes until you have 
reached 90 minutes.  You may use Table 1, but you should also record 








Table 1. Empty data table to record absorbance at 630 nm data for the dissolvable strips 
laboratory. 
Time (min) 
Absorbance readings at 630 nm 
Room Temperature (20°C) 
Body Temperature 
(37°C) 
0 0 0 
5   
10   
15   
20   
25   
30   
40   
50   
60   
70   
80   
90   
 
11.  Once you have taken all the necessary measurements, make sure to turn 
off the spectrophotometer and the incubator/oven. 
12. Dispose of all equipment used in this lab, and make sure that any water 
spills were cleaned up before exiting the laboratory. 
RESULTS 
Be sure to record all the data you collected in this experiment into your laboratory 
notebook.  If you split into two groups to complete this experiment, be sure that 
you share the data sets. 
DATA ANALYSIS 
To analyze the data, the best method is to create a graph of the time versus 
absorbance reading.  In this case, the x-axis will be the time axis and the y-axis 
will be the absorbance axis.  Create one of these graphs using Excel or another 
program and turn it in along with the rest of your laboratory report. 
QUESTIONS 
1. Now, you will take your absorbance readings and figure out the 
concentration of menthol in your solutions.  You will do this using the 
following graph, which correlates absorbance at 630 nm to concentration 
in mg/mL.  Once you have the concentrations, create another graph of 




Table 2.  Make a copy of this table and turn in along with the rest of the 
deliverables for this experiment. 
 
 
Table 2. Empty data table for recording concentrations in the dissolvable strips laboratory. 
 
2. Now that you have found the concentration of the solution over time, you 
will need to use concentration and absorbance readings to determine the 
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molar absorption coefficient, is defined as how strongly a substance 
absorbs light at a particular wavelength4.  This coefficient is seen in the 
Beer-Lambert Law, an important law that governs the absorbance of light.  
This law is shown below: 
 




             (             ) 
                               
                                                      (  ) 
                                              ( ) 
 
a) Use one of the higher time points (70 to 90 minutes) of both the 
room temperature and body temperature experimental runs to 
determine the molar absorption coefficients of both runs.  Use the 
following constants to help you in this calculation. 
 
       
                         
 
   
 
 
b) Based on the values, do you think that the temperature affects the 
molar absorption coefficient? 
 
 
3. Determine how well the molar absorption coefficients can determine the 
concentration of the solution based on absorbance readings.  Use the 
molar coefficients you previously found and determine the concentration 
that the solution should be at based on the Beer-Lambert Law.  Use a time 
point between 30 and 50 minutes in both cases.  Determine how different 
these two numbers are by using percent difference. The equation for 
percent difference is shown below.  In this case, the “E” terms are the 
molar concentrations.  It should be noted that percent difference is a 
dimensionless number.  Make sure you do all the necessary unit 
conversions before calculating the percent difference.  
                   
|     |
(
     
 )




4. It is known that the molar absorptivity coefficient of the blue food dye used 





a) How different is the molar absorptivity coefficient that you found 
using your experimental data from this known value?  Use 
experimental error to determine this difference.  The equation for 
percent error is shown below. 
 
 
               
|   |
 
      
(3) 
 
Here, the “E” term is the molar absorptivity coefficient obtained 
through the experimental data, while the “A” term is the molar 
absorptivity coefficient given to you above.  It should be noted that 
when using this equation, the two terms need to be in the same 
units. It should be noted that percent error is also a dimensionless 
number. 
 
b) Now, use the same time point that you used in Question 6 and 
determine the concentration based on the given molar absorptivity 
coefficient.  Again, compare using percent error.  Do this for both 
experimental runs.  Here, the “E” term will be the concentration that 
you obtained during experimentation, while the “A” term will be the 
concentration that you obtained using the given molar absorptivity 
coefficient.   
 
5. The Beer-Lambert Law is one of the most important laws used in 
spectroscopy (the interactions between light and matter).  How could you 
use this law in an engineering aspect? 
 
6. Now, we will discuss a rate law.  A rate law, or rate equation, is an 
equation that governs the rate of a process as a function of a variable, 
such as time.  These laws are used by engineers to determine the design 
of a chemical process.  Rate laws applied to this experiment relate 
absorbance with time.  For example, an important variable of a rate law, 
the rate coefficient/constant (k), can be determined using absorbance 
data.  This can be done using the following equation: 
  
  
(    )
(     )










A Absorbance at time t 
A0 Absorbance at t=0 
A∞ Absorbance at t=∞ 
k Rate coefficient 
  
a) Determine the rate coefficient from your absorbance data.  To do this, 
you will need to determine A∞ based on your data.  Use a point earlier 
in your experiment, and determine a rate coefficient for both sets of 
data. 
b) Based on these results, does temperature affect the dissolution rate?  
Use the rate constant values you obtained to verify your answer.  
 
REFERENCES 
1. InnovateUs, Inc. “What are Breath Strips?” 
http://www.innovateus.net/health/what-are-breath-strips. 
2.  Donaldson James, Susan.  “Sheets Give Caffeine Jolt, Potential for 
Abuse.” ABC News. 10 June, 2011. http://abcnews.go.com/Health/lebron-
james-shills-sheets-caffeine-strips-bad-
idea/story?id=13805037#.UeWj2m1nA6e. 
3. Particle Sciences Drug Development Services.  “Dissolving Films.”  2010. 
Volume 3. 
4. Biology Online.  Molar Extinction Coefficient.  Biology Online.org.  22 June 
2008.  Accessed 11 September 2013.  http://www.biology-
online.org/dictionary/Molar_extinction_coefficient. 
5. Reeves, J.  Beer’s Law.  Laboratory for science majors at The University 









A.5 Effervescence Reaction Lab 
Effervescence Laboratory Experiment  
Developed by:  Alex Jannini, David Krause, Heather Malino and Kevin Sweeney, 
Rowan University, Department of Chemical Engineering 
Edited by:  C. Stewart Slater and Mariano Savelski, Rowan University, 
Department of Chemical Engineering 
Date of Experiment: 
 
OBJECTIVES 
 Students will perform a basic mass balance on an effervescence reaction 
in pharmacology 
 Students will conduct theoretical stoichiometric calculations and compare 
to experimental results  
 Students will learn about the equilibrium constants and other fundamental 
aspects of reactions 
 
INTRODUCTION 
Alka-Seltzer® is an effervescent 
antacid (NaCO3, KCO3 plus 
anhydrous citric acid) containing 
acetylsalicylic acid (aspirin), which is 
an analgesic, antipyretic, and anti-
inflammatory drug.  Simply put, Alka-
Seltzer® relieves upset stomach, 
provides pain relief, breaks fevers, 
and reduces inflammation.  
The effervescence allows for a faster rate of drug 
dissolution into a liquid medium (water in this 
case) by increasing the surface area of the drug 
exposed to solution and by “bubbling” the mixture, 
causing a stirring effect.  The effervescence 
reaction is: 
 C6H8O7(aq) + 
NaHCO3(aq) → H2O(l) + 




Figure 1. Standard original strength packet 




In this lab you will determine how much CO2 is generated and released to the 
atmosphere by taking the initial and final weights of an Alka-Seltzer® solution.  
This is an introduction to mass balances, an important concept for engineers.  
This experimental value will then be compared to the theoretical amount of CO2 
mass generated, found through stoichiometry.   
MATERIALS NEEDED 
 2 Alka-Seltzer® tablets (1 packet) 
 Analytical scale (+/- 0.0001 g) 
 Weigh boat 
 Graduated cylinder 




1. Make sure safety glasses and examination 
gloves are on before entering the lab. 
2. Remove both Alka-Seltzer® tablets from the 
packet.  If the tablets are broken, be careful to 
not lose any pieces.  How do you think a 
broken tablet will affect the rate of the tablets 
dissolving? 
3. Place a weigh boat on the scale.  Tare the instrument so it calibrates to 
zero with the added weight of the boat. 
4. Weigh the Alka-Seltzer® tablets and record in your notebook.  
5. Alka-Seltzer® is supposed to be dissolved in 4 oz. (118.3 mL) of water 
according to the manufacturer’s directions.  Using deionized water, 
measure out this volume of water with a graduated cylinder and add it to 
the beaker. 
6. Weigh the beaker plus the added water and record it in your notebook.  
This weight plus the weight of the Alka-Seltzer® tablets is your initial 
weight. 
7. Drop both tablets into the beaker. 
8. For the first five minutes, take a weight every 60 seconds.  After five 
minutes have passed, measure the weight every five minutes until an hour 
has elapsed.  Tap the bubbles off of the sides of the beaker as they form. 
9. Dispose of the solution down the sink.  
 
PART II 
10. Fill the beaker back up with the same amount of deionized water and 
weigh the water and the beaker. 





11. On a weigh boat, measure out 2.0 g citric acid and 3.832 g sodium 
bicarbonate. 
12. Drop the powder into the beaker and record weights at the same time 
intervals as Part I. 
13. Dispose of the solution down the sink and clean up the lab area. 
 
QUESTIONS 
1. Fill in the tables: 
 
 
1. You should notice that the initial weights of the two solutions are different.   
a. What may cause this? 
b. To fix this, take the difference between the two sets, find the 
difference between the two initial points.  This difference will need 
to be subtracted from the solution with the higher weights.  Find the 









Adjusted Weight Time 
Initial:   0 m 
 
  1 m 
 
  2 m 
 
  3 m 
 
  4 m 
 
  5 m 
 
  10 m 
 
  15 m 
 
  20 m 
 
  25 m 
 
  30 m 
 
  35 m 
 
  40 m 
 
  45 m 
 
  50 m 
    55 m 
Final:   60 m 
 
c. Please graph the revised data set along with the other set that was 
not changed. 
 
2. Determine the experimental amount of CO2 generated and released to the 
atmosphere by subtracting the initial weight from the final weight. 
 





4. According to the manufacturer’s website, each tablet contains 1000 mg of 
citric acid and 1916 mg of sodium bicarbonate.  Determine the moles of 
each reactant. 
 
5. Determine which reactant is the limiting reactant.  What is the percent 
excess?  Why do you think there is extra added? 
 
6. Using the effervescence reaction given in the beginning of the lab, 
determine the moles produced of CO2 gas. 
 
7. How many milligrams of CO2 were made in both reactions? 
 
8. What is the theoretical final weight of each solution?  Use the weight of the 
beaker and water measured in the lab. 
 
9. Determine your percent error at each point with the given equation: 
 
       (
(                     (             
                    
             ))
                   





10. What were some sources of error in this lab? 
 
11. Was there if a difference in the way the pure components dissolved versus 
the tablets?  Why do you think they behaved the same/differently?  It is 
known that Alka-Seltzer tablets use a milling process to reduce the size of 
their powder.1 Do you think that the use of milling the powders when 
forming the tablets adds into the difference in behavior? 
 
12. What is a different way that this experiment can be designed so that the 
gas released could be directly measured? 
 
13. In reaction engineering, it is important to understand the mathematics 
behind chemical reactions.  One of the important concepts is the reaction 
rate of a chemical reaction.  This reaction rate determines how many 
moles of a reactant are being converted to a product over a period of time.  
The rate of reaction is commonly symbolized by rA.  The  basic equation of 
the rA is: 
      [  ]
  (4) 
 
Where k is the rate constant and CA is the concentration of the limiting 
reactant in a chemical reaction.  This is also known as a rate law.  A rate 
law can be linear or nonlinear in regards to the concentration.  In most 




(x=2).  Now, you will determine the rate constant and order of the rate law 
for a sub-reaction that takes place in the effervescent reaction. 
 
This sub-reaction is the formation of bicarbonate to carbon dioxide: 
     
     
            (5) 
 
In this reaction, the limiting reactant is the bicarbonate ion.  To determine 
the concentration of the bicarbonate ion (     ), we can use the following 
equation. 
        
              
         
           
 (6) 
We can assume that all the sodium bicarbonate breaks down to sodium 
ions and bicarbonate ions, giving us the initial moles of bicarbonate ions. 
a. Using the data you collected, determine the moles of CO2 
generated at each time point, and use that to determine the 
concentration of bicarbonate ions at each time point.  Once this is 
done, make graphs of the following:        vs. time, ln(     ) vs. 
time, and 1/      vs. time.  Determine which one is a linear 
relationship, and print out that graph.  Do this for both sets of data. 
b. The rate constant can be found by determining the slope of the 
linear relationship.  Find the k for both sets of data. 
c. Now, determine the order of both sets of data.  As a reminder; a 
zero-order reaction will be linear for concentration vs. time; a first-
order reaction will be linear for ln(concentration vs. time;  a second-
order reaction will be linear for 1/concentration vs. time. 
d. Do the orders match for the tablet and raw ingredients?  What 
about the k values? 
 
REFERENCES 
1. H. Phykitt, "Analgesic Composition and Method of Making the Same". 





A.6 Dextromethorphan Crystallization Lab 
Dextromethorphan Crystallization Laboratory 
Developed by:  Alex Jannini, David Krause, Heather Malino and Matthew Van 
der Wielen, Rowan University, Department of Chemical Engineering 
Edited by: C. Stewart Slater and Mariano J. Savelski, Rowan University, 
Department of Chemical Engineering  
Date of Experiment: 
 
OBJECTIVES 
 Students will develop a solubility curve for dextromethorphan.  
 Students will gain an understanding of the techniques of crystallization 
and how it is used in the pharmaceutical industry. 




A crystal is defined as a solid material whose atoms, molecules, or ions are 
arranged in an ordered pattern in three dimensions.  Crystallization is the 
process by which solid crystals precipitate out of a solution.  After the 
precipitation occurs, there will be a solid phase and a liquid phase in the solution.  
Then, the solution will be filtered to separate the two phases.  Sometimes the 
solid phase is the desirable phase while other times the liquid phase is desired. 
Crystallization is a commonly used method of separating solid-liquid solutions in 
industry.  Crystallization has been utilized in many different processes for 
decades.  For example, many commodity chemicals like xylene and inorganic 
salts such as sodium chloride are formed using crystallization1.   
 
In more recent years, crystallization is used in the pharmaceutical industry.  The 
most common reason for using crystallization in the pharmaceutical industry is to 
obtain a high purity active pharmaceutical ingredient (API).  In the case of vitamin 
C purification, crystals are formed in either an aqueous or alcohol based media 
and then filtered out of solution2.   
 
One of the tools used in designing crystallization processes is the solubility 
curve.  A solubility curve can be used to determine the saturated concentration of 
a solution of solids in a liquid.  An example solubility curve is shown on the next 
page.  The solubility curve is usually based on the concentration of solid in the 
solution and the temperature of the solution.  In most cases, solubility curves are 
made with a solute in a solvent.  In this lab, you will be making a solubility curve 








Dextromethorphan (DXM) is the active pharmaceutical ingredient (API) in several 
cough syrups.  Dextromethorphan is a strong antitussive agent.4 It is often found 
as a monohydrated hydrobromated salt.  This means that one molecule of HBr is 
attached to the dextromethorphan crystal. It belongs to the morphine group of 
alkaloids.  A typical amount of dextromethorphan in one dose of cough medicine 
is approximately 15 mg.     
 
SAFETY AND CONSIDERATIONS 
Safety googles must be worn at all times in the lab.  Gloves should also be worn 
during this experiment.  When working with the powder, a dust mask should be 




















































 Dextromethorphan HBr (one lab that contains 6 groups of students will 
need approximately 30 grams) 
 Citric Acid, Anhydrous (one lab that contain 6 groups of students will need 
approximately 180 grams) 
 Analytical scale (capable of reading 10-3 grams) 
 Weigh boats 
 14 test tubes 
 Test tube rack 
 1 large (approximately 800 mL or higher) beaker 
 Heat/stir plate 
 Stir bar 
 2 thermocouples with rod attachments 
 Large graduated cylinder (1000 mL) 
 5mL micropipette 
 Sharpie® or marking pencil  
 Ring stand with test tube clamp 
 
PROCEDURE 
PART 1:  DXM  
For time limitations, divide the lab up so that half the team completes steps 1-2 
while the other half of the group completes step 3-6. 
1. Using the marking pencil or Sharpie®, number 7 test tubes and place them 
into a test tube rack. 
2. Using the analytical scale, measure the dextromethorphan and prepare 
the test tubes as indicated below:  
 









Tube #7 is a choice. You may choose any value (other than 600 mg) to 
place in this vial.  Make sure to record this number. 
3. Note the maximum volume of the large beaker.  You will need to fill the 
beaker ¾ of the way full.  Use the large graduated cylinder in order to 
precisely measure the amount of water you add to the beaker.  Record the 
volume of water that you added to the beaker.  
4. The beaker that you filled with water will be used as a hot water bath. 




Figure 2.  Proper setup of a test 
tube in the hot water bath. 
Figure 3.  The 




Figure 4.  The 
DXM and water 
solution once 
crystallization has 
begun.  Notice the 
white substance 
at the bottom of 
the tube. 
beaker. Place the heat control setting somewhere in the middle, and set 
the stir setting to the lowest possible setting.   
5. Place one of the thermocouple rods in 
the water.  The water bath needs to stay 
within 80 to 90 °C, which is the 
temperature suitable for dissolving all 
the DXM.  This will require supervision 
and maintenance. 
6. Now, setup the test tube clamp on the 
ring stand so that the clamp is just 
above the beaker.  
7. Once you have measured out the 
masses of DXM necessary, use the 
micropipette and place 5 mL of water in 
each of the test tubes. 
8. Now, secure test tube #1 in the tube 
clamp, and place the second 
thermocouple rod in the tube.  Lower the 
clamp so that the test tube is as 
submerged as possible in the water 
bath.  
9. Stir the test tube with the rod of the 
thermocouple.  Keep stirring the 
solution until you see the DXM 
completely dissolve in the water.  
Loosen the clamp and remove 
the tube.  Use a test tube holder 
if the tube is too hot.  
10. Now hold the thermocouple in the 
solution. You may also need to 
wipe off the tube if there is 
excess condensation on the tube.  
Hold the test tube up to the light 
and examine the solution for the 
first signs of crystallization. 
Record the temperature 
immediately as crystallization 
begins in the data table. 
11. Repeat steps 8 through 10 for 
the other test tubes.  Record all 
data.  You may use the table 
below, but you should also 







Figure 5.  A screenshot of 
the graph you will need in 
Excel. 
RESULTS 
You may use the table below to record your data.  However, it is encouraged to 
also write your results down in your lab notebook. 














For this section, you will be using Microsoft 
Excel.  Once you have completed the lab and 
collected all the data, open up a new Excel file 
and place the data in a spreadsheet.  Now, the 
concentration that we have right now is in 
mg/5mL.  Change this to g/L.  Remember that 
there are 1000 mg per g and 1000 mL per L.  
 
Once this is done, we need to create a solubility 
curve.  To do this, we will be using the chart 
wizard.  In excel, go to the insert tab and chose to 
insert a scatter graph.  Look specifically for the “scatter with smooth lines and 
markers” option.  Create a scatterplot that has temperature on the X-axis and 
concentration on the Y-axis for the first six points of the data collected.  In 













   






Figure 6.  A screenshot of the “Major tick mark” option. 
 
Once this is done, change the chart layout so that you have titles for the x- and y-
axis.  This should be the first option in the chart layout section.  Once you have 
titles for the axes, label them accordingly.  Label the chart with your group 
number or the last names of your group members, and then delete the “Series 1” 
label. 
 
Once you have a chart, you will need to edit the x-axis.  To do this, click on the 
values on the x-axis.  You should see these values boxed.  Once done, right 
click, and click on the “Format Axis” option.  You should now see the Axis Option 
menu.  In this menu, look for “Major tick mark type.”  In the dropdown menu, 
select the inside option.  Once this is done, print out your graph.    Do the same 
thing for the citric acid data.  Make sure to print out that graph as well.  You will 
















1. Now that we have a graph, we can check the accuracy of it.  We will do 
this by using the random point that you collected during the procedure.   
a. We will check the accuracy of the graph through a process known 
as interpolation.  In interpolation, you determine a new data point 
that lies within data that has already been collected.  To do this, 
you will need a ruler.  First, determine the concentration of your 
unknown in grams/L.  Once you know that value, locate it on your 
chart.  If your concentration lies within two tick marks, you will need 
to use the ruler.  First, determine the length between the two tick 
marks.  Next, solve the following equation: 
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Once you have found the length between the concentration and the 
lower tick, mark that on your graph.  Once that is done, draw a 
straight line from this point to the line generated.  Then, draw a 
straight line down to the x-axis.  Now, you will have to determine 
the temperature this corresponds to.  Here, you will have to do the 
same thing that you did previously.  Determine the length between 
the tick marks on the x-axis, and then determine the length 
between the lower tick mark and the line you drew down.  Using the 
equation below, determine the temperature: 
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b. Now that we have the temperature obtained from interpolation, we 
will determine the percent error between the temperature obtained 
through part a. and the temperature obtained experimentally.  Use 
the following equation: 
 
         
|                             |
              
      
(3) 
 




2. Energy is required to heat the water bath to 90°C.  The most basic 
equation that models the energy required to heat the water from room 
temperature to 90°C is: 




Where “Q” is the energy required in J/g, “m” is the mass of water and “Cp” 
is the specific heat capacity of water. 
a. Using the specific heat as 4.18 J/(g * °C) and the density of water 
as 1.00 g/mL, determine the amount of energy required to heat the 
water to 90°C.  You may assume that the water was at room 
temperature (20 °C) before heating. 
b. If a tank in an industrial process needs to heat 200 gallons of water 
to 90°C, how much energy would be needed? 
 
3.  Whenever there is a flow of heat from one source to another, there is an 
exchange of energy.  This flow of energy is studied in the field of heat 




transfer; conduction.  Conduction can be defined as the transfer of energy 
from more energetic particles to less energetic particles due to their 
interactions.7 One important term in conduction is the thermal diffusivity of 
a substance.  The thermal diffusivity (represented from now on by the 
variable, α) measures the ability of a material to conduct thermal energy in 
relation to its ability to store thermal energy.7 To find α, we can use the 
following equation: 
 
    
 
   
 (5) 
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a. The term α is considered a dimensionless constant.  With the units 
provided, prove that this is so. 
b. Determine the thermal diffusivity of water at 25 °C and aluminum at 
25 °C.  Which is higher?  What does this tell you about the two 
substances in regards to the conduction and storage of thermal 
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] 
290 0.598 0.999 4.184 235 2708 0.868 
300 0.613 0.997 4.179 237  2702 0.903 
  
Obviously, you will need to use interpolation in order to obtain the 
correct data points.  Use a similar method as used in Question 1. 
 
c. Now, determine the thermal diffusivity for aluminum at 200 and 400 
K.  Use the following data below.  What does this tell you about the 
thermal diffusivity of aluminum in regards to temperature?  Do you 
think this is true for all temperature ranges?  Try with 400 and 800.  
Does this provide more insight into the thermal diffusivity of 





Table 2.  Thermophysical properties for water and aluminum at varying temperatures.  
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200 2719 237 
400 2681 240 
800 2591 218 
 
4. In simple heat transfer, we can model the flow of heat using one-
dimensional, steady-state conduction.  What this means is that we model 
the flow of energy as though it were in one direction at an unvarying rate.  
This allows us to model the flow of heat over a certain distance.  We will 
do this for the case of the test tubes we used in this experiment. 
 
First, we must show how to properly model this flow of heat.  Picture the 
test tubes used in this.  We will say that in the direct middle of the water 
will be the starting point.  Then, we will say that top of the water level 
(where water meets air) is the ending point.  So with these start and end 
points, we will be modeling the flow of heat from the middle of the test 








Table 3.  Thermophysical data for aluminum at varying temperatures.  Adapted from 
Incropera et al and Thermal Fluids Central.
7,8 
Figure 7.  A representation of the one-dimensional, steady-state conduction 




In order to model this, we need to make two assumptions: 1) that the heat 
flows at a steady-state (does not fluctuate over time) and 2) that all the 
sides except for the end point are perfectly insulated.  (NOTE: The other 
assumption that is made in order to use this model is that the surface 
temperature of the water is the same as the air temperature.  If this 
assumption is not made, the flow of heat from the surface via natural 
convection, or the natural flow of air on the surface of the water, needs to 
be taken into account.  This makes the model much more difficult; and as 
such, is eliminated from the model.) 
With these assumptions made, we can use the following equation to 
model the flow of heat from the starting point to the end point.  To do this, 
we can use the following equation to solve for the heat flow7: 
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Now, we will also say that half the volume of the water added to the test 
tube is in this specific space used for the model (2.5 mL).  Assuming that 
the water is a perfect cylinder, and that the test tube has an inner diameter 
of 0.55 in, you find all the information necessary to model this flow of heat. 
 
a. First, we will model this as though it were pure water.  Take the 
temperature of recrystallization you found for test tube #1 in your 
DXM experiments, and state that this is To.  T1 will be the 
temperature of the air (20 °C).  Determine the heat transfer rate if 
the thermal conductivity of water is at a weighted average of 0.58 
W/m*K. 
b. Now, we are going to find the thermal conductivity (k) for a mixture 
of the salts used in this experiment.  To do this, we will use a 
thermal conductivity approximation for salt solutions.  This is shown 
below9: 
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Make sure to use these units when using the calculation.  Again, 
use data obtained from test tube #1 for this.  For the temperature, 
determine the average between the air and the temperature of 
crystallization.  Determine the k value for DXM using this equation, 
then find qx using the equation from part a. 
c. Determine the percent difference between parts a and b.  Is there a 
considerable difference?  Which do you think is more accurate?  
Keep in mind that the thermal conductivity approximation you were 
given was developed using sea salt.  
d. In order to calculate this, we made two assumptions about the heat 
flow.  Can these assumptions be made for our experiment?  Why or 
why not? 
 
5. Citric acid is often used as a flavoring agent in pharmaceuticals.  The 
saturation point for citric acid in water is provided.  This is another way of 
showing the solubility of a substance, but with different units.  Instead of 
concentration in mass solute per volume solution, we give the 
concentration in mass solute per mass solution. 
 
 
a. Now, we have discussed solubility curves in great detail.  In the 
introduction of this experiment, we discussed how a solubility curve 
tells you the point where a solution of solid crystals will completely 
dissolve into a solvent.  Using the graph above, describe what 


























Figure 8.  The saturated weight percent of citric acid in water with 






(example, 60 wt% and 10 °C) and what would happen if you picked 
below the solubility curve (example, 50 wt% and 60°C). 
b. During the production of the new pharmaceutical tablet, 75 kg of 
citric acid is placed in a mixer with 100 kg water at 40 °C.  The 
operators on duty notice that not all of the powder is dissolving into 
the water.  Using the solubility curve, explain why this occurs.  If we 
needed to fully dissolve the citric acid in the water, what would you 
recommend doing? 
c. In another operation that uses citric acid, 78 pounds of citric acid is 
dissolved in 60 pounds of water and is heated to 80 °C.  The 
solution needs to be cooled so that 18 pounds of crystals can be 
collected.  To what temperature should this solution be cooled to? 
 
6.   In the previous question, you were given a scenario in which a solution of 
crystals and solvent were cooled past the solubility point.  Indeed, this is 
what is commonly done in industry in order to separate crystals from 
liquids.  Usually, the solution is sent to a cooler, a type of machine that 
drops the temperature of the solution.  This allows crystals and saturated 
solution to form.  This mixture is sent to a filter, which physically separates 
the liquid from the solid.  Then, the solid (known as “cake”) is sent to a 
dryer, so that more liquid can be removed from the crystals.  An example 






Figure 9.  A simplified version of the setup used to separate crystals from 





a. 100 kg of a solution with a concentration of 150 grams of DXM per 
liter of water is sent through this process.  The temperature of the 
solution is initially 75 °C, and is cooled down to 45 °C.  Using your 
DXM data, determine the mass of crystals that would precipitate 
out. Assume that the solution has the same density as water. 
b. Now, say this cooled solution is sent to a filter.  The filter is 
considered 100% effective at removing the crystals.  If the 
composition of the cake is 80% crystal by mass, calculate the mass 
of saturated solution that has been separated with the crystals. 
c. If the dryer only allows the water to evaporate, what is the overall 
mass of crystals that was collected?  If compared to the original 
amount of crystals in solution, what is the overall yield of this 
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A.7 Creation of Dissolvable Strips Lab 
Creation of Dissolvable Strips 
Developed by:  Alex Jannini, David Krause, Heather Malino, and Matthew van 
der Wielen, Rowan University, Department of Chemical Engineering  
Edited by:  C. Stewart Slater and Mariano J. Savelski, Rowan University, 
Department of Chemical Engineering 
Date of Experiment: 
 
OBJECTIVES 
 Students will learn about the commonly used processes for industrial thin 
film production 
 Students will learn and use basic quality control testing methods 
 Students will gain insight into energy requirements for drying thin films 
 
INTRODUCTION 
Dissolvable strips have become an important mechanism for drug delivery.  
Orginially created as candy, dissolvable strips fill a niche role, providing rapid-
release drug delivery.  Due to the drug being dissolved directly into the blood 
stream through the tounge, it bypasses the metabolism of the body, which can 
cause drugs to lose some of their bioavaliability (the amount of drug that will 
circulate through the body).  Other advantages of using thin films include not 
having to take the drug with water, no risk of choking, and reduced dose size 
because the drug is more bioavailable sublingually (tissues under the tounge).1 
 The ingredients of a dissolvable strip will vary, depending on the desired drug 
release rate, the sensitivity of the drug, and several other factors.  However, all 
strips will contain the following ingredients; an active pharmaceutical ingredient 
(API), polymers, placticzers, and sweetners/flavoring.2  A polymer is often 
determined based on its reactions with water.  The more hydrophilic (attraction to 
water) the polymer is, the faster the film will dissolve and release the API.  The 
plasticzer helps improve flexibilty and prevent brittleness in the strip, while the 
sweetners and flavorings help to improve palatability and increases patient 
compliance. 
On an industrial level, dissolvable strips are primarily made with either a solvent-
casting film system or a film extrustion system.  Solvent-casting systems are the 
most common process, as they do not require heat, which could damage an API, 
and are relatively inexpensive to construct.  A typical setup for a solvent-casting 
system can be seen on the next page.3  The drawbacks to solvent-casting 





Alternatively, hot melt extrusion 
is also used to create strips.  
The advantages to extrusion 
are a simpler design and the 
lack of water needed to run the 
process, but the materials used 
in the dissolvable strip must be 
heat resistant and be able to 
flow as a dry powder.  A sample 
of both of these systems can be 
seen in Figures 1 and 2.   
In this lab, you will be creating your own dissolvable strips.  This procedure is 
based on the solvent casting method described above.  Through this lab, you will 
have a better understanding of the way that dissolvable strips are created, and 
some of the engineering principles behind the process. 
SAFETY CONSIDERATIONS 
Make sure to wear safety goggles at all time.  Laboratory safety gloves should 




Figure 2. Screw-forced extrusion of dry feedstock 
as adapted from Particle Sciences.
3
 






MATERIALS NEEDED  
 1000 mL beaker 
 Hot plate and mixer 
 Magnetic stir bar 
 CMC (carboxymethylcellulose) 
 Pectin 
 Xanthan gum 
 Sodium lauryl sulfate 
 Citric acid (anhydrous) 
 Glycerol 
 Sucrose 
 Blue Food Dye (Blue #40)  
 3 drops of Peppermint oil 
 Dropper 
 
 Deionized water 
 3 mL syringe 
 2 Buchner (vacuum) flasks 
 Funnel 
 Fine mesh screen 
 Vacuum tubing 
 Vacuum source 
 Spatula 
 Petri Dish 
 Teflon-lined sheet/plate 
apparatus with thickness 
guiding bars 
 Analytical scale 




Table 1: CMC preparation 
Species Weight (g) Weight % 
CMC 7.7 1.6 
Glycerol 2.6 0.6 
Peppermint oil 0.5 0.1 




Sucrose 1.5 0.3 
Water 500 97 
TOTAL 514.3 100 
 
 
1. Weigh out the appropriate amounts of all powdered ingredients. 
2. Add the required amount of deionized water to the large beaker.  
Reminder:  density of water = 1 g/mL. 
3. Place the beaker on the hot plate and add the stir bar.  Set the heat to the 
lowest setting and set the stir to a low-medium rate (4 out of 10). 
4. Add the CMC to the water at a very slow rate, dusting the powder over the 
surface of the water and waiting for it to be absorbed.  Once most of it is 




Figure 3. Funnel and 
screen setup for pouring 
into flask. 
 
Figure 4: The setup that should 
be used when using the 
vacuum. 
 
Once the viscosity increases, you will need to increase the stirring 
intensity.  Do this slowly. 
5. Add the glycerol to the solution with the 3 mL 
syringe.  You will need approximately 2 mL of 
glycerol to correspond to the weight shown in 
Table 1. 
6. Add the remaining components to the solution 
similarly to how the CMC was added.  At this 
point, the solution should be extremely 
viscous and appear opaque white. 
7. Add three drops of peppermint oil to the 
solution.  
8. Add one drop of blue food dye.  The mixture 
should now be a light blue color. 
9. Transfer the solution into the vacuum flask 
with the mesh and funnel, pouring through 
the mesh, to catch any large clumps of 
solidified product and the stir bar.  Discard 
the solidified product. 
10. We will now make a vacuum filtration 
system.  The purpose of this is to de-
aerate the mixture.  This minimizes the 
bubbles in the solution.  Hook the 
vacuum flask up to a tube and place a 
rubber stopper in the top of the flask.  
Then, connect the tube to the other 
vacuum flask.  Next, place a stopper 
with an attachment into the top of the 
other flask and connect this to the 
vacuum source.  See Figure 4 for the 
appropriate setup.  This second beaker 
will stop any foam from entering the vacuum. 
11. Turn on the vacuum and wait approximately 30 minutes for the gas to 
leave the solution.  The solution should slowly turn clear and may get 
frothy.  The froth will subside. 
12. Turn off the vacuum and disconnect the tubing from the vacuum source.  
Then, remove the beaker with solution from the setup. 
13. Carefully pour some of the solution into a 500 mL graduated cylinder.  





14. Take a petri dish and weigh it. Record this weight. 
15. Prepare a sample of the film in the petri dish by adding 10 mL to the dish.  
Do this by using a small graduated cylinder (10 to 25 mL).  If any bubbles 
remain on top of the solution, be sure to draw solution from under the 
surface.  
16. Weigh the wet petri dish and record this weight. 
17. Pour out 400 mL of the remaining solution onto the sheet using the 500 
mL graduated cylinder. 
18.  Allow 1-2 days for the samples to dry.  The batch should appear much 
thinner and have a glossy finish on its surface.  Take a final weight of the 
petri dish sample and record its weight.  
 
QUALITY ANALYSIS 
How uniform is your batch?  In industry, this is done 
by sampling a batch and testing it in several ways to 
ensure that specifications are met.  Several samples 
are taken and their results are averaged.  Quality 
analysis is critical to the success of a company, so 
that deviations can be caught and fixed before they 
become a costly problem. 
Sample Creation 
1. Carefully peel the strip out of the mold with a 
spatula. 
2. Take a ruler and measure 4 samples with 
dimensions of 1” x 1.5”.  Try to find room for 
samples from each of the four corners so that 
the samples are representative of the entire 
batch. 
3. Using a scalpel carefully cut out the four 
samples. 
 
Thickness Measurements  
1. Using a caliper, take each sample and place it 
in the jaws of the caliper. 
2. Adjust the jaws so that the sample fits snugly 
between them.  Do not over tighten the caliper 
so that the sample tears.  The sample should 
Figure 6. How to use the 
calipers to determine 
thickness 




be pinched, but also be able to slide out from between the jaws when a 
small force is applied to it.  
3. Record your results and repeat for all samples. 
Folding endurance 
1. Take a sample and fold it in half along the 1.5” face (At the 0.75” mark). 
Pinch the folding point with your fingers so that a distinct crease is formed.  
2. Unfold the strip and flip it over.  Carefully fold the strip in the opposite 
direction, along the same crease and pinch.  This has now been 2 folds. 
3. Repeat steps 1 and 2, counting the number of folds that you perform. 
4. Record the final number of folds, and repeat for the rest of the samples. 
Surface pH 
1. Using one of the halves from each sample, use a 
pipette to drop a small quantity of DI water on 
the strip. 
2. Place a broad-range litmus paper strip in the 
drop. 
3. Compare the color of the strip to the package to 
determine the pH of the sample. 
4. Record your results and repeat for the rest of the 
samples.  Again, you only need to measure the 
pH from one half of each sample. 
Analysis 
1. Average the results from each test. 
2. Find the range of results for all tests.  Was there significant variance in the 
data you collected? 
3. Do you think that the average pH of the samples would be dangerous to 
ingest?  What about the highest/lowest pH sample? 
4. The average number of folds it takes to break a Sheets® brand strip was 
found to be in the range of 15-20 folds.  Does your average fall in this 
range?  If not, why do you think it didn’t? 
5. What could be a dangerous consequence from a lot of variance in the 
thickness of each sample?  Would you sell the strips you made to 
pharmacies?  
Moisture Content Analysis 
In this section, you will use the initial and final weights of the petri dish sample, 
as well as an introductory energy balance, to find the energy required to dry the 
sample and the amount of water remaining in the sample. 
Figure 7. Ensure a good 





1. Find the change in mass of the sample.  Assume that the mass that 
evaporated was 100% water.   
2. Find the moisture content with the following equation: 
 
          [   (
     
  
)]      
Where, 
   = final weight of the sample 
   = initial weight of the sample 
3. You will now calculate the amount of energy required to evaporate all of 
the water that was lost.  This energy was transferred into the sample from 
its surroundings, so the balance of energy transferred appears as such: 
 
           
     
Where, 
  = energy required to dry the sample 
      = mass of water vaporized, (     ) 
     
    = Latent heat of vaporization for water, 2260 kJ/kg 
Make sure to watch your units! 
4. Where do you think this energy came from? 
 
QUESTIONS 
1. For the following APIs, research the drug’s therapeutic value and 
determine if a hydrophilic or hydrophobic polymer matrix would be best 
suited for drug delivery: 
a) Salbutamol 
b) Zolpidem tartrate 
c) Ondansetron 
d) Fentanyl citrate 
2. Your boss approaches you with a new design project.  The 
pharmaceutical company you work for has recently signed a contract with 
a client, requiring that you produce 800,000 dissolvable strips/year of a 
new API designed to treat the common cold.  The API, referred to as DK-
12, is potent in very small doses, but degrades rapidly when it hits 
stomach acid.  Therefore, a dissolvable strip is the perfect method for 
introducing the drug into the body.  The film must be fast-dissolving.   
a) Before any equipment can be decided upon, you must create the 




 DK-12 (10% w/w) 
 Water soluble polymer (40-50% w/w) 
 Plasticizers (0-20% w/w) 
 Sweetening agent (3-6% w/w) 
 Saliva stimulating agent (2-6% w/w)  
 Colors and flavors (1-10% w/w) 
Find a suitable chemical for each of these components and compile 
a list for your boss. 
b) Now that you’ve selected the ingredients for the strip film, you have 
to select whether you are going to use a hot-melt extruder or a 
solvent casting system.  The material dissolves easily in water and 
polar solvents, and is not friable (does not degrade from heat).  It 
must be noted that since DK-12 is new, it is very expensive, and 
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Instructor’s Versions of Laboratory Experiments 
B.1 Tablet Statistical Analysis Lab 
Tablet Statistical Analysis Lab – Instructor’s Version  
Developed by:  Alex Jannini, David Krause, Heather Malino and Kevin Sweeney, 
Rowan University, Department of Chemical Engineering 
Edited by:  C. Stewart Slater and Mariano Savelski, Rowan University, 
Department of Chemical Engineering 
Date of Experiment: 
 
OBJECTIVES 
 Students will perform a basic statistical analysis applied to an over-the-
counter drug 
 Students will learn about pharmaceutical engineering, including key terms 
and concepts 
INTRODUCTION 
In the pharmaceutical industry, drugs are manufactured, produced, and marketed 
for therapeutic use.  The industry has been one of the highest earning industries 
of the last decade, with 791 billion dollars in worldwide sales in 2010.  The 
majority of these sales were in North American companies, totaling 335 billion 
dollars1. 
A pharmaceutical product is not just one specific chemical, but many chemicals 
combined together to make a final product.  Tablets, which the students will be 
working with in this lab, are composed of a few chemicals mixed together and 
then compressed.  The therapeutic ingredient is known as the active 
pharmaceutical ingredient (API).  The API is what causes the desired effect of 
the drug.  The rest of the ingredients that remain inert are known as the 
excipients.   
Excipients can have different functions, which is why there are sub-categories of 
excipients found in pharmaceuticals.  For example, a filler is a type of excipient 
used to make up the volume of a medicine so that it can be taken in the form of a 
pill. In some cases, excipients known as binders are used to act as glue and 
make sure the ingredients stick together.  Lubricants and glidants are used in 
combination since they reduce wall friction and interparticle friction, respectively.  
This prevents the tablet from clumping and sticking to equipment.  Excipients 
may also be flavors or colors, which will mask any unpleasant tastes that the 




In any engineering field, statistical analysis is an important tool.  In the 
pharmaceutical industry, statistics can be used in various ways.  For example, 
statisticians use statistics to create trials for experimental drugs.  A chemical 
engineer might use statistics in order to figure out a new process that creates 
more product for less.  In these cases, statistics play an important role in 
analyzing data in order to come to a conclusion. 
In this lab, the students will be looking at two different over the counter 
medications that contain the API ibuprofen, a known pain reliever and fever 
reducer.  The rest of the inactive ingredients in the tablets are binders, fillers, or 
any other kind of excipient.  This lab will consist of a statistical analysis on the 
difference in mass between the ibuprofen tablets, and also the difference in the 
mass of a generic brand and the trademarked brand Advil®.  An introduction to 
creating a flow diagram will also be incorporated into this experiment. 
MATERIALS NEEDED  
 Container of Advil® tablets (minimum of 10 tablets)  
 Container of generic ibuprofen tablets (minimum of 10 tablets) 
 Weigh boat 
 Tweezers 
 Bench scale (accurate up to 1/1,000 g). 
SAFETY CONSIDERATIONS  
Always wear laboratory safety glasses when working in the lab. 
PROCEDURE 
1. Make sure that the bench scale is turned on, and that the scale is set to 
measure weight in grams. 
2. Take the Advil package and note where they list the active and inactive 





Figure 1.  Where to find the active and inactive ingredients 
3. Place the weigh boat on the bench scale.  Record the weight, and then 
tare the instrument.  The bench scale should now read 0 grams. 
4. Open the box of Advil®, and with tweezers, place one tablet in the weigh 
boat.  You may use the table provided below, but you should also record 
your findings in your lab notebook.  
5. Once the mass has been recorded, tare the scale again. 
6. Repeat the two previous steps until you have weighed ten Advil tablets.  
Empty your weigh boat, place it back on the bench scale, and tare the 
instrument.  You should now have the Advil® portion of the data table filled 
out. 
7. Now, look at your generic brand.  Record all the non-active ingredients. 
8. Open the container, and using the tweezers, place one tablet in the weigh 
boat.  Once again, tare the instrument after recording the mass. 
9. Repeat until you have collected ten measurements of the generic brand.  
You should now have the generic brand portion of the data table filled out. 
10. Once all measurements have been completed, dispose of the measured 
















You will need your calculator to do the following calculations.  You must show all 
work to receive credit. 
1. First, take the average of each set of data.  Use the equation below, with i 
being the trial number (given in the data table), n being the total number of 
trials (10), and x being the mass recorded for the specific trial number.  
Record this in your lab notebook and include in your results. 
 ̅   
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Trial Number Name Brand Mass (grams) Generic Brand Mass (grams) 
1   
2   
3   
4   
5   
6   
7   
8   
9   
10   





2. Standard deviation is defined as the variation from the average.  In other 
words, it is the average of the difference between each value obtained and 
the average value obtained.  So, in this case, it would be important to 
know the standard deviation of the mass of the tablets for the trademarked 
brand and also the generic brand.  To calculate the standard deviation, 
use the equation below, with i once again being the trial number, n being 
the total number of trials, and x being the mass recorded. 
   √
∑ (|     ̅| )
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3. Now, we will look for any outliers in our data.  An outlier can be defined as 
a data point significantly different than the mean of the data.  In other 
words, an outlier is a datum point that significantly distant from other 
points.  To do this, find the median data point in both sets of data.  To find 
the median, list the data in order from lowest value to highest value, and 
find the point that resides in the middle.  If you have an even number of 
data points, the median is found by averaging the two middle data points.  
From now on, this median (the median of the entire data set) is known as 
overall median.  From here, find the first and third quartiles.  These 
values are found by splitting the list of data in half.  In this case, we now 
have two sets of five data points; one with the lower data points, and the 
other with the higher data points.  The first quartile can be found by 
taking the median of the lower data points.  The third quartile is the 
median of the higher data points.  Lastly, we state that the overall median 
is the second quartile.  Using the equations below, calculate if any of 
your data points are outliers.   
 
          (     ) (3)  
 
 
Where, OL is the low-value outlier cutoff, Q1 is the first quartile, and Q3 is the third 
quartile. 
 






Where, OH is the high-value outlier cutoff, Q3 is the third quartile, and Q1 is the 
first quartile. 
Are any weights you measured above OH or below OL?  If so, they are outliers.  














 Be sure to record all findings for this lab.  Answer any questions that might 
have been asked in the procedure section of the lab. 
QUESTIONS 
1. During the statistical analysis section, you were asked to find the standard 
deviation of the trademarked and the generic brand. Explain what this 
value tells you.  Compare the two standard deviations you calculated, and 
determine what this means. 
 
2. Now, you will determine whether or not these two brands are different 
from each other.  To do this, you will use a statistical analysis technique 
known as an F-test.  An F-test is used to compare two samples.  This test 
can become difficult if the samples are not done in a similar manner.  In 
this case, the number of measurements taken in each sample is similar, 




so this makes the F-test much simpler.  To conduct an F-test, do the 
following: 
 
a. Find the variance of the two samples.  The variance of a sample is 
defined as the average of the squared difference of the means.  An 
equation of what this would look like is shown below: 
 
 
           
 
                                                     




     






Another way of looking at the variance is it’s relation to the standard deviation of 
a sample.  The relation of the variance of a sample to the standard deviation of a 
sample is shown below: 
 
       (7) 
 
If you compare the equation of variance to the equation of standard deviation, 
you can see how this is true.  Use the relation between standard deviation and 
variance to find a value of variance for the two samples. 
 
b. Now, find the F-value for your experiment.  To find your F-value, 
use the following equation: 
 









For this equation, the variance in the numerator “s1” has to be the larger of the 
two variances.   
 
c. Now, compare this value to a critical value.  This is known as the F-
critical value.  The F-critical value is dependent on the number of 
measurements taken in each sample, and the percent confidence 
that is desired.  The percent confidence is another way of saying 
how accurate one wishes to be in their experiments.  The higher 




experiments.  In this case, you will use a standard percent 
confidence of 95%.  So, you will need an F-critical value which 
corresponds to a 95% percent confidence, a variance based on 10 
measurements in the numerator, and a variance based on 10 
measurements in the denominator.  Usually, these would be looked 
up in tables, as seen in appendix A Figure 1.  However, below you 
will find an critical F value for your calculations3: 
 
           
 
If the F value you calculated in part b of this problem is larger than the critical 
value given, then the two samples are significantly different.  If the F value you 
calculated in part c of this problem is smaller than the critical value given, then 
the two samples are not significantly different.  State whether or not there is 
significant difference between the two samples . 
 
3. Research suggests that one ibuprofen tablet should have a mass of 480 
mg.2 Do you think there is significant difference between the values you 
obtained and this literature value for a typical formulation?  To answer this, 
you will use another statistical test known as the t-test.  There are several 
different types of t-tests used in statistics.  In this case, you will be using a 
one-sample t-test, which compares a single mean to a fixed value.  So for 
this test, the fixed value will be the 480 mg.  You will conduct a t-test on 
both samples.  In order to conduct this analysis, do the following: 
 
a. For a t-test, you will need to find a t-value.  The t-value for an 
experiment relates the average, standard deviation, and number of 
measurements to a given value.  Using the symbols found 
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  In this case, μo will be the mass found in research (480 mg). 
 
b. You will now compare this value to a critical value.  This is known 




dependent on the percent confidence that is desired and the 
number of measurements taken in the sample.  Again, you will use 
a percent confidence of 95%.  For an example of a t-Table, see 
Appendix A Figure 2. The critical t-value you will be using is given 
below3: 
 
             
 
Just like with the F-test, if the critical t-value is higher than the value obtained 
earlier, then there is no difference between your sample and the value from 
literature.  If the t-value calculated earlier is higher than the critical t-value, then 
there is a significant difference between the sample and the value obtained from 
literature.  State whether or not there is significant difference between the value 
obtained from experiments and the value obtained from literature. 
 
c. Repeat this process for whichever sample you did not already 
conduct the analysis on. 
 
4. It has been estimated that the world production of ibuprofen is in the 
vicinity of 15,000 tons per year.4 It has also been estimated that the 
average price for one ibuprofen tablet is roughly 0.12 USD.5  Using this 
information, calculate the total price of ibuprofen production for a year.  
 
5. Remember that you listed the inactive ingredients from each of the 
brands.  Research the first three ingredients from both brands and state 
what type of excipient you believe them to be (i.e. filler, preservative, 
lubricant, etc.). 
 
6. It is your first day on the job working for Pfizer and you are told to do an 
experiment on the Advil production line.  A new tablet press has been 
installed and your boss wants to know if it is producing tablets with 
consistent weight.  To start your experiment, you pull a sample of 20 
tablets off of the line and weigh them.  The data is arranged in a table 
below.  Your boss tells you that each pill must be 90% to 110% of the 
mean tablet size, which is 0.485 g.  Do any pills in your sample fall outside 
of these bounds?  Furthermore, did you find any outliers in your sample?  








Advil Sample - 20 Tablet weights (g) 
0.4850 0.5435 0.4686 0.4837 
0.5198 0.4448 0.5211 0.5895 
0.5048 0.4668 0.4863 0.5227 
0.4857 0.4465 0.4217 0.4662 
0.4786 0.4835 0.4481 0.5101 
 
 
7. You will now have an introduction to creating process flow diagrams.  
These diagrams are an important part of engineering, as they are used in 
most plants.  A process flow diagram indicates the major equipment used 
in a process.  In this case, a box with a label will be acceptable as a piece 
of equipment.  An example is shown below: 
 
 





If you have more than one stream entering or exiting a process, multiple lines 
can be drawn.  For example, if a mixer blends water and titanium dioxide to make 




a. Make a process flow diagram for the creation of the ibuprofen 
tablets as described by the steps below: 
i. Mix the powder (maize starch) for 15 minutes at high speed.  
Add 10.67 g of cold water and check weight (theoretical 
weight, 58.00g).  If required adjust with hot water.  Record 
the quantity of extra water added. 
ii. Mix this binding solution with Mixture 1 (Ibuprofen and maize 
starch). 
iii. Collect and spread the granules onto the trays, one third the 
thickness of the tray. 









iv. Load the trolley into the oven and dry the granules in the 
trays and change the position of the trays for uniform drying. 
v. Mix stearic acid and corn starch separately and add to the 
granules before sending them to a compressor.  Compress 
into 330-mg tablets, using 10-mm convex punches at 4 to 9 
kPa. 
vi. Put the tablets into the coating and rolling pan. 
b. Make another process flow diagram that shows the coating of the 
ibuprofen tablets as described by the steps below: 
i. Make sugar coating: 
1. Heat 72.0 g of item 6 (purified water) in mixer to 
boiling. 
2. Dissolve 168.0g of item 4 (sucrose) and then cool to 
25°C. 
3. Filter the syrup through a 180-µm stainless steel 
sieve. 
4. Dispense item 5 (titanium dioxide) into the sugar 
syrup from the previous step and homogenize. 
5. Check for evenness of the dispersion. 
ii. Apply Sugar Coating to tablets in coating pan by rolling 
tablets and slowly adding the sugar solution over 30 
minutes.   
iii. Make gloss solution  
1. Melt items 1 - 3 (bee’s wax, polyethylene glycol, 
carnauba wax) in a steam-heated vessel by gentle 
heating to 70°C or in a stainless steel container on a 
hotplate heater. 
2. Mix thoroughly. 
3. Pass the mixture through a homogenizer. 
4. Store the polishing emulsion in a closed container at 
room temperature. 
iv. Apply gloss solution to tablets in coating pan by rolling 
tablets. Once the desired polish appears, stop rolling the 
pan. 
v. Dry the tablets in the pan at 30°C for 30 minutes.  Final 




Table 3.  Sample data used for the answer key section of this guide. 
ANSWER KEY 
PROCEDURE 
2. Take the Advil package and note where they list the active and inactive 
ingredients. Record all of the ingredients that are listed as non-active 
ingredients Ans: On the container of a bottle of Advil purchased 
November 2012, the inactive ingredients listed were acetylated 
monoglycerides, colloidal silicon dioxide, corn starch, croscarmellose 
sodium, methylparaben, microcrystalline cellulose, pharmaceutical glaze, 
pharmaceutical ink, povidone, pregelatinized starch, propylparaben, 
sodium benzoate, sodium lauryl sulfate, stearic acid, sucrose, synthetic 
iron oxide, titanium dioxide, and white wax. 
7. Now, look at your generic brand.  Record all the non-active ingredients.  
Ans: This answer will vary depending on the generic brand that was purchased 
for this experiment.  For a bottle of CVS Pharmacy® brand ibuprofen tablets 
purchased November 2012, the non-active ingredients are carnauba wax, corn 
starch, and fumed silica gel, hypromellose, lactose, magnesium stearate, 
microcrystalline cellulose, polydextrose, polyethylene glycol, red iron oxide, 
sodium starch glycolate, stearic acid, and titanium oxide. 
STATISTICAL ANALYSIS 










1. First, take the average of each set of data.  Record this in your lab 
notebook and include in your results.  
Trial 
Number 
Name Brand Mass 
(grams) 
Generic Brand Mass 
(grams) 
1 0.4784 0.3354 
2 0.4837 0.3300 
3 0.4715 0.3296 
4 0.5019 0.3280 
5 0.4840 0.3383 
6 0.4842 0.3284 
7 0.5050 0.3307 
8 0.4930 0.3365 
9 0.4804 0.3272 




Ans: The average for the Advil data was found to be 0.487g.  The average for 
the generic brand was found to be 0.332g. 
 
2. Standard deviation is defined as the variation from the average.  In other 
words, it is the average of the difference between each value obtained and 
the average value obtained.  So, in this case, it would be important to 
know the standard deviation of the mass of the tablets for the trademarked 
brand and also the generic brand.   
Ans: The standard deviation for the Advil data was found to be 0.010g.  The 
standard deviation of the generic brand was found to be 0.004g. 
 
3. Are any weights you measured above OH or below OL?  If so, they are 
outliers.  Arrange your findings in a box-and-whisker plot as described in 
the diagram below. (Omitted from solutions, see above for diagram.) 
Ans: FOR THE ADVIL® BRAND: 
    
(             )
 
          ;             ;             
             (             )           
Since the minimum value in this data set is 0.4715 g, a low-value outlier does not 
exist. 
              (             )           
Again, all data points are less than this number, so a high-value outlier does not 
exist.  A Box-and-Whisker plot of this is shown below. 
 Figure 4. Box-and-Whisker plot for the Advil® brand.  The x-axis here is 




FOR THE GENERIC BRAND: 
   
(             )
 
          ;             ;             
             (             )           
Since the minimum value in this data set is 0.3272 g, a low-value outlier does not 
exist. 
              (             )           
Again, all data points are less than this number, so a high-value outlier does not 





1. During the statistical analysis section, you were asked to find the standard 
deviation of the trademarked and the generic brand. Explain what this 
value tells you, and why it is important.  Compare the two standard 
deviations you calculated, and determine what this means. Ans: As stated 
in this lab, the standard deviation of the variation from the average.  This 
Figure 5. Box-and-Whisker plot for the generic brand.  The x-axis here is 




shows the precision of each of the brands.  If a brand has a lower 
standard deviation, then it is more precise.  From the statistical analysis 
section, the generic brand had a smaller standard deviation.  This means 
that the process used to make the generic brand is more precise. 
 
2. Now, you will determine whether or not these two brands are different 
from each other.  To do this, you will use a statistical analysis technique 
known as an F-test.  Ans: The answers for each piece are as follows: 
a) The variance for the Advil® brand was found to be 9.72E-05, while the 
generic brand was found to have a variance of 1.52E-05. 
b) The F-value was found to be 40.63. 
c) Since the F-value calculated was higher than the F-critical value given, 
there is significant difference between the two brands at 95% 
confidence. 
 
3. Research suggests that one ibuprofen tablet should have a mass of 480 
mg.2 Do you think there is significant difference between the values you 
obtained and this literature value for a typical formulation?  To answer this, 
you will use another statistical test known as the t-test.  Ans: The answer 
for each piece are as follows: 
a) For the Advil® brand, the experimental t-value was found to be 2.14. 
b) Since the critical t-value is higher than the experimental t-value, there 
is no significant difference between the literature value and the Advil® 
brand. 
c) For the generic brand, the experimental t-value was found to be 
119.79.  Since this value is considerably higher than the critical t-value, 
there is significant difference between the value obtained from 
literature and the generic brand value.  
 
4. It has been estimated that the world production of ibuprofen is in the 
vicinity of 15,000 tons per year.4 It has also been estimated that the 
average price for one ibuprofen tablet containing 200 mg of ibuprofen is 
roughly 0.12 USD.5 Using this information, calculate the total price of 
ibuprofen production for a year. Ans: To determine the price of ibuprofen 
production, this was done: 
     
    
    
      
   
      
  
      
     
      
  
   
      
 
  




         
   






5. Remember that you listed the inactive ingredients from each of the 
brands.  Research the first three ingredients from both brands and state 
what type of excipient you believe them to be (i.e. filler, preservative, 
lubricant, etc.).   
Ans: The answer to each of the ingredients is as follows: 
FOR THE ADVIL® BRAND: 
1) The first listed inactive ingredient was acetylated monoglycerides.  
According to Lipid Technologies and Applications,  this ingredient is 
often used as a coating ingredient.6 
2) The second inactive ingredient, colloidal silicon dioxide, is also known 
as silicon dioxide or silica.  In nature, it is also known as sand or 
quartz.  According to Pharmaceutical Dosage Forms: Tablets, a 
compendium of information on tablets, colloidal silicon dioxide is often 
used as a glidant.7 
3) The third inactive ingredient listed was corn starch.  As described in 
the excipients catalog on PharmaHUB.org, corn starch consists of the 
starch granules separated from the mature grain of corn.  This 
excipient can fit into many categories, including binders, diluents, and 
disintegrants.8 
FOR THE GENERIC BRAND: 
1) The first listed non-active ingredient listed on the CVS® brand was 
carnauba wax.  Carnauba wax is also known as palm wax or Brazil 
wax, and comes from the leaves of a palm tree grown only in Brazil.  
According to About.com, carnauba wax is often used as a coating 
agent for candies and also for cars.  Likewise, it is most likely used to 
coat the tablet.9 
2) The second listed non-active ingredient was corn starch.  As stated in 
number 3) of the Advil section of this answer, it is used as a 
disintegrant, binder, or diluent.8 
3) The third non-active ingredient listed was fumed silica gel.  What 
makes fumed silica gel unique is that it has a rather large surface area.  
Fumed silica gel has many applications, but in this case, it is probably 
used as a thickening agent, or a thickener.10  
 
6. Do any pills in your sample fall outside of these bounds?  Furthermore, did 
you find any outliers in your sample?  What does this say about the 
consistency of the new pill press?   
Ans:  By taking the percent error of each data point from the average point of 
0.4850 grams, we find that three tablets are out of the speculated range.  The 
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Table 4.  Percent error of each of the mass samples.  The rows and columns correspond 
to the same points as seen in the questions section. 
0.000 12.062 3.381 0.268 
7.175 8.289 7.443 21.546 
4.082 3.753 0.268 7.773 
0.144 7.938 13.052 3.876 
1.320 0.309 7.608 5.175 
 
Through outlier testing, one outlier was found.  Through the use of the quartiles, 




First Quartile 0.4665 





Through these values, we find one outlier.  The data point 0.5895 is larger than 
the OH value, and therefore an outlier to the series.  A Box-and-Whisker plot was 










This tells us that this pill press is not consistent enough for the product 
specifications and is not precise enough to produce no outliers.  
 
7. For this exercise, read the following description on the creation of 
ibuprofen tablets, and then create a process flow diagram of the process. 






Figure 6. Box-and-Whisker plot for Problem 6.  The x-axis here is the 
mass of the ibuprofen tablets in grams.  One outlier is clearly visible in 
this plot. 
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Figure 1:  Simple schematic of a 
fluidized bed 
B.2 Fluidization of Pharmaceutical Excipients Lab 
Fluidization of Pharmaceutical Excipients – Instructor’s Guide 
Developed by:  Alex Jannini, David Krause, Heather Malino and Kevin Sweeney, 
Rowan University, Department of Chemical Engineering 
Edited by:  C. Stewart Slater and Mariano Savelski, Rowan University, 
Department of Chemical Engineering 
 




 Students will fluidize a pharmaceutical excipient, and learn about the 
variables affecting fluid-particle transport 
 Students will construct and interpret fluidization graphs using experimental 
data 




A fluidized bed occurs when solid 
particulate matter is put under specific 
conditions that allow it to behave as a 
fluid.  This is usually performed in some 
sort of vessel and achieved through the 
use of a pressurized fluid, such as air.  
Some of the properties that the particulate 
matter has in its fluidized state include the 
ability to be transported in a manner that 
is similar to other fluids.  This 
phenomenon is called fluidization.  
Fluidization and fluidized beds are used in 
several different industries for several 
different purposes. 
 
In fluidization, there are many different 
variables that need to be considered.  If one 
was to design a fluidized bed, equipment 
parameters such as the pressure of the 
incoming fluid, the flow rate of the incoming 
fluid, and the temperature of the system would need to be part of the design 
process.  In addition, the material that is to be fluidized will also need to be 
investigated.  Material properties such as particle size, density, and porosity (also 
known as the void fraction, or the fraction of empty space in a packed vessel) are 








As the solids are fluidized, they behave as common fluids.  As such, flow 
variables can be investigated with the moving particles.  One such variable is 
called pressure drop.  Pressure drop is the difference in pressure between two 
points along the path of fluid movement in the process.  Pressure drop is caused 
by frictional forces, resistances to the flow, as the fluid flows through the vessel. 
 
In the pharmaceutical industry, fluidized beds have many different applications.  
Initially, fluidized beds were mainly used for the drying and coating of solids1. 
Granulation, the act of forming or crystallizing substances into grains or granules 
in fluidized beds, was later investigated for pharmaceutical purposes.1 
Fluidization can also be used for the transportation of solids, as the fluidized 
solids can be transported via pipes rather than conveyer belts or in discrete 
amounts1. 
 
In this experiment, you will be investigating four different variables of a fluidized 
bed; air flowrate, air pressure, pressure drop, and bed height.  You will then use 
the data you collected to perform some fluidized bed calculations.  By the end of 
this experiment, you should have a better understanding on how fluidization 
occurs, and why it is an important aspect of pharmaceutical manufacturing.   
 
MATERIALS NEEDED 
 PART I 
 250 mL plastic graduated cylinder 
 1000 mL plastic graduated cylinder 
 Bench scale capable of reading at least 1 kg 
 Avicel® PH 200 
 Kaolin powder 
 DI water 
 Stirrer 
PARTS II & III 




As part of a pre-lab assignment, have the students obtain a material safety data 
sheet (MSDS) for both kaolin and Avicel® PH 200.  Any Avicel® may be accepted, 
but additional literature will be needed for future problems.  This lab uses 
fluidized beds that are described in the Hesketh et al. article, “Fluidized Bed 
Polymer Coating Experiment.”2 This article describes how to create fluidized bed. 
 
SAFETY CONSIDERATIONS 
Laboratory goggles must be worn at all times when in the laboratory.  Laboratory 
gloves and a dust mask must be worn if handling pharmaceutical powders.  







PART I – DETERMINING BULK AND PARTICLE DENSITIES 
1. Begin by placing the empty 250 mL graduated cylinder on the bench 
scale.  Tare the instrument. 
2. Place approximately 50 to 60 grams worth of one of the powders into the 
graduated cylinder.  If you are a little over or under, that is fine, as long as 
the powder does not surpass a measureable level on the graduated 
cylinder.  You may have to use a scoop or a beaker to do this. 
3. Record both the mass of the powder you added to the cylinder, and how 
much volume it takes up.  Use these values to calculate the bulk density 
by dividing the mass added by the volume it takes up.  Set aside this 
graduated cylinder. 
4. Now, fill the 1000 mL graduated cylinder with DI water to around the 700 
to 800 mL mark.  Again, this does not need to be precise.  Record the 
volume of water you added. 
5. Place the graduated cylinder filled with water on the bench scale, and 
once again tare the instrument. 
6. Slowly, add the powder from the small graduated cylinder into the large 
one.  You may need to stir the solution at intervals of the pouring process 
so that all the particles are suspended.  Remember that you do not want 
to surpass the readable levels of the graduated cylinder. 
7. Once the particles have been poured in, stir the mixture thoroughly, but 
carefully.  You do not want to lose any of the water.  Once stirred, place 
back on the scale bench and record the mass of the powder you added to 
the water.  Also, record the new volume of the water and powder mixture. 
8. Now, find the particle density.  The particle density is the mass of the 
powder added to the water and the volume taken up by the particles.  You 
can determine the volume taken up by the particles by subtracting the 
volume of water from the volume of the mixture. 
9. Do this for the other powder.  Make sure that you clean and dry the 
graduated cylinders thoroughly, and use new cylinders before starting to 
work with the new powder.  You may use the following table to record your 
findings, but you should copy this table into your lab notebook. 
 
 
Table1. Empty table for recording data during the fluidization lab. 
Measurement Kaolin Avicel PH 200 
Mass of substance (g)   
Volume of substance (mL)   
Bulk density (g/cm3)   
Volume of water (mL)   
Volume of mixture (mL)   
Volume of particles (mL)   
Mass of substance (g)   





Figure 2.  Laboratory scale fluidized bed. 
Figures 3 and 4.  From left to right; the inlet air valve 
and the flow meter used in the fluidized bed setup. 
 
PART II – THE FLUIDIZED BED 
1. The first step in running these experiments is to become acquainted with 
the equipment.  First, briefly look over the equipment and the station in 
front of you.  Note where your pressurized air is coming from. 
2. After investigating your system, measure the inner diameter of the 






PART III – SUBSTANCE INVESTIGATIONS 
1. After becoming familiarized with your equipment, 
you may begin testing.  Begin by measuring the 
height of the fixed 
bed. 
2. Set the incoming air 
at a pressure of 60 
pounds per square 
inch (psi).  Make 
sure that the 
flowmeter is closed, 
but the air valve is 
open (make sure you 
know which is 
which!).  
3. With the inlet air 




Figure 5.  Plug flow occurring in 
the fluidized bed. 
incoming air to 5 gallons per minute (gpm).  At this reading, take a 
pressure drop measurement and a bed height measurement.   
4. Once the measurements have been recorded, increase the air flow rate by 
5 gpm.  Again, measure the pressure drop and the bed height. 
5. Repeat this until you reach 30 gpm.  Now, increase the intervals to 10 
gpm.  If you notice plug flow, bubbling, or channeling in the fluidized bed, 
record the flow rate and pressure drop, but make a note of the 
phenomenon that occurred.  Also, it might be necessary to check on the 
air pressure periodically during the experiment.  You should make sure 
this is done before taking any measurements. 
6. Once you have taken the pressure drop and bed height at the maximum 
flow rate of air, bring the flow rate back down to zero.  
7. Complete the same steps as above, but now using an air pressure of 100 
psi.  You may use the tables below to record your data, but you should 












Table 2. Empty data table for recording pressure drop at an air pressure of 60 psi and bed 
expansion in the fluidization lab  
Air Pressure of 60 psi 
Flow Meter Reading (gpm) Pressure Drop (in H2O) 
Bed Expansion 
(inches) 
0   
5   
10   
15   
20   
25   
30   
40   
50   
60   
70   
80   
90   
100   
 
Table 3. Empty data table for recording pressure drop at an air pressure of 60 psi and bed 
expansion in the fluidization lab 
Air Pressure of 100 psi 
Flow Meter Reading (gpm) Pressure Drop (in H2O) 
Bed Expansion 
(inches) 
0   
5   
10   
15   
20   
25   
30   
40   
50   
60   
70   
80   
90   









1. Based on your results, what was the point of minimum fluidization (the 
point where fluidization was first noticed) for both of the data sets?  What 
does this tell you about air pressure when it comes to minimum 
fluidization?  Does this mean that air pressure is a negligible variable 
when it comes to fluidization?  Why or why not? 
 
2. You will make a graph of the air flow rate versus the bed height (this 
means that the air flow rate is on the x-axis and the bed height is on the y-
axis) for both of the air pressures.  Using the graph, determine when the 
bed goes from behaving as a packed bed to a fluidized bed.   
 
3. Prepare a fluidization graph.  A fluidization graph is obtained by plotting 
the air flow rate versus the pressure drop.  When you make these graphs, 
there will be a change in the slope at a certain point.  This point is known 
as the point of minimum fluidization.  At this point, the bed of solids 
changes from behaving like a packed bed to behaving like a fluidized bed.  
Label where you believe this point is on the graphs you made.  Also label 
what sections of the graph model the packed bed behavior and fluidized 
bed behavior. 
 
4. For this experiment, we have delved into some of the properties of fluid 
mechanics, a branch of science that deals with the properties of fluids and 
some of the phenomenon that occurs when they are placed under certain 
conditions.  One of the first variables you will learn in fluid mechanics is 
known as the Reynolds Number, a dimensionless quantity that is used to 
determine a flow regime.  Today you will determine the Reynolds number 
of the system at minimum fluidization.  To do this, you will use the 
following formula: 
 
    
       
 
 (1)  
a. The Reynolds Number is considered a dimensionless quantity.  








   = Average diameter of the particle (m) 
    = Velocity of minimum fluidization (m/s) 
   = Density of the gas (kg/m
3) 




Figure 6.  A few fluid regimes of fluidized beds.  





b. Find the Reynolds number for the minimum fluidization point for 
both of your experimental runs. To help you in the calculation of this 
number, use the following values3,4,5: 
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In addition, determine which of the fluidization regimes the fluidized 







5. The following fluidization data was collected using kaolin powder with the 









Table 4. Fluidization data using kaolin powder at an air pressure of 60 psi 
GPM Bed Height (in.) ΔP (psi) 
0 5.00 0.0 
5 5.00 0.5 
10 5.00 1.8 
15 5.50 1.8 
20 5.75 2.4 
25 5.75 2.4 
30 6.00 2.5 
40 6.00 2.8 
50 6.50 3.2 
60 6.50 3.6 
70 6.50 3.8 
80 6.75 4.1 
90 6.75 4.2 
100 6.50 4.6 
 
 
a. Create a flow rate versus bed height graph and a flow rate versus 
pressure drop graph. 
b. Determine if there is a point of minimum fluidization using the 
graphs. 
c. If you could determine a point of minimum fluidization, determine 
the Reynolds number at that point.  If not, find the Reynolds 
number at the same point you used for Question 4.  Use an 
average particle diameter of 1.4 µm for this problem.7  
 
6. Now, we will go over another important tool for engineers; design 
equations.  Design equations are used by engineers to determine 
information about a process without having to do extensive 
experimentation.  These equations are usually based on data obtained by 
research.  For example, the following equation can be used to determine 
the Reynolds number at minimum fluidization8: 
 
       √(  
       )      (2) 
Where Ar (Archimedes Number), C1, C2, are shown below: 
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   = Average diameter of the particle (m) 
   = Density of the gas (kg/m
3) 
   = Particle density of the excipient (kg/m
3) 
  = Acceleration due to gravity (9.81 m/s2) 
  = Dynamic viscosity of the gas (Pa*s) 
 
In order to use the equations above, you will need to determine the 
porosity at minimum fluidization (εmf).  This can be a difficult characteristic 
to determine, which is why many researchers have come up with different 
constants to approximate the porosity.9 However, we have enough 
information to determine εmf, so we will solve for C1 and C2. 
To determine εmf, we first need to know the normal porosity, ε.  This can 
be determined by using the bulk density (ρb) and the particle density (ρs): 




We also have to determine the total volume (Vtot).  For this, use the bed 
height at the 0 gpm air flowrate, and multiply by the cross-sectional area of 
the bed.  Now, we can determine the void volume (Vv) using the following 
equation: 
    
  
    
 (7) 
Now, to determine the volume occupied by the particles (Vp): 
             (8) 
From here, we now need to use the point of minimum fluidization to 
determine the volume (Vmf).  This can be done by using the bed height at 
the point of minimum fluidization and the cross-sectional area.  Using Vmf, 
you can determine the void volume at minimum fluidization (Vvmf): 





Finally, determine εmf: 
      
    
   
 (10) 
 
e) Determine εmf for the Avicel
® trial at the air pressure of 60 psi. 
f) Determine the Remf using Equation (2) for the same conditions as part 
a). 
g) Calculate the percent difference between your answer for part b) and 
the answer you obtained in Question 4. 
 
           
  
|       |
(
       
 )
      (11) 
 
h) You should notice a considerable (>10%) difference in part c).  This is 
because you are using superficial velocity, as opposed to interstitial 
velocity.  Superficial velocity is defined as the theoretical flow through 
the bed based on the flow rate of the liquid divided by the cross 
sectional area of the tube.  Interstitial velocity takes into account how 
the flow is affected by the volume occupied by particles.  Interstitial 
velocity is the flow velocity post a particle, and is the “correct” velocity 
to use in the Remf equation.  To determine the interstitial velocity (vi): 
     
   
      
 (12) 
Where: 
    = volumetric flow rate at minimum fluidization (m
3) 
   = cross sectional area (m
2) 
    = porosity at minimum fluidization (dimensionless) 
 
Determine vi, calculate a new Re as in Question 4, and then compare 
as in part c). 
 
7. It is important to learn how to use the online library tools that you have 
available.  These online tools have thousands of scientific papers and 
articles in databases that you have free access to.  Using one of the 
scientific online resources (i.e. Science Direct, SciFinder, etc.) available, 
you and your lab partners will find an article online about pharmaceutical 
manufacturing practices.  Try to find an article that also discusses either 
fluidization or fluidized beds.  Print out the article, and as a group, be 




understand all of the technical details of the paper, but you should have a 
good understanding of the overall concept being discussed. 
In addition, use the MSDS’s that you obtained as part of your pre-lab and 




The data below was used in answering the questions. 
Table 5.  Sample data collected to carry out calculations for the questions below. 
Measurement Kaolin Avicel PH 200 
Mass of substance (g) 61.5 63.67 
Volume of substance (mL) 220 177 
Bulk density (g/cm3) 0.2795 0.3597 
Volume of water (mL) 850 700 
Volume of mixture (mL) 875 740 
Volume of particles (mL) 25 40 
Mass of substance (g) 61.25 63.40 
Particle density (g/cm3) 2.450 1.585 
 
Table 6: Sample fluidization data at 60 psi used for calculations. 
Air Pressure of 60 psi 
Flow Meter Reading (gpm) Pressure Drop (in H2O) 
Bed Expansion 
(inches) 
0 0.00 4.75 
5 0.30 4.75 
10 0.65 4.75 
15 1.00 4.75 
20 1.40 4.75 
25 1.85 4.75 
30 2.20 4.75 
40 2.50 5.25 
50 2.80 5.50 
60 3.00 5.75 
70 3.40 6.00 
80 3.80 6.25 
90 4.00 6.50 






Table 7. Sample fluidization data at 100 psi used for calculations. 
Air Pressure of 100 psi 
Flow Meter Reading (gpm) Pressure Drop (in H2O) 
Bed Expansion 
(inches) 
0 0.00 5.25 
5 0.20 5.25 
10 0.60 5.25 
15 0.90 5.25 
20 1.20 5.25 
25 1.60 5.00 
30 2.00 5.00 
40 2.40 5.25 
50 2.80 5.50 
60 3.10 5.75 
70 3.40 6.00 
80 3.80 6.25 
90 4.00 6.25 
100 4.40 6.50 
 
In both cases, channeling occurred after reaching 60 gpm, which could not be 
stopped.  Increasing agitation of the bed was seen in the 70-100 gpm data 
points.  The 60 air pressure could not move past the flow rate of 70 gpm. 
1. Based on your data, what was the point of minimum fluidization (the point 
where fluidization was first noticed) for both of the data sets?  What does 
this tell you about air pressure when it comes to minimum fluidization?  
Does this mean that air pressure is a negligible variable when it comes to 
fluidization?  Why or why not?  Ans: This may vary from group to group.  
Using the data above, the point of fluidization was at approximately 40 
gpm for both sets of data. From the data, it would appear that air pressure 
doesn’t affect the minimum fluidization requirement of the particles.  This 
does not mean that the air pressure is a negligible variable when it comes 
to fluidization, however.  As shown in the data, the air pressure does limit 
the flow rate of air through the system.  The flow rate of air is known to 
affect the fluidization of the particles.  Therefore, the air pressure does 
influence the fluidization of the particles. 
 
2. The following graph was made.  It is easy to see when fluidization occurs 
because it is at that point that the bed height starts to increase.  When the 
air pressure was at 100 psi, the bed height was shown to decrease at 2 
points, 25 and 30 gpm, before increasing.  This could have been because 




Figure 7.  Air flow rate versus the height of the bed.  Here, we 
can see that the bed fluidizes as the bed height increases.  
 
Figure 8.  Air flow rate versus the pressure drop.  The black line was added 
to show where the students thought that the packed bed starts to behave as 
a fluidized bed. 
 
the channeling.  This shaking also settled the particles, decreasing the 







3. You will need to make a fluidization graph.  A fluidization graph is obtained 
by plotting the air flow rate versus the pressure drop (this means that the 
air flow rate is on the x-axis and the pressure drop is on the y-axis).  Label 





































































When we graph the data, it would appear that the two sets have the same 
point of minimum fluidization (around 35 gpm). 
 
4. One of the first variables you will learn in fluid mechanics is known as the 
Reynolds Number, a dimensionless constant that is used to determine a 
flow regime.   
a. The Reynolds Number is considered a dimensionless quantity.  
This means that there are no units attached.  Prove this.  Ans:  
Using the table of information given, we plug in all the units for the 
different variable that determine the Reynolds Number: 
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As shown, the unit will cancel out, making the Reynolds Number a 
dimensionless quantity. 
 
b. Find the Reynolds number for the minimum fluidization point for 
both of your experimental runs.  Ans:  Through the calculations, it 
was found that the Reynolds number for the two experimental runs 
was as follows. 
 
Reynolds Number at 60 psi: 15 
Reynolds Number at 100 psi: 27 
 
The first, and not entirely correct, way to solve this is to use the 
cross-sectional area of the cylindrical bed.  Taking the minimum 
fluidization flow rate and dividing that number by the cross-sectional 
area to obtain the minimum fluidization velocity, as shown below.  It 
should be noted that this is based on superficial velocity, and is not 
necessarily an accurate model for what is happening in the system. 
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The density of air is converted from pounds per cubic feet to 
kilograms per cubic meters, as shown below. 
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Now, to find the Reynolds number at 60 psi: 
 
    
       
 
  




             
    
 
Based on the figure given, the minimum fluidization point is in the 
particulate fluidization regime in both instances. 
 
5. Using the data provided, do the following: 
a. Create a flow rate versus bed height graph and a flow rate versus 
pressure drop graph. 



























b. Determine if there is a point of minimum fluidization using the 
graphs. 
Ans:  From the graphs above, it is slightly difficult to determine 
when the particle starts to behave like a fluidized bed.  Using the 
graph, it is estimated that the point of minimum fluidization occurs 
at 20 gpm. 
c. If you could determine a point of minimum fluidization, determine 
the Reynolds number at that point.  If not, find the Reynolds 
number at the same point you used for Question 4. 
Ans:  Using the same equations as in Question 4, the Reynolds 
number was found.  Again, this is not entirely correct because we 
are using a superficial velocity, so this may not be the most 
accurate model. 
    
       
 
  




             










































Air Flow Rate (gpm) 
Figure 9.  a) Air flow rate versus bed height for the 
kaolin powder.  b) Air flow rate versus pressure drop 





6. Now, we will go over another important tool for engineers; design 
equations.  Design equations are used by engineers to determine 
information about a process when only limited information is given. 
a) Determine εmf for the Avicel
® trial at the air pressure of 60 psi. 
Ans:  First, use Equation (6): 
     
  
  
    
      
  
  
     
  
  
       
Now, determine Vv using Equation (7): 
 
                           
                               
 
  
                
 
   
  
    
         
  
              
 
 
           
     
 
To determine Vp, use Equation (8): 
 
                      
                                
 
Solving for Vvmf using Equation (9): 
 
                           
                               
 
  
               
 
                      
                         
 
             
     
 
Finally, determine εmf using Equation (10): 
 
     
    
   
  
            
             
       
 





Ans:  We begin by finding Ar, C1, and C2 using Equations (3), (4), and 
(5), respectively: 
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c) Calculate the percent difference between your answer for part b) and 
the answer you obtained in Question 4. 
Ans:  Using Equation (11): 
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This large difference is mainly because the Remf equation should use 
the interstitial velocity (vi). 
 
d) Determine vi, calculate a new Re as in Question 4, and then compare 
as in part c). 
Ans:  Using Equation (12): 
 
    
   
       
  
          
  
 
                  










Figure 10.  A screenshot of the Science Direct search. 
    
      
 
  




             
       
 
Calculate the percent difference using Equation (11): 
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Using the correct velocity, the percent error decreases significantly. 
 
7. Using one of the scientific online resources (i.e. Science Direct, SciFinder, 
etc.) available, you and your lab partners will find an article online about 
pharmaceutical manufacturing practices.  Try to find an article that also 
discusses either fluidization or fluidized beds.  In addition, use the MSDS’s 
that you obtained as part of your pre-lab and any other literature to 
compare the bulk densities that you found in part I of the experiment. 
Ans:  On August 1, 2013, a Science Direct search was made with the 







The articles found by the groups of students should be discussed on the 




students roughly five minutes to discuss their paper.  You might find it 
helpful to have the students notify you in advance of their choice, so as to 
limit the amount of repeating reports. 
 
Using other literature sources, it was determined that the density of kaolin 
was in the range of 1.8 to 2.6 grams per cubic centimeter (g/cc).10 For 
Avicel® PH 200, the bulk density was found to be in the range of 0.29 to 
0.36 g/cc.11 While the kaolin value found in experimentation was smaller 
than specified by the literature, it could still be correct, as the density given 
was not specified as either bulk or particle density.  If considered particle 
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B.3 Asthma Drug Delivery Lab 
Asthma Drug Delivery Laboratory Experiment – Instructor’s Guide 
Developed by:  Alex Jannini, David Krause, Heather Malino and Kevin Sweeney, 
Rowan University, Department of Chemical Engineering 
Edited by:  C. Stewart Slater and Mariano Savelski, Rowan University, 
Department of Chemical Engineering 
Date of Experiment: 
  
OBJECTIVES 
 Students will learn 
about intrusive 
laboratory experiments 
 Students will gain 
experience in reverse 
engineering strategies 
and project designs 
 Students will conduct a 




ADVAIR® is a dry powder 
inhaler prescribed to patients with asthma and chronic obstructive pulmonary 
disease that uses two active pharmaceutical ingredients.  Fluticasone propionate, 
one of the two, is a corticosteroid, which is used to reduce the inflammation of 
the lungs.  Salmeterol xinofoate, the second, is a bronchodilator, which relaxes 
the muscles in the airways to help improve breathing.1  
 
ADVAIR® is not only used as an option for people with asthma, but also can be 
used as a maintenance treatment for chronic obstructive pulmonary disease.¹ 
Chronic obstructive pulmonary disease (COPD) is a disease that makes it difficult 
to breathe.  It also takes the form of chronic bronchitis, causing a long-term 
cough with mucus, and emphysema, which destroys the lungs over time.  Most 
sufferers of COPD have a combination of the two symptoms.² Asthma occurs 
when the airways of the lungs tighten and narrow, which leads to wheezing, 
shortness of breath, coughing, and a tightening in the chest.³ 
 
ADVAIR® comes in three varieties: ADVAIR DISKUS® 100/50; ADVAIR DISKUS® 
250/50; ADVAIR DISKUS® 500/50.  The three varieties of ADVAIR® have 
different amounts of fluticasone propionate in the powder.  For example, in an 
ADVAIR DISKUS® 100/50, there will be 100 μg (micrograms) of fluticasone 




propionate and 50 μg of salmeterol.  The 250/50 prescription of ADVAIR® is used 
for COPD treatment.¹ 
 
In this lab, the teams will be examining an ADVAIR DISKUS®, and conduct an 
invasive reverse engineering experiment on the diskus.  They will then compare 
the dry powder inhaler to two other types of inhaled medication transport 
systems; a nasal spray and a traditional metered dose inhaler.  The goal is to see 
the difference in the transport process that each system uses, and to also see if 
there is any way to improve the design of the diskus.  A quality control study on 
the packaging of powder in the ADVAIR DISKUS® is also provided.  This will 
include an average and a standard deviation of the powder packages. 
 
INSTRUCTOR’S NOTE 
All of these forms of drug delivery can be 
purchased online.  It may also be possible to 
obtain these through the companies that 
make them.  GlaxoSmithKline is the creator 
of the ADVAIR DISKUS®, and may be 
contacted for assistance.  They may be 




● ADVAIR DISKUS® 
● Small flathead screwdriver 
● Analytical scale (able to read 
at least 1/10,000g) 
● Albuterol metered dose 
inhaler (or suitable substitute) 
● Fluticasone propionate nasal 
spray (or suitable substitute) 
● Narrow-headed spatula 
● KimWipes 
● Weigh boats 
 
SAFETY CONSIDERATIONS 
All students should know that laboratory gloves and eyewear must be worn at all 
times to protect from sharp edges and medicines. 
 
 
Figure 3: Proper removal of mouthpiece 





PART I - REVERSE ENGINEERING 
1. Open up the diskus box and remove the information packets.  Make 
general observations on the diagrams and information included. 
2. Remove the inhaler from the tinfoil package.  Based on its outside 
appearance, how do you think it works?  Sketch the diskus.  
3. With the flathead screwdriver, proceed to remove the outer shell of 
the inhaler.  Be careful to not 
break or shatter any plastic. 
4. Insert the screwdriver 
under the mouthpiece and use it 
as a lever to dislodge the 
mouthpiece. 
5. Along the outside 
circumference of the diskus you 
will notice several slots and tabs 
that hold each half of the inhaler 
together.  One by one, carefully 
depress each tab and pry the inhaler open.   
6. This should expose the inside of the 
inhaler.  Make observations on its 
appearance and the gears.  Sketch the 
inside of the diskus. 
7. Pull the lever down and reset it a few 
times.  Discard the powder inside the 
blisters.  Note how the gears move.  Based 
on this, do you have any other ideas as to 
how the inhaler works?    
8. Remove the foil strip.  It will be stuck 
at one part after the foil has been split in half.  
Cut this section away to fully remove the rest 
of the foil strip.  
9. The large white plastic mold that the 
foil fits into can be removed.  Look for white 
tabs interlocking with the purple exterior shell 
by the mouthpiece.  Push these tabs in to 
remove the white mold. 
10. At this point, the gears should be fully 
exposed.  Move the lever up and down.  Was your hypothesis as to how 
the diskus worked correct?  If not, what is actually happening? 
Figure 5: Inside the Diskus 




Figure 6: Operating the open Diskus 
11. Set the diskus aside and look at the aerosol inhaler and nasal 
spray.  Compare and contrast these methods of asthma drug delivery to 















PART II - QUALITY CONTROL/MEASUREMENT 
You may wish to place your findings in the table found in the RESULTS section 
of this experiment, but you should also record them in your laboratory notebook. 
 
ADVAIR® Quality Control 
1. Take the foil strip that was previously removed over to a weighing 
station that has a precise analytical scale. 
2. Place a weigh boat on the scale and tare the instrument.   
3. Remove the boat and pull back the foil strip exposing the powdered 
drug in one blister.  Carefully empty its contents into the weigh boat using 
a spatula to scrape off any remaining powder. 
4. Place the boat back on the scale and record the result.  Tare the 
scale once again so the powder does not have to constantly be thrown out 
in between measurements.  Repeat this nine more times so that the 
weights of ten blister packs have been recorded. 
5. After all measurements have been taken, dispose of the boat and 
powder in the trash. 
6. Reassemble the diskus and place it back in the box along with 
included pamphlets.     
 




Figure 8: Proper removal of medicine from blister pack  
 
Metered Dose Inhaler Quality Control (See Figure 9 for proper techniques for this 
section) 
1. First, take a weight boat, and place it on the analytical scale. 
2. Now, take a KimWipe and fold it until you have a small rectangle that will 
fit over the end of the metered dose inhaler.  Place this folded KimWipe in 
the weigh boat, and then zero the analytical scale. 
3. Take the metered dose inhaler, and shake well.  Remove the KimWipe 
from the weigh boat, and place on the end of the inhaler where the 
propellant will exit. 
4. With the KimWipe on the end of the inhaler, press down on the canister 
section of the inhaler, allowing the propellant to exit the inhaler and the 
KimWipe to capture it. 
5. Quickly place the Kimwipe back on the weigh boat and take a mass 
measurement. (This may be difficult as the excipient, which acts as a 
propellant, will evaporate.)  Take the measurement once the scale stays 
on the same value for at least a second. 
6. Dispose of the KimWipe.  Repeat steps 2 to 5 with fresh KimWipes until 
you have ten mass measurements. 
Nasal Spray Quality Control (See Figure 9 for proper techniques for this section) 
1. Once again, take a weight boat, and place it on the analytical scale. 
2. Now, take a KimWipe and fold it.  Place this folded KimWipe in the weigh 
boat so that it covers the bottom and most of the sides of the weigh boat. 





3. Take another KimWipe or a paper towel and fold several times.  Take the 
nasal spray and shake.  Prime the device by spraying it a few times into 
this second wipe. 
4. With the spray primed, take the weigh boat off the scale, and place on a 
slightly downward angle. Spray the propellant into the weigh boat once. 
5. Place the weigh boat back on the scale and take a mass measurement.  
6. Dispose of the KimWipe.  Repeat steps 2 to 5 until you have ten mass 
measurements. (Step 3 may not need to be repeated every time, but once 
every 2 to 3 measurements.) 
 
 
Figure 9:  Different examples of the correct technique for metered dose inhaler (MDI) and 
nasal spray quality control measurements.  a) The folding of the KimWipe before taking a 
mass sample of the MDI.  b) The MDI cartridge being pushed down so that the medicine 
will be ejected into the KimWipe, and a mass measurement taken.  c) The lining of a 
KimWipe on the bottom of a weigh boat far nasal spray mass measurements.  d) Priming 
the nasal spray apparatus before taking a mass measurement.  e) Taking a mass 
measurement using the nasal spray. 
 
RESULTS 
Make sure that the students record all results in a lab notebook, and that all 
members of the teams receive the data.  These results can be placed in the table 
below and turned in along with solutions to the questions below.  Questions were 




Table 1.  Empty data table for collecting data in the Asthma Drug Delivery laboratory 
experiment 
Diskhaler Trial Mass (g) MDI Trial Mass (g) Nasal Spray Trial Mass (g) 
1  1  1  
2  2  2  
3  3  3  
4  4  4  
5  5  5  
6  6  6  
7  7  7  
8  8  8  
9  9  9  




















1. Compare and contrast the different styles of drug delivery that you 
examined in part I.  Which of these systems did you think had the most 
appeal?  Which do you think will work the best? 
 
2. When comparing the MDI and the nasal spray, which of the two has a 
higher standard deviation?  Compare all three standard deviations.  
Determine the highest and the lowest standard deviation.  Explain what 
these results imply about the quality control measures of the three 
devices. 
 
3. What were some sources of error in part II?  How do you think you could 
fix some of these problems? 
 
4. Based on the average weight of the blisters, what percentage of the 
powder are active pharmaceutical ingredients (API’s) and what 
percentage is inactive?  Assume that the amount of active ingredient from 
each sample is equal to the amount stated in the prescription dosage. 
The formula for finding the percentage of inactive ingredients is as 
follows: 
          (
      
   
  ∑    
      
   )        
(2)  





From this, find the percentage of active ingredients. 
5. Do you think that the assumption made for problem 4 was a valid 
assumption to make?  Why or why not? 
 
6. The Advair dry powder inhaler, as described in the introduction section, 
contains two active ingredients, fluticasone propionate and salmeterol 
powder.  There is one other ingredient listed on the label, lactose. 
a. What is lactose? Where else is lactose commonly found? 
b. Why would lactose be used in the inhaler?  What type of excipient 
should it be considered? 
c. What are some negatives of using lactose? 
Be sure to site all references. 
 
7. All metered dose inhalers (MDIs) need a propellant.  A propellant makes 
up almost 99% of the dose of an inhaler.  The propellant must have 
specific properties.  Some of these include the boiling point, solubility of 
the API, toxicity and others.  The API is suspended in the propellant and 
when the medication is dispensed the propellant creates an aerosol cloud, 
that the medication can be inhaled by the patient.4 
a. What is a CFC? 
b. Why are CFCs no longer used as propellants in inhalers? 
c. What type of propellant is used in the Ventolin inhaler?  Which type 
of propellant did it replace? 
d. Compare the two propellants.  Why do you think they replaced the 
propellant? 
Be sure to cite all references. 
 
ANSWER KEY 
PROCEDURE - PART I 
 
8. Make general observations on the diagrams and data included.  
Ans: The handouts included with the diskus contained very detailed 
directions for the use of the diskus.  Diagrams displaying how to use this 
diskus were also included in the handouts.  Several sections of the 
handouts included legal issues, such as side effects, copyrights, 
warranties, and other information that is assumed to be included by legal 
regulation. 
 
9. Based on its outside appearance, how do you think it works?  
Ans: The lever needs to be pressed down to release the medicine, 





6. Make observations on its appearance and the gears. 
Ans: The inside of the diskus is hollow, with several gears that 
work to release the drug from the folder. 
 
7. Based on this, do you have any other ideas as to how the inhaler 
works? 
Ans: There is no device that punctures the blisters that hold the 
powder.  Instead, the device rips the blister open using the lever. 
 
10. Was your hypothesis as to how the diskus worked correct?  If not, 
what is     actually happening?  
Ans: If hypothesis is correct:  Yes, the diskus works as 
hypothesized earlier in the experiment.  If hypothesis is 
incorrect:  No, the diskus works in a way that is different than 
hypothesized.  In fact, the lever helps tear the blister pack open, 
which releases the powder so that it can be inhaled from the 
mouthpiece. 
11. Sketch both of these and take observations as to how they deliver 
the drug.  
Ans: Both the aerosol inhaler and the nasal spray work by 
suspending the drug in fluid.  This fluidized drug is then delivered to 
the body by the use of a propellant. 
 
 
PROCEDURE - PART II 
 
The table in the results section was filled out.  Below are the results. 
 
Table 2.  Sample data collected in the Asthma Drug Delivery laboratory experiment. 
Diskhaler Trial Mass (g) MDI Trial Mass (g) Nasal Spray Trial Mass (g) 
1 0.0130 1 0.0130 1 0.0867 
2 0.0130 2 0.0128 2 0.0979 
3 0.0127 3 0.0088 3 0.0989 
4 0.0132 4 0.0107 4 0.0854 
5 0.0126 5 0.0130 5 0.1004 
6 0.0123 6 0.0140 6 0.0983 
7 0.0130 7 0.0140 7 0.1022 
8 0.0129 8 0.0148 8 0.1000 
9 0.0124 9 0.0120 9 0.0991 
10 0.0130 10 0.0121 10 0.0986 















1. Compare and contrast the different styles of drug delivery that you 
examined in part I.  Which of these systems did you think had the 
most appeal?  Which do you think will work the best?  
Ans: The ADVAIR DISKUS® releases the drug in the most 
controlled manner.  However, some patients suffering from an 
asthma attack or unable to inhale deeply may find it difficult to 
generate enough force to inhale the entire dosage and therefore 
would prefer a metered dose inhaler.  Due to the aesthetics of the 
ADVAIR DISKUS®, it is most likely the drug delivery system with 
the highest appeal. 
 
2. When comparing the MDI and the nasal spray, which of the two has 
a higher standard deviation?  Compare all three standard 
deviations.  Determine the highest and the lowest standard 
deviation.  Explain what these results imply about the quality control 
measures of the three devices 
Ans: When comparing the MDI and the nasal spray, the nasal 
spray has the higher standard deviation.  Of the three sets of data, 
the one with the lowest standard deviation was the ADVAIR 
Diskus® while the nasal spray had the largest standard deviation.  If 
we consider no error in the measurement taking process, it would 
appear that the Diskus® is the most precise when it comes to the 
delivery of medication, while the nasal spray is the least precise.  It 
would appear that the Diskus® has the highest quality control 
measures in place for drug manufacturing and delivery. 
  
3. What were some sources of error in part II?  How do you think you could 
fix some of these problems?  Which of these systems do you think had the 
smallest source of error?  Why?   
Ans: Inconsistency in weights for the ADVAIR Diskus® can be attributed 
to powder remaining on the foil strip, the spatula, and not being caught in 
the weigh boat.  A more accurate method would be to not use a spatula 
and tap each blister in with as little space between the weigh boat and foil 
strip as possible.  Residue remaining on the foil strip could be washed off 
with water, collected in a separate beaker, and the water allowed to 
evaporate. The small quantity of the measurements can be a problem, as 
well.  If there is a breeze and the wind guards are not shut on the scale 




measurement.    A more accurate scale could be used, if one could be 
acquired (capable of reading 10-5 grams).   
As far as the metered dose inhaler, error could be made in the 
measurement process.  Since the propellant will evaporate off, there is 
difficulty in keeping an accurate measurement.  With the nasal spray, error 
could be included if the mechanism is not primed, causing a variable 
amount of drug to be released each time. These problems with the 
metered dose inhaler and the nasal spray are design flaws.  It is difficult to 
take an accurate mass measurement of the MDI because an excipient 
used as a propellant evaporates off of the KimWipe.  If you wait until after 
the excipient evaporates, you will see little if any change in mass from 
when the analytical scale was zeroed.  There is little you can do to change 
this, as it is part of the MDI design.   To get more accurate results, a high-
end spectrophotometer could be used to obtain more accurate results.  
The spectrophotometer could be set to the absorbance level of the API 
and then sample could be taken in water to find the amount of API release 
with each spray.5 For the nasal spray, it depends on how well you prime 
the apparatus, and at what angle you place it while spraying.  If the angle 
is too small, the apparatus will not spray the same amount as it would at a 
higher angle.  However, you cannot spray at too high an angle, or else the 
KimWipe will fall out of the weigh boat.   
In other words, these errors are based on the design of the apparatus and 
the inability to obtain quality measurements in a simple way, such as the 
ADVAIR Diskus.® The Diskus is obviously the system with the smallest 
source of error based on the design of the system.  It is much easier to 
determine the mass of the blister packets because they are in a solid form, 
and do not require a gas propellant in order to be properly administered to 
the lungs.  The Diskus also does not require priming or a proper angle in 
order to take mass measurements.  With that being said, it can also be 
determined that the Diskus will have the best results when it comes to 
precisely administering a pharmaceutical substance.  
 
4. Based on the average weight of the blisters, what percentage of the 
powder are active pharmaceutical ingredients (API’s) and what 
percentage is inactive? Assume that the amount of active ingredient from 
each sample is equal to the amount stated in the prescription dosage. 
Ans: This number will vary, but preliminary experimentation yields an 
average weight of around 12.62 mg per blister.  Using the 250/50 mcg 




the %inactive will be roughly (12.32/12.62 * 100) = 97.62%.  To find 
%active, subtract this number from 100%:  100-97.62 = 2.38%. 
 
5. Do you think that the assumption made for problem 4 was a valid 
assumption to make?  Why or why not? 
Ans: Technically, the assumption made to solve problem 4 cannot be 
made, since there is no way to tell whether or not the mass of API is 
exactly that which is prescribed for each dosage.  Therefore, we cannot 




6. The Advair dry powder inhaler, as described in the introduction section, 
contains two active ingredients, fluticasone propionate and salmeterol 
powder.  There is one other ingredient listed on the label, lactose. 
a. What is lactose? Where else is lactose commonly found? 
Ans: From the Elmhurst college website, Lactose is a disaccharide 
sugar derived from galactose and glucose and it is found in cow 
and human milk. It has a formula of C12H22O11.
6 
 
b. Why would lactose be used in the inhaler?  What type of excipient 
would it be considered? 
Ans:  Lactose is used as a powder excipient in the inhaler because 
it is inexpensive, tasteless (except for a mild sweetness), and 
harmless to humans, in most cases.  In this type of product, lactose 
would be used to enhance the API aerosolisation and delivery to 
the lungs.7 
 
c. What are some negatives of using lactose? 
Ans: Lactose can cause some people to have an allergic reaction.  
This could prohibit people with severe lactose allergies from using 
this medication.1  
 
7. All metered dose inhalers (MDIs) need a propellant.  A propellant makes 
up almost 99% of the dose of an inhaler.  The propellant must have 
specific properties.  Some of these include the boiling point, solubility of 
the API, toxicity and others.  The API is suspended in the propellant and 
when the medication is dispensed the propellant creates an aerosol cloud, 
that the medication can be inhaled by the patient.4 




Ans:  CFC is a chlorofluorocarbon, a molecule that contains 
carbon, chlorine, and fluorine.  They are often is in the 
manufacturing of aerosol sprays and as refrigerants.8  
b. Why are CFC’s no longer used as a propellant in inhalers? 
Ans:  CFC’s were found to be harmful to the Earth’s ozone layer, 
and so the use of CFCs have been heavily regulated and 
eventually eliminated by the Montreal Protocol to Reduce 
Substances that Deplete the Ozone Layer (along with the London 
Amendment).8 
c. What type of propellant is used in the Ventolin inhaler?  Which type 
of propellant did it replace? 
Ans:  The Ventolin inhaler uses propellant HFA-134a.  This 
propellant is norflourane and it replaced the propellants CFC-11 
and CFC 12, otherwise known as trichloromethane and 
dichlorodifluoromethane.9 
d. Compare the two propellants.  Why do you think they replaced the 
propellant? 
Ans:  The two compounds have similar properties and are both 
non-toxic to humans when used as directed by a physician.  HFA-
134a does not contain CFCs and is a much greener propellant than 
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Figure 1.  The energy strips you 
will be using in class. 
B.4 Degradation of Dissolvable Strips Lab 
Degradation of Dissolvable Strips – Instructor’s Version 
Developed by:  Alex Jannini, David Krause, Heather Malino and Kevin Sweeney, 
Rowan University, Department of Chemical Engineering 
Edited by:  C. Stewart Slater and Mariano Savelski, Rowan University, 
Department of Chemical Engineering 
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OBJECTIVES 
 Students will learn about mass transfer and degradation rates of drug 
delivery films 
 Students will learn how to properly operate a spectrophotometer 
 Students will determine the effect of temperature on this process 
INTRODUCTION 
In 2000, the pharmaceutical company Pfizer 
introduced a new over-the-counter product for 
the treatment of bad breath.  This product 
came in a novel form that was not seen before; 
a small, orally dissolvable strip.  This product 
revolutionized the industry, generating roughly 
250 million dollars in sales.  By 2002, many 
other brands of dissolvable strips were also on 
the shelves.1 In 2011, the energy supplement 
industry also saw the potential profits of 
sheets.  One company, known as Sheets, 
introduced a caffeine based strip which they 
claim has zero calories, zero sugar, and has 
the same caffeine as one cup of coffee, shown 
in Figure 1.  The brand also states that 
negative side effects, such as a “crash,” are not common when taking the 
product.  Although the company has faced controversy, especially with the 
endorsement of LeBron James, Sheets continues to make energy supplement 
strips.2 
While the use of dissolvable strips is a relatively new delivery method, it has 
become a popular method of drug delivery.  In fact, many other fields of over-the-
counter pharmaceutical products have introduced dissolvable strip products.  
Dissolvable strips that contain medicines for flu and sinus infection symptoms 




With dissolvable strips, the delivery vehicle is a thin, flexible sheet of polymer.  
The active pharmaceutical ingredient (API) is incorporated into this polymer to 
form the final product.  Depending on the nature of the medicine, the API can be 
incorporated in one of two ways; either through liquid dissolution or solid 
suspension in the polymer.  The size and thickness of these strips is dependent 
on the dosage of API that needs to be delivered.3 
In this experiment, you will investigate the dissolution and degradation rate of a 
dissolvable strip that contains menthol.  You will be using a spectrophotometer to 
take absorbance readings.  These absorbance readings will then be used to find 
the amount of menthol that was released from the strips.  You will also be 
comparing these rates for two different temperatures; ambient, otherwise known 
as room (roughly 20°C), and body (37°C). 
MATERIALS NEEDED 
 2 Sheets™ brand Mint Boost dissolvable strips 
 2 petri dishes 
 2 timers 
 Incubator or oven capable of reaching and maintaining 37°C 
 Pair of tweezers 
 Deionized water 
 500 µL to 5000 µL pipette 




This laboratory requires deionized (DI) water at a temperature of 37 °C (98.6 °F).  
It may be necessary that you have a batch of DI water kept in an incubator/oven 
at this temperature overnight or a few hours before the start of experimentation.   
In addition, this lab models the release of blue food dye, not caffeine.  To model 
the release of caffeine, an advanced spectrophotometer that can take 
absorbance readings at 273 nm must be used.  While it may be possible to take 
readings at the 273 nm wavelength, it is encouraged to use the 630 nm for this 
experiment.  A separate time versus absorbance chart is shown in the appendix, 
along with separate answers based on using this other absorbance. 
SAFETY CONDITIONS 
Laboratory gloves and eyewear must be worn at all times inside the lab.  Be sure 




Figures 2 and 3.  From left to right, the proper (l) and 
improper (r) way to take a sample. 
PROCEDURE 
1. Start by turning on the spectrophotometer and setting it to take 
absorbance readings at 630 nm. 
2. While the spectrophotometer warms up, place 2.5 mL of deionized water 
into each of the petri dishes. 
3. Place one of the petri dishes into the oven/incubator that is set at 37°C. 
4. Allow 20 minutes to pass so that the water may reach 37°C and the 
spectrophotometer may warm up. 
5. After the 20 minutes 
have passed, fill a 
cuvette with 
deionized water and 
zero the 
spectrophotometer. 
6. Now that the 
spectrophotometer 
has been zeroed, use 
the tweezers to place 
a strip into one of the 
petri dishes.  Once 
the strip has been 
placed in the petri 
dish, cover and start 
the timer. 
7. Place the other strip in the other petri dish using the tweezers.  Once 
placed, close the petri dish and start a secondary timer. NOTE: It is a 
good idea to stagger the starting times so that you do not find yourself 
rushing to take two measurements.  It may also be a good idea if you are 
working in teams to split the team so that one section of the group is in 
charge of one specific temperature study. 
8. After five minutes have elapsed, take a sample of your water into a 
cuvette.  Make sure that this sample is relatively far from the dissolvable 
strip so that you do not accidentally pick up any large portions of the 
dissolvable strip, as in Figures 2 and 3. 
9. Take an absorbance reading then return the sample to the corresponding 
petri dish. 
10.  Take absorbance readings every five minutes for the first thirty minutes.  
After that, take absorbance readings every ten minutes until you have 
reached 90 minutes.  You may use Table 1, but you should also record 




Table 1. Empty data table to record absorbance at 630 nm data for the dissolvable strips 
laboratory. 
Time (min) 
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11.  Once you have taken all the necessary measurements, make sure to turn 
off the spectrophotometer and the incubator/oven. 
12. Dispose of all equipment used in this lab, and make sure that any water 
spills were cleaned up before exiting the laboratory. 
 
RESULTS 
Be sure to record all the data you collected in this experiment into your laboratory 
notebook.  If you split into two groups to complete this experiment, be sure that 
you share the data sets. 
DATA ANALYSIS 
To analyze the data, the best method is to create a graph of the time versus 
absorbance reading.  In this case, the x-axis will be the time axis and the y-axis 
will be the absorbance axis.  Create one of these graphs using Excel or another 








7. Now, you will take your absorbance readings and figure out the 
concentration of menthol in your solutions.  You will do this using the 
following graph, which correlates absorbance at 630 nm to concentration 
in mg/mL.  Once you have the concentrations, create another graph of 
concentration versus time for both temperature sets.  In addition, fill in 
Table 2.  Make a copy of this table and turn in along with the rest of the 
deliverables for this experiment. 
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8. Now that you have found the concentration of the solution over time, you 
will need to use concentration and absorbance readings to determine the 
molar absorptivity of the blue food dye.  The molar absorptivity, or the 
molar absorption coefficient, is defined as how strongly a substance 
absorbs light at a particular wavelength4.  This coefficient is seen in the 
Beer-Lambert Law, an important law that governs the absorbance of light.  
This law is shown below: 
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c) Use one of the higher time points (70 to 90 minutes) of both the 
room temperature and body temperature experimental runs to 
determine the molar absorption coefficients of both runs.  Use the 
following constants to help you in this calculation. 
 
       
                         
 
   
 
 
d) Based on the values, do you think that the temperature affects the 
molar absorption coefficient? 
 
 
9. Determine how well the molar absorption coefficients can determine the 
concentration of the solution based on absorbance readings.  Use the 
molar coefficients you previously found and determine the concentration 
that the solution should be at based on the Beer-Lambert Law.  Use a time 
point between 30 and 50 minutes in both cases.  Determine how different 
these two numbers are by using percent difference. The equation for 
percent difference is shown below.  In this case, the “E” terms are the 
molar concentrations.  It should be noted that percent difference is a 
dimensionless number.  Make sure you do all the necessary unit 
conversions before calculating the percent difference.  
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10. It is known that the molar absorptivity coefficient of the blue food dye used 
in these sheets is 1.3x106 M-1cm-1.5 
 
c) How different is the molar absorptivity coefficient that you found 
using your experimental data from this known value?  Use 
experimental error to determine this difference.  The equation for 
percent error is shown below. 
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(3) 
 
Here, the “E” term is the molar absorptivity coefficient obtained 
through the experimental data, while the “A” term is the molar 
absorptivity coefficient given to you above.  It should be noted that 
when using this equation, the two terms need to be in the same 
units. It should be noted that percent error is also a dimensionless 
number. 
 
d) Now, use the same time point that you used in Question 6 and 
determine the concentration based on the given molar absorptivity 
coefficient.  Again, compare using percent error.  Do this for both 
experimental runs.  Here, the “E” term will be the concentration that 
you obtained during experimentation, while the “A” term will be the 
concentration that you obtained using the given molar absorptivity 
coefficient.   
 
11. The Beer-Lambert Law is one of the most important laws used in 
spectroscopy (the interactions between light and matter).  How could you 
use this law in an engineering aspect? 
 
12. Now, we will discuss a rate law.  A rate law, or rate equation, is an 
equation that governs the rate of a process as a function of a variable, 
such as time.  These laws are used by engineers to determine the design 
of a chemical process.  Rate laws applied to this experiment relate 
absorbance with time.  For example, an important variable of a rate law, 
the rate coefficient/constant (k), can be determined using absorbance 
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A Absorbance at time t 
A0 Absorbance at t=0 
A∞ Absorbance at t=∞ 
k Rate coefficient 
  
c) Determine the rate coefficient from your absorbance data.  To do this, 
you will need to determine A∞ based on your data.  Use a point earlier 
in your experiment, and determine a rate coefficient for both sets of 
data. 
d) Based on these results, does temperature affect the dissolution rate?  
Use the rate constant values you obtained to verify your answer.  
ANSWER KEY 
The following data shown in Table 3 will be used when answering the questions 
section of this report: 
Table 3.  Sample absorbance readings at 630 nm for the dissolvable strips laboratory 
Time (min) 
Absorbance readings at 630 nm 
Room Temperature (20°C) Body Temperature (37°C) 
0 0 0 
5 0.049 0.107 
10 0.133 0.268 
15 0.182 0.421 
20 0.245 0.424 
25 0.29 0.457 
30 0.299 0.485 
40 0.356 0.459 
50 0.371 0.476 
60 0.387 0.453 
70 0.417 0.451 
80 0.425 0.458 









1. Once you have the concentrations, create another graph of concentration 
versus time for both temperature sets.  Fill in the table and turn in along 
with the graphs generated and the rest of the report. 
Ans: The unit conversions were made and the table was filled in with the 
following data points, yielding the graph shown below. 
 
Table 4.  Sample data for the concentrations in the dissolvable strips laboratory 






0 0.00E+00 0.00E+00 
5 2.77E-05 6.05E-05 
10 7.52E-05 1.52E-04 
15 1.03E-04 2.38E-04 
20 1.39E-04 2.40E-04 
25 1.64E-04 2.59E-04 
30 1.69E-04 2.74E-04 
40 2.01E-04 2.60E-04 
50 2.10E-04 2.69E-04 
60 2.19E-04 2.56E-04 
70 2.36E-04 2.55E-04 
80 2.40E-04 2.59E-04 

































2. a) Use one of the higher time points (70 to 90 minutes) of both the room 
temperature and body temperature experimental runs to determine the 
molar absorption coefficients of both runs.  Ans. For this answer, the time 
point of 80 minutes was used.  The molar absorption constants were 
found to be: 
ε at room temperature = 1.401* 106 M-1 cm-1 
ε at body temperature = 1.401* 106 M-1 cm-1 
  
 
This was found by first calculating the molar concentration: 
 
                                  
  
  




                               
         
 
 
    
 
   
            
   
 
               
 Now, using the Beer-Lambert Law: 
   
 
   
 
   
     
                
                   
b) Based on the values, do you think that the temperature affects the 
molar absorption coefficient?  Ans.  Since the molar absorptivity 
coefficient is identical between the two sets of data, the temperature of the 
system does not affect the molar absorption coefficient.  This is 






























molar absorptivity coefficient does depend on the temperature of the 
system.6,7 Then again, it might be different since we are working in the 
visible spectrum range, and not the ultra violet region or the infrared 
region.  It should also be noted that we are only working in a temperature 
range of 17 °C.  This might not be enough of a difference to thoroughly 
conclude that temperature has no effect on the molar absorption 
coefficient. 
3. Determine how well the molar absorption coefficients can determine the 
concentration of the solution based on absorbance readings.  Use the 
molar coefficients you found previously and determine the concentration 
that the solution should be at based on the Beer-Lambert Law.  Use a time 
point between 30 and 50 minutes in both cases.  Determine how different 
these two numbers are by using percent difference.  Ans. Using the time 
of 40 min, the Beer-Lambert Law was completed: 
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Then, find the percent difference: 
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The percent difference should be very small, as the molar absorption 
coefficient was found using these readings. 
4. a) How different is the molar absorptivity coefficient that you found using 
your experimental data from this known value?  Use experimental error to 
determine this difference.  Ans. Using the percent error equation, the 
percent error was found to be: 
               
|                              |
               
     
       
b) Now, use the same time point that you used in Question 6 and 
determine the concentration based on the given molar absorptivity 
coefficient.  Again, compare using percent error.  Do this for both 
experimental runs.  Ans.  The sample calculations were done with the 
room temperature experimental run.  Using the Beer-Lambert Equation: 
                        
                 
 
   
           
 
 









Now, find the percent difference: 
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The same was done for the body temperature experimental run. The 
concentration was found to be 2.27 *10-4 and a percent error of 14.5%. 
5. How could you use this law in an engineering aspect?  Ans. This law is 
one of the governing laws of spectrophotometry.  This is used in several 
areas for determining concentrations based on absorbance data.  Some of 
these areas are analytical chemistry, algal studies, and organic chemistry.  
In the case of engineering aspects, this can be useful to chemical and 
civil/environmental engineers.  For example, civil/environmental engineers 
would use this to determine the growth of algae or the concentration of a 
contaminant in water.  Chemical engineers can use this to determine 
contaminants in a system, determine the dissolution rate of a drug, and 
determine the concentration of product in a chemical reaction. 
 
6. a) Determine the rate coefficient from your absorbance data.  To do this, 
you will need to determine A∞ based on your data.  Use a point earlier in 
your experiment, and determine a rate coefficient for both sets of data.  
Ans. Using the time of 15 minutes, the calculations were followed, and k 
was determined for both of the data sets.  These values are shown below: 
 
k @ room temperature 0.0374 min-1 
k @ body temperature 0.1683 min-1 
 
This is obtained through the following calculation: 
 
  
(    )
(     )
        
  
(           )
(       )
     (     ) 
              
 





b) Based on these results, does temperature affect the dissolution rate?  
Use the rate constant values you obtained to back up your answer. Ans. 
Based on the rate constants, the temperature of the system does affect 
the dissolution rate.  From the values obtained, we can see that the rate 
constant increases as the temperature increases.  This means that the 
dissolution rate also increases with temperature.  This makes sense, 
especially when you look at the graph made of the absorbance data. 
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B.5 Effervescence Reaction Lab 
Effervescence Reaction – Instructor’s Version 
Developed by:  Alex Jannini, David Krause, Heather Malino and Kevin Sweeney, 
Rowan University, Department of Chemical Engineering 
Edited by:  C. Stewart Slater and Mariano Savelski, Rowan University, 
Department of Chemical Engineering 
Date of Experiment: 
 
OBJECTIVES 
 Students will perform a basic mass balance on an effervescence reaction 
in pharmacology 
 Students will conduct theoretical stoichiometric calculations and compare 
to experimental results  
 Students will learn about the equilibrium constants and other fundamental 
aspects of reactions 
 
INTRODUCTION 
Alka-Seltzer® is an effervescent 
antacid (NaCO3, KCO3 plus 
anhydrous citric acid) containing 
acetylsalicylic acid (aspirin), which is 
an analgesic, antipyretic, and anti-
inflammatory drug.  Simply put, Alka-
Seltzer® relieves upset stomach, 
provides pain relief, breaks fevers, 
and reduces inflammation.  
The effervescence allows for a faster 
rate of drug dissolution into a liquid medium 
(water in this case) by increasing the surface 
area of the drug exposed to solution and by 
“bubbling” the mixture, causing a stirring effect.  
The effervescence reaction is: 
 C6H8O7(aq) + NaHCO3(aq) 





Figure 1. Standard original strength packet 




In this lab you will determine how much CO2 is generated and released to the 
atmosphere by taking the initial and final weights of an Alka-Seltzer® solution.  
This is an introduction to mass balances, an important concept for engineers.  
This experimental value will then be compared to the theoretical amount of CO2 
mass generated, found through stoichiometry.   
MATERIALS NEEDED 
 2 Alka-Seltzer® tablets (1 packet) 
 Analytical scale (+/- 0.0001 g) 
 Weigh boat 
 Graduated cylinder 




1. Make sure safety glasses and examination 
gloves are on before entering the lab. 
2. Remove both Alka-Seltzer® tablets from the 
packet.  If the tablets are broken, be careful to 
not lose any pieces.  How do you think a 
broken tablet will affect the rate of the tablets 
dissolving? 
3. Place a weigh boat on the scale.  Tare the 
instrument so it calibrates to zero with the 
added weight of the boat. 
4. Weigh the Alka-Seltzer® tablets and record in 
your notebook.  
5. Alka-Seltzer® is supposed to be dissolved in 4 oz. (118.3 mL) of water 
according to the manufacturer’s directions.  Using deionized water, 
measure out this volume of water with a graduated cylinder and add it to 
the beaker. 
6. Weigh the beaker plus the added water and record it in your notebook.  
This weight plus the weight of the Alka-Seltzer® tablets is your initial 
weight. 
7. Drop both tablets into the beaker. 
8. For the first five minutes, take a weight every 60 seconds.  After five 
minutes have passed, measure the weight every five minutes until an hour 
has elapsed.  Tap the bubbles off of the sides of the beaker as they form. 










10. Fill the beaker back up with the same amount of deionized water and 
weigh the water and the beaker. 
11. On a weigh boat, measure out 2.0 g citric acid and 3.832 g sodium 
bicarbonate. 
12. Drop the powder into the beaker and record weights at the same time 
intervals as Part I. 
13. Dispose of the solution down the sink and clean up the lab area. 
 
QUESTIONS 
1. Fill in the tables: 
 
 
2. You should notice that the initial weights of the two solutions are different.   
a. What may cause this? 
b. To fix this, take the difference between the two sets, find the 




to be subtracted from the solution with the higher weights.  Find the 
new weights and record them in the table below. 
 
 
Adjusted Weight Time 
Initial:   0 m 
 
  1 m 
 
  2 m 
 
  3 m 
 
  4 m 
 
  5 m 
 
  10 m 
 
  15 m 
 
  20 m 
 
  25 m 
 
  30 m 
 
  35 m 
 
  40 m 
 
  45 m 
 
  50 m 
    55 m 
Final:   60 m 
 
c. Please graph the revised data set along with the other set that was 
not changed. 
 
3. Determine the experimental amount of CO2 generated and released to the 





4. Balance the reaction given in the beginning of the laboratory. 
 
5. According to the manufacturer’s website, each tablet contains 1000 mg of 
citric acid and 1916 mg of sodium bicarbonate.  Determine the moles of 
each reactant. 
 
6. Determine which reactant is the limiting reactant.  What is the percent 
excess?  Why do you think there is extra added? 
 
7. Using the effervescence reaction given in the beginning of the lab, 
determine the moles produced of CO2 gas. 
 
8. How many milligrams of CO2 were made in both reactions? 
 
9. What is the theoretical final weight of each solution?  Use the weight of the 
beaker and water measured in the lab. 
 
10. Determine your percent error at each point with the given equation: 
 
       (
(                     (             
                    
             ))
                   





11. What were some sources of error in this lab? 
 
12. Was there if a difference in the way the pure components dissolved versus 
the tablets?  Why do you think they behaved the same/differently?  Do you 
think that the use of milling the powders when forming the tablets adds 
into the difference in behavior? 
 
13. What is a different way that this experiment can be designed so that the 
gas released could be directly measured? 
 
14. In reaction engineering, it is important to understand the mathematics 
behind chemical reactions.  One of the important concepts is the reaction 
rate of a chemical reaction.  This reaction rate determines how many 
moles of a reactant are being converted to a product over a period of time.  
The rate of reaction is commonly symbolized by rA.  The  basic equation of 
the rA is: 
      [  ]
  (4) 
 
Where k is the rate constant and CA is the concentration of the limiting 
reactant in a chemical reaction.  This is also known as a rate law.  A rate 




cases, rate laws are zero-order (x=0), first-order (x=1), or second-order 
(x=2).  Now, you will determine the rate constant and order of the rate law 
for a sub-reaction that takes place in the effervescent reaction. 
This sub-reaction is the formation of bicarbonate to carbon dioxide: 
     
     
            (5) 
 
In this reaction, the limiting reactant is the bicarbonate ion.  To determine 
the concentration of the bicarbonate ion (     ), we can use the following 
equation. 
        
              
         
           
 (6) 
We can assume that there is 0.029 moles of bicarbonate ions in solutions. 
a. Using the data you collected, determine the moles of CO2 
generated at each time point, and use that to determine the 
concentration of bicarbonate ions at each time point.  Once this is 
done, make graphs of the following:        vs. time, ln(     ) vs. 
time, and 1/      vs. time.  Print out all three graphs.  Do this for 
just the tablet set of data. 
b. Now, determine the order of both sets of data.  As a reminder; a 
zero-order reaction will be linear for concentration vs. time; a first-
order reaction will be linear for ln(concentration vs. time;  a second-
order reaction will be linear for 1/concentration vs. time. 
c. The rate constant can be found by determining the slope of the 
linear relationship.  Find the k for the tablet. 
  
ANSWER KEY 
1. Fill in the table: 
Ans: Data will vary depending on the team.  However, the table should 






2. You should notice that the initial weights of the two solutions are 
different. 
a. What may cause this? 
Ans:  This may be due to the aspirin in the Alka-Seltzer® tablets.  
However, this would only account for roughly 0.6 g of difference.  
The other difference in mass could be due differences in the 
volume of water.  Human error could have led to the difference 
in water volume between the two trials. 
b. To fix this, take the difference between the two sets, find the 
difference between the two initial points.  This difference will 
need to be subtracted from the solution with the higher weights.  
Find the new weights and record them in the table below. 
Ans:  The difference found between the two starting points was 
3.163 g.  The first trial (Alka-Seltzer® tablets) had to have this 
difference subtracted from all points taken during 






Adjusted Weight Time 
Initial: 119.9593 0 m 
 
119.2441 1 m 
 
119.1068 2 m 
 
119.0503 3 m 
 
119.0183 4 m 
 
118.9997 5 m 
 
118.9390 10 m 
 
118.9056 15 m 
 
118.8749 20 m 
 
118.8506 25 m 
 
118.8290 30 m 
 
118.8067 35 m 
 
118.7835 40 m 
 
118.7601 45 m 
 
118.7356 50 m 
  118.7115 55 m 
Final: 118.6858 60 m 
 
 
c. Please graph the revised data set along with the other set that 
was not changed. 
Ans:  The following graph was made using the fixed Alka-






Figure 4.  Mass lost over time during the effervescence reactions. 
 
3. Determine the experimental amount of CO2 generated and released to 
the atmosphere by subtracting the initial weight from the final weight. 
Ans: With the data obtained above for part I, it was determined that 
the mass lost was 1.36 grams. 
 
                      
 The amount of mass lost in Part II was 0.338 grams. 
                            
4. Balance the reaction given in the beginning of the laboratory. 
Ans:  
 
C6H8O7(aq) + 3NaHCO3(aq) → 3H2O(l) + 3CO2(g) + Na3C6H5O7(aq) 
 
5. According to the manufacturer’s website, each tablet contains 1000 mg 
of citric acid and 1916 mg of sodium bicarbonate.  Determine the 
moles of each reactant by converting each mass. 
Ans: 
(   ) (
    
         
)                             
(       ) (
    
        
)                       
6. Determine which reactant is the limiting reactant.  How much of the 

























(                            ) (
           
                
)
                                   
 
Therefore, citric acid is the limiting reactant 
 
                                                        
 
There is extra sodium bicarbonate added.  In addition to driving the 
reaction, it also acts as an antacid when it enters the stomach. 
 
7. Using the effervescence reaction given in the beginning of the lab, 
determine the moles produced of CO2 gas. 
Ans: 
(                            ) (
         
                
)
                                 
 
8. How many milligrams of CO2 are made in this reaction?  
Ans: 
(                  ) (
       
        
)                                
 
9. What is the theoretical final weight of the solution?  Use the weight of 
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 Part II 
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10. Determine your percent error at each point with the given equation: 
Ans: A sample calculation for this is shown.  Using this, the table was 
filled out: 
       (
(                     (             
                    
             ))
                   
)        
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(         (                     ))
       







Alka-Seltzer difference from 
theoretical 
Pure difference from 
theoretical 
0 100 100 
1 48.014 81.247 
2 38.034 62.435 
3 33.927 54.105 
4 31.601 49.562 
5 30.249 46.502 
10 25.837 39.161 
15 23.410 35.650 
20 21.178 33.448 
25 19.412 31.958 
30 17.842 30.751 
35 16.221 29.639 
40 14.535 28.672 
45 12.834 27.756 
50 11.053 26.862 
55 9.3010 25.997 






Figure 5.  The percent difference from stoichiometry seen in the effervescence 
reaction. 
 
A graph of this was made: 
 
 
11. What were some sources of error in this lab?  
Ans. Some sources of error in this lab include (most obviously) not all 
of the CO2 leaving solution.  In addition, a portion of CO2 could have 
been absorbed by the water, as described by Henry’s Law.  The 
addition of aspirin (an acid) could have had some effect on the pH of 
the system, which could affect the rate and extent of the reaction.  The 
pure powder may have not been well-mixed, which may have caused 
the reaction to not occur in optimal conditions. 
12. Was there if a difference in the way the pure components dissolved 
versus the tablets?  Why do you think they behaved the 
same/differently?  It is known that Alka-Seltzer tablets use a milling 
process to reduce the size of their powder.1 Do you think that the use 
of milling the powders when forming the tablets adds into the 
difference in behavior? 
Ans:  The pure components will dissolve at a much slower rate if not 
properly mixed.  It is not specified in the procedure to thoroughly mix 
the components together, so it is expected of students to realize why 
this case dissolves slower.  The milling of the powder, the first step 
listed in the Handbook of Pharmaceutical Manufacturing Formulations2 
for the creation of effervescent tablets, will of course affect the 
behavior of the reaction. Milling the powder creates particles of smaller 
size, and the smaller the particle, the greater the surface area for the 
reaction to take place.  Since the powder is finer in the tablets, the 
powder will dissolve quicker, which is shown above in Question 10. 
13. What is a different way that this experiment can be designed so that 







































Ans:  If the reaction is carried out in a container that has a flow meter 
attached to it than the amount of CO2 released can be directly 
measured.  A similar, but more crude method, would be to attach a 
balloon to the top of a flask then estimate the volume occupied by the 
gas and density of CO2 at experimental conditions to find a mass 
released. 
14. Now, you will determine the rate constant and order of the rate law for 
a sub-reaction that takes place in the effervescent reaction. 
a. Using the data you collected, determine the moles of CO2 
generated at each time point, and use that to determine the 
concentration of bicarbonate ions at each time point.  Once this 
is done, make graphs of the following:        vs. time, ln(     ) 
vs. time, and 1/      vs. time.  Print out all three graphs.  Do 
this for just the tablet set of data. 
Ans: First, we need to find the mass of CO2 that is being 
generated in the reaction.  This can be found by taking the total 
weight and subtracting the weight at the different time points. 
                                      
Then we can find the moles by dividing the grams of CO2 by the 
molar mass (44 g/mol). 
        
    
   
 
   
 
Then, we use Equation 6 to find the concentration HCO3 in 
mol/L.  A sample of this calculation is shown for the time of 10 
minutes: 
                                    
        
       
   
 
   
          
       
                
        
       
   
 
 























0 0.0000 0.0000 0.2451 -1.4059 4.0793 
1 0.2580 0.0059 0.1956 -1.6318 5.1129 
2 0.5168 0.0117 0.1459 -1.9250 6.8551 
3 0.6314 0.0143 0.1239 -2.0886 8.0733 
4 0.6939 0.0158 0.1119 -2.1905 8.9397 
5 0.7360 0.0167 0.1038 -2.2655 9.6363 
10 0.8370 0.0190 0.0844 -2.4725 11.8518 
15 0.8853 0.0201 0.0751 -2.5890 13.3159 
20 0.9156 0.0208 0.0693 -2.6696 14.4345 
25 0.9361 0.0213 0.0653 -2.7281 15.3043 
30 0.9527 0.0216 0.0622 -2.7782 16.0894 
35 0.9680 0.0220 0.0592 -2.8266 16.8879 
40 0.9813 0.0223 0.0567 -2.8707 17.6494 
45 0.9939 0.0226 0.0542 -2.9144 18.4369 
50 1.0062 0.0229 0.0519 -2.9589 19.2765 
55 1.0181 0.0231 0.0496 -3.0039 20.1649 
60 1.0299 0.0234 0.0473 -3.0507 21.1307 
 
 









































Figure 6.  The bicarbonate concentration versus time.   
Figure 7.  The natural log of the bicarbonate concentration 
versus time.   
Figure 8.  The inverse of the bicarbonate concentration 


















b. Now, determine the order of both sets of data.  As a reminder; a 
zero-order reaction will be linear for concentration vs. time; a 
first-order reaction will be linear for ln(concentration vs. time;  a 
second-order reaction will be linear for 1/concentration vs. time. 
Ans: Of the three graphs, the inverse of the bicarbonate 
concentration versus time is the closest to being linear.  With 
this in mind, it is determined that the tablet effervescence 
reaction is a second-order reaction.  A trendline was put through 





c. The rate constant can be found by determining the slope of the 
linear relationship.  Find the k for the tablet. 
Ans: The equation that fits through the trendline was found to 
be: 
                
The k would then be 0.2504. 
Figure 9.  Trendlines added to a) the bicarbonate concentration, b) the natural log 
of the bicarbonate concentration, and c) the inverse of the bicarbonate 
concentration versus time graphs.  From the R
2
 values, it would appear that the 
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B.6 Dextromethorphan Crystallization Lab 
Dextromethorphan Crystallization Laboratory – Instructor’s Version  
Developed by:  Alex Jannini, David Krause, Heather Malino and Matthew Van 
der Wielen 
Edited by: C. Stewart Slater and Mariano J. Savelski, Rowan University, 
Department of Chemical Engineering  
Date of Experiment: 
 
OBJECTIVES 
 Students will develop a solubility curve for dextromethorphan.  
 Students will gain an understanding of the techniques of crystallization 
and how it is used in the pharmaceutical industry. 
 Students will learn the fundamentals of energy balances and heat transfer.  
 
INTRODUCTION  
A crystal is defined as a solid material whose atoms, molecules, or ions are 
arranged in an ordered pattern in three dimensions.  Crystallization is the 
process by which solid crystals precipitate out of a solution.  After the 
precipitation occurs, there will be a solid phase and a liquid phase in the solution.  
Then, the solution will be filtered to separate the two phases.  Sometimes the 
solid phase is the desirable phase while other times the liquid phase is desired. 
Crystallization is a commonly used method of separating solid-liquid solutions in 
industry.  Crystallization has been utilized in many different processes for 
decades.  For example, many commodity chemicals like xylene and inorganic 
salts such as sodium chloride are formed using crystallization1.   
In more recent years, crystallization is used in the pharmaceutical industry.  The 
most common reason for using crystallization in the pharmaceutical industry is to 
obtain a high purity active pharmaceutical ingredient (API).  In the case of vitamin 
C purification, crystals are formed in either an aqueous or alcohol based media 
and then filtered out of solution2.   
One of the tools used in designing crystallization processes is the solubility 
curve.  A solubility curve can be used to determine the saturated concentration of 
a solution of solids in a liquid.  An example solubility curve is shown on the next 
page.  The solubility curve is usually based on the concentration of solid in the 
solution and the temperature of the solution.  In most cases, solubility curves are 
made with a solute in a solvent.  In this lab, you will be making a solubility curve 







Dextromethorphan (DXM) is the active pharmaceutical ingredient (API) in several 
cough syrups.  Dextromethorphan is a strong antitussive agent.4 It is often found 
as a monohydrated hydrobromated salt.  This means that one molecule of HBr is 
attached to the dextromethorphan crystal. It belongs to the morphine group of 
alkaloids.  A typical amount of dextromethorphan in one dose of cough medicine 
is approximately 15 mg.     
INSTRUCTOR’S NOTE 
Each group will need roughly 5 grams of DXM.  Dextromethorphan HBr is a 
controlled substance.  In order to obtain the API, you may need to send in a 
formal request letter stating the purpose of the experiment to your preferred 
vendor (Dextromethorphan HBr was obtained through Spectrum Chemical®).  It 
should be noted that dextromethorphan can be illicitly used as a recreational 
drug.  For this reason, we suggest that you provide a lecture on the dangers of 
working with pure API’s and the discussion of specific MSDS information 
(LC50/LD50, toxicological effects, etc.).  It is also suggested that you have the 


















































SAFETY AND CONSIDERATIONS 
Safety googles must be worn at all times in the lab.  Gloves should also be worn 
during this experiment.  When working with the powder, a dust mask should be 
worn.  The chemical is of USP grade. 
MATERIALS NEEDED 
 
 Dextromethorphan HBr (one lab that contains 6 groups of students will 
need approximately 30 grams) 
 Citric Acid, Anhydrous (one lab that contain 6 groups of students will need 
approximately 180 grams) 
 Analytical scale (capable of reading 10-3 grams) 
 Weigh boats 
 14 test tubes 
 Test tube rack 
 1 large (approximately 800 mL or higher) beaker 
 Heat/stir plate 
 Stir bar 
 2 thermocouples with rod attachments 
 Large graduated cylinder (1000 mL) 
 5mL micropipette 
 Sharpie® or marking pencil  
 Ring stand with test tube clamp 
 
PROCEDURE 
PART 1:  DXM  
For time limitations, divide the lab up so that half the team completes steps 1-2 
while the other half of the group completes step 3-6. 
1. Using the marking pencil or Sharpie®, number 7 test tubes and place them 
into a test tube rack. 
2. Using the analytical scale, measure the dextromethorphan and prepare 










Figure 2.  Proper setup of a test 
tube in the hot water bath. 









Tube #7 is a choice. You may choose 
any value (other than 600 mg) to place in 
this vial.  Make sure to record this 
number. 
3. Note the maximum volume of the large 
beaker.  You will need to fill the beaker 
¾ of the way full.  Use the large 
graduated cylinder in order to precisely 
measure the amount of water you add to 
the beaker.  Record the volume of water 
that you added to the beaker.  
4. The beaker that you filled with water will 
be used as a hot water bath. Place the 
water bath on the hot/stir plate, and 
place a stir bar in the beaker. Place the 
heat control setting somewhere in the 
middle, and set the stir setting to the 
lowest possible setting.   
5. Place one of the thermocouple rods in 
the water.  The water bath needs to 
stay within 80 to 90 °C, which is the temperature suitable for dissolving all 
the DXM.  This will require supervision and maintenance. 
6. Now, setup the test tube clamp on the ring stand so that the clamp is just 
above the beaker.  
7. Once you have measured out the masses of DXM necessary, use the 
micropipette and place 5 mL of water in each of the test tubes. 
8. Now, secure test tube #1 in the tube clamp, and place the second 
thermocouple rod in the tube.  Lower the clamp so that the test tube is as 
submerged as possible in the water bath.  
9. Stir the test tube with the rod of the thermocouple.  Keep stirring the 
solution until you see the DXM completely dissolve in the water.  Loosen 
the clamp and remove the tube.  Use a test tube holder if the tube is too 
hot.  
10. Now hold the thermocouple in the solution. You may also need to wipe off 




Figure 3.  The 




Figure 4.  The 
DXM and water 
solution once 
crystallization has 
begun.  Notice the 
white substance 
at the bottom of 
the tube. 
to the light and examine the solution for the first signs of crystallization. 
Record the temperature immediately as crystallization begins in the data 
table. 
11. Repeat steps 8 through 10 for the other test tubes.  Record all data.  You 
















You may use the table below to record your data.  However, it is encouraged to 















Figure 5.  A screenshot of 
the graph you will need in 
Excel. 
DATA ANALYSIS 
For this section, you will be using Microsoft 
Excel.  Once you have completed the lab and 
collected all the data, open up a new Excel file 
and place the data in a spreadsheet.  Now, the 
concentration that we have right now is in 
mg/5mL.  Change this to g/L.  Remember that 
there are 1000 mg per g and 1000 mL per L.  
 
Once this is done, we need to create a 
solubility curve.  To do this, we will be using 
the chart wizard.  In excel, go to the insert tab and chose to insert a scatter 
graph.  Look specifically for the “scatter with smooth lines and markers” option.  
Create a scatterplot that has temperature on the X-axis and concentration on the 
Y-axis for the first six points of the data collected.  In addition, please use the 
following data points when creating your graph of the DXM data: 
 
 





Once this is done, change the chart layout so that you have titles for the x- and y-
axis.  This should be the first option in the chart layout section.  Once you have 
titles for the axes, label them accordingly.  Label the chart with your group 
number or the last names of your group members, and then delete the “Series 1” 
label. 
Once you have a chart, you will need to edit the x-axis.  To do this, click on the 
values on the x-axis.  You should see these values boxed.  Once done, right 
click, and click on the “Format Axis” option.  You should now see the Axis Option 
menu.  In this menu, look for “Major tick mark type.”  In the dropdown menu, 
select the inside option.  Once this is done, print out your graph.    Do the same 
thing for the citric acid data.  Make sure to print out that graph as well.  You will 
need these later. 

















1. Now that we have a graph, we can check the accuracy of it.  We will do 
this by using the random point that you collected during the procedure.   
a. We will check the accuracy of the graph through a process known 
as interpolation.  In interpolation, you determine a new data point 
that lies within data that has already been collected.  To do this, 
you will need a ruler.  First, determine the concentration of your 
unknown in grams/L.  Once you know that value, locate it on your 
chart.  If your concentration lies within two tick marks, you will need 
to use the ruler.  First, determine the length between the two tick 
marks.  Next, solve the following equation: 
 
 (                              )
                         
 
(                            )





Once you have found the length between the concentration and the 
lower tick, mark that on your graph.  Once that is done, draw a 
straight line from this point to the line generated.  Then, draw a 
straight line down to the x-axis.  Now, you will have to determine 
the temperature this corresponds to.  Here, you will have to do the 
same thing that you did previously.  Determine the length between 




between the lower tick mark and the line you drew down.  Using the 
equation below, determine the temperature: 
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b. Now that we have the temperature obtained from interpolation, we 
will determine the percent error between the temperature obtained 
through part a. and the temperature obtained experimentally.  Use 
the following equation: 
 
         
|                             |
              
      
(3) 
 




2. Energy is required to heat the water bath to 90°C.  The most basic 
equation that models the energy required to heat the water from room 
temperature to 90°C is: 




Where “Q” is the energy required in J/g, “m” is the mass of water and “Cp” 
is the specific heat capacity of water. 
a. Using the specific heat as 4.18 J/(g * °C) and the density of water 
as 1.00 g/mL, determine the amount of energy required to heat the 
water to 90°C.  You may assume that the water was at room 
temperature (20 °C) before heating. 
b. If a tank in an industrial process needs to heat 200 gallons of water 
to 90°C, how much energy would be needed? 
 
3.  Whenever there is a flow of heat from one source to another, there is an 
exchange of energy.  This flow of energy is studied in the field of heat 
transfer.  We will now discuss one of the basic conventions of heat 
transfer; conduction.  Conduction can be defined as the transfer of energy 
from more energetic particles to less energetic particles due to their 
interactions.7 One important term in conduction is the thermal diffusivity of 




variable, α) measures the ability of a material to conduct thermal energy in 
relation to its ability to store thermal energy.7 To find α, we can use the 
following equation: 
 
    
 
   
 (5) 
With: 
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] 
a. The term α is considered a dimensionless constant.  With the units 
provided, prove that this is so. 
b. Determine the thermal diffusivity of water at 25 °C and aluminum at 
25 °C.  Which is higher?  What does this tell you about the two 
substances in regards to the conduction and storage of thermal 
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] 
290 0.598 0.999 4.184 235 2708 0.868 
300 0.613 0.997 4.179 237  2702 0.903 
  
Obviously, you will need to use interpolation in order to obtain the 
correct data points.  Use a similar method as used in Question 1. 
 
c. Now, determine the thermal diffusivity for aluminum at 200 and 400 
K.  Use the following data below.  What does this tell you about the 
thermal diffusivity of aluminum in regards to temperature?  Do you 
think this is true for all temperature ranges?  Try with 400 and 800.  
Does this provide more insight into the thermal diffusivity of 








Table 2.  Thermophysical properties for water and aluminum at varying temperatures.  Adapted 
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200 2719 237 
400 2681 240 
800 2591 218 
 
4. In simple heat transfer, we can model the flow of heat using one-
dimensional, steady-state conduction.  What this means is that we model 
the flow of energy as though it were in one direction at an unvarying rate.  
This allows us to model the flow of heat over a certain distance.  We will 
do this for the case of the test tubes we used in this experiment. 
 
First, we must show how to properly model this flow of heat.  Picture the 
test tubes used in this.  We will say that in the direct middle of the water 
will be the starting point.  Then, we will say that top of the water level 
(where water meets air) is the ending point.  So with these start and end 
points, we will be modeling the flow of heat from the middle of the test 








Table 3.  Thermophysical data for aluminum at varying temperatures.  Adapted from 
Incropera et al and Thermal Fluids Central.
7,8 
Figure 7.  A representation of the one-dimensional, steady-state conduction model 




In order to model this, we need to make two assumptions: 1) that the heat 
flows at a steady-state (does not fluctuate over time) and 2) that all the 
sides except for the end point are perfectly insulated.  (NOTE: The other 
assumption that is made in order to use this model is that the surface 
temperature of the water is the same as the air temperature.  If this 
assumption is not made, the flow of heat from the surface via natural 
convection, or the natural flow of air on the surface of the water, needs to 
be taken into account.  This makes the model much more difficult; and as 
such, is eliminated from the model.) 
With these assumptions made, we can use the following equation to 
model the flow of heat from the starting point to the end point.  To do this, 
we can use the following equation to solve for the heat flow7: 
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Now, we will also say that half the volume of the water added to the test 
tube is in this specific space used for the model (2.5 mL).  Assuming that 
the water is a perfect cylinder, and that the test tube has an inner diameter 
of 0.55 in, you find all the information necessary to model this flow of heat. 
 
a. First, we will model this as though it were pure water.  Take the 
temperature of recrystallization you found for test tube #1 in your 
DXM experiments, and state that this is To.  T1 will be the 
temperature of the air (20 °C).  Determine the heat transfer rate if 
the thermal conductivity of water is at a weighted average of 0.58 
W/m*K. 
b. Now, we are going to find the thermal conductivity (k) for a mixture 
of the salts used in this experiment.  To do this, we will use a 
thermal conductivity approximation for salt solutions.  This is shown 
below9: 
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Make sure to use these units when using the calculation.  Again, 
use data obtained from test tube #1 for this.  For the temperature, 
determine the average between the air and the temperature of 
crystallization.  Determine the k value for DXM using this equation, 
then find qx using the equation from part a. 
c. Determine the percent difference between parts a and b.  Is there a 
considerable difference?  Which do you think is more accurate?  
Keep in mind that the thermal conductivity approximation you were 
given was developed using sea salt.  
d. In order to calculate this, we made two assumptions about the heat 
flow.  Can these assumptions be made for our experiment?  Why or 
why not? 
 
5. Citric acid is often used as a flavoring agent in pharmaceuticals.  The 
saturation point for citric acid in water is provided.  This is another way of 
showing the solubility of a substance, but with different units.  Instead of 
concentration in mass solute per volume solution, we give the 
concentration in mass solute per mass solution. 
 
 
a. Now, we have discussed solubility curves in great detail.  In the 
introduction of this experiment, we discussed how a solubility curve 
tells you the point where a solution of solid crystals will completely 
dissolve into a solvent.  Using the graph above, describe what 


























Figure 8.  The saturated weight percent of citric acid in water with 






(example, 60 wt% and 10 °C) and what would happen if you picked 
below the solubility curve (example, 50 wt% and 60°C). 
b. During the production of the new pharmaceutical tablet, 75 kg of 
citric acid is placed in a mixer with 100 kg water at 40 °C.  The 
operators on duty notice that not all of the powder is dissolving into 
the water.  Using the solubility curve, explain why this occurs.  If we 
needed to fully dissolve the citric acid in the water, what would you 
recommend doing? 
c. In another operation that uses citric acid, 78 pounds of citric acid is 
dissolved in 60 pounds of water and is heated to 80 °C.  The 
solution needs to be cooled so that 18 pounds of crystals can be 
collected.  To what temperature should this solution be cooled to? 
 
6.   In the previous question, you were given a scenario in which a solution of 
crystals and solvent were cooled past the solubility point.  Indeed, this is 
what is commonly done in industry in order to separate crystals from 
liquids.  Usually, the solution is sent to a cooler, a type of machine that 
drops the temperature of the solution.  This allows crystals and saturated 
solution to form.  This mixture is sent to a filter, which physically separates 
the liquid from the solid.  Then, the solid (known as “cake”) is sent to a 
dryer, so that more liquid can be removed from the crystals.  An example 





Figure 9.  A simplified version of the setup used to separate crystals from 





a. 100 kg of a solution with a concentration of 150 grams of DXM per 
liter of water is sent through this process.  The temperature of the 
solution is initially 75 °C, and is cooled down to 45 °C.  Using your 
DXM data, determine the mass of crystals that would precipitate 
out. Assume that the solution has the same density as water. 
b. Now, say this cooled solution is sent to a filter.  The filter is 
considered 100% effective at removing the crystals.  If the 
composition of the cake is 80% crystal by mass, calculate the mass 
of saturated solution that has been separated with the crystals. 
c. If the dryer only allows the water to evaporate, what is the overall 
mass of crystals that was collected?  If compared to the original 
amount of crystals in solution, what is the overall yield of this 




The following data was collected and used for the data analysis section: 
 
Test tube # 
Milligrams (mg) of DXM 
/5 mL water 
Temperature of 
Recrystallization (°C) 
1 200 32.2 
2 400 43.4 
3 600 52.4 
4 800 53.0 
5 1000 56.1 
6 1200 58.2 
7 750 52.5 
 
 
Since the concentrations are in mg/5mL water, the concentration was changed to 
g/L. An example of the conversion is shown below using the 200 mg/5mL 
concentration: 
     
   
  




      
  
      
 







Using this conversion, the data is now: 
Test tube # Concentration (g/L) 
Temperature of 
Recrystallization (°C) 
1 40 32.2 
2 80 43.4 
3 120 52.4 
4 160 53.0 
5 200 56.1 
6 240 58.2 
7 150 52.5 
 




The solubility curve generated has similar features to other solubility curves 
shown previously.  In fact, this appears to be similar to the solubility curve of 
KNO3, where it grows in a large, nonlinear way with increasing temperature.
2 
Some of the limitations to this data is that it can only be used for concentrations 
and temperatures that were used in this experiment.  This isn’t a severe 
limitation, though, as the boiling point of water is 100 °C.  Going beyond the 




























Figure 10.  Example data for the Dextromethorphan 





1. Now that we have a graph, we will be checking the accuracy of it.  We will 
do this by using the random point that you collected during the procedure. 
a. First, we will check the accuracy of the graph through a process 
known as interpolation…   
ANS.  Using point 7, we found that the concentration in g/L was 150.  
This was already marked on the y-axis, so interpolation was not 
needed.  If needed, however, Equation (1) would be: 
 
       
      
  
      
              
                        
 
From there, a horizontal line would be drawn until it intersected the 
trendline at that concentration.  Again, since this was already marked, 
the developers simple marked where the intersection occurred.  From 
there, a vertical line was drawn until it intersected the x-axis.  Equation 
(2) was used to determine the temperature: 
(     )  
    
  
(    )  
      
         
b. Now that we have the temperature obtained from interpolation, we 
will determine the percent error between the temperature obtained 
through part a. and the temperature obtained experimentally.  What 
does this tell you about the possible shape of the solubility curve? 
ANS.  Using Equation 3, the percent error was found to be 0.95% for 
part a.  An example calculation for part a) is shown below: 
         
|       |
    
             
This shows us that the solubility curve seems to be an accurate model 
of the effects of temperature on concentration. 
2.   Energy is required to heat the water bath to 90°C… 
a. Using the specific heat as 4.18 J/g and the density of water as 1.00 
g/mL, determine the amount of energy required to heat the water to 
90°C. You may assume that the water was at room temperature (20 
°C) before heating. 
ANS.  First, the mass of water was found using the volume of water for 




           
 
  
       
Then, using Equation (4), and assuming water was at room 
temperature prior to heating: 
             
 
    
 (     )                     
b. If a tank in an industrial process needs to heat 200 gallons of water 
to 90°C, how much energy would be needed? 
ANS. First, to obtain the mass, we use the same density: 
                  
  
   
   
 
  
            
Then, we use Equation (4) and again assume room temperature at the 
starting point: 
                 
 
    
 (     )            
             
3. The thermal diffusivity (represented from now on by the variable, α) 
measures the ability of a material to conduct thermal energy in relation to 
its ability to store thermal energy.7 
a. The term α has specific units.  With the terms provided, find the 
units of α. 
ANS. If we plug in the units of the equation: 
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After cancelling out all like terms, α can be found to have the following 
units: 




b. Determine the thermal diffusivity of water at 25 °C and aluminum at 
25 °C.  Which is higher?  What does this tell you about the two 
substances in regards to the conduction and storage of thermal 




ANS. To do this, interpolation is needed.  Using the table of data 
available, interpolation can be carried out to find the k, Cp, and ρ 
values.  An example of this is shown for the k value of water: 
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Water 0.6100 0.9974 4.18 
Aluminum 236.6 2703 0.896 
 
Using these values, α was determined.  The following is a sample 
calculation for water: 
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The α value for aluminum was found to be 9.77 * 10-5 m2/s.  It appears 
that water has a higher thermal diffusivity than aluminum at 25 °C. It 
appears that a higher thermal diffusivity means that it has more of an 
ability to conduct thermal energy than to store it. 
 
c. Now, determine the thermal diffusivity for aluminum at 200 and 400 
K.  What does this tell you about the thermal diffusivity of aluminum 
in regards to temperature?  Do you think this is true for all 
temperature ranges?  Try with 400 and 800.  Does this provide 
more insight into the thermal diffusivity of aluminum with respect to 
temperature? 
ANS. Again, we will go through the thermal diffusivity calculation.  A 
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Using this calculation, the thermal diffusivity was found to be: 





From the first range in temperatures, it would appear that the thermal 
diffusivity will decrease with temperature.  By looking at the list of 
terms that are used to determine the thermal diffusivity, it might be 
thought that the thermal diffusivity will increase at the 800 K 
temperature point.  However, when the thermal diffusivity is calculated 
at 800 K, it was found to decrease from the value at 400 K.  This 
reinforces the idea that the thermal diffusivity will decrease with 
temperature. 
4. Now, we will also say that half the volume of the water added to the test 
tube is in this specific space used for the model (2.5 mL).  Assuming that 
the water is a perfect cylinder, and that the test tube has an inner diameter 
of 0.045 in, you can find all the information necessary to model this flow of 
heat. 
a. First, we will model this as though it were pure water.  Take the 
temperature of recrystallization you found for test tube #1 in your 
DXM experiments, and state that this is To.  T1 will be the 
temperature of the air (20 °C).  Determine the heat transfer rate if 
the thermal conductivity of water is at a weighted average of 0.58 
W/m*K. 
ANS. First, using the information, we determine the surface area using 
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Now, we determine the height of the cylinder with the area and the 
volume: 




     
        
  
       
        





Now, we can find qx: 
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b. Now, we are going to find the thermal conductivity (k) for a mixture 
of the salts used in this experiment.  To do this, we will use a 
thermal conductivity approximation for salt solutions. Make sure to 
use these units when using the calculation.  Determine the k value 
for DXM using this equation, then find qx using the equation from 
part a. 
ANS. First, we determine the temperature: 
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And, we use the approximation equation: 
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And then, we use this k for the qx equation. 
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c. Determine the percent difference between parts a and b.  Is there a 
considerable difference?  Which do you think is more accurate?  
Keep in mind that the thermal conductivity approximation you were 
given was developed using sea salt.  
ANS. The percent difference was found to be: 
             
|            |
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It is hard to determine which is more accurate.  Since the concentration 
is quite dilute, the thermal diffusivities probably wouldn’t vary too much.  
The fact that the thermal conductivity approximation was gathered with 
sea salt solutions is probably not the most accurate approximation 
method for DXM, but again, the fact that the sample was a small 
concentration accounted for minimal difference between the two. 
d. In order to calculate this, we made two assumptions about the heat 
flow.  Can these assumptions be made for our experiment?  Why or 
why not? 
ANS. Technically, we cannot assume that all but one side is perfectly 
insulated.  These sides are not perfectly insulated, and therefore, heat 
is being lost from all sides. 
5. Citric acid is often used as a flavoring agent in pharmaceuticals  
a. Using the graph above, describe what would happen if you picked a 
point above the solubility curve (example, 60 wt% and 10 °C) and 
what would happen if you picked below the solubility curve 
(example, 50 wt% and 60°C). 
ANS. If you were to pick a point above the solubility curve, such as the 
one provided, the concentration is passed the saturation point.  
Therefore, crystals will not be dissolved in the solvent.  Any point 
below the solubility curve is below the saturation point, so the crystals 
will fully dissolve in the solvent. 
b. During the production of the new pharmaceutical tablet, 75 kg of 
citric acid is placed in a mixer with 100 kg water at 40 °C.  The 
operators on duty notice that not all of the powder is dissolving into 
the water.  Using the solubility curve, explain why this occurs.  If we 
needed to fully dissolve the citric acid in the water, what would you 
recommend doing? 
ANS. Upon reviewing the graph, it is clear that the concentration of this 
mixture is beyond the saturation point for that specific temperature.  
This would explain the powder will not dissolve fully in the water.  For a 




citric acid per 100 kg of water.  In order to get the citric acid to fully 
dissolve into the citric acid into the solution, it would be suggested to 
be somewhere between 65 and 70 °C.  It would be safe to be on the 
higher end of this temperature range, just to make sure that the 
concentration is below the saturation point, and that crystals will not 
start forming in the solution. 
c. In another operation that uses citric acid, 78 pounds of citric acid is 
dissolved in 60 pounds of water and is heated to 80 °C.  The 
solution needs to be cooled so that 18 pounds of crystals can be 
collected.  To what temperature should this solution be cooled to? 
ANS. First, we find that the weight percent of citric acid in the initial 
solution is roughly 56%.  If we needed to crystallize out 18 pounds, the 
weight percent of citric acid would change to 50%.  Therefore, we need 
to cool the solution down to the temperature where the saturation point 
of the solution would be 50% citric acid.  Using the graph, we can 
determine that to be around 7°C.  A graph of this is shown below. 
 
 
Here, the gray line is how to answer the problem.  Interpolation is used 
to determine the initial weight percent and the final temperature. 
 
6. In the previous question, you were given a scenario in which a solution of 
crystals and solvent were cooled past the solubility point.  Indeed, this is 
what is commonly done in industry in order to separate crystals from 
liquids. 
a. 100 kg of a solution with a concentration of 150 grams of DXM per 
liter of water is sent through this process.  The temperature of the 





























DXM data, determine the mass of crystals that would precipitate 
out.  Assume that the solution has the same density as water. 
ANS. We know that 75°C is beyond the point of saturation for a 150 
g/L solution of DXM and water.  So, we first go to the point of 150 g/L 
and 45°C.  This is above the saturation point, so we should first 
determine the saturation concentration at 45°C.  First, a vertical line is 
made to intersect the point of this example and the solubility curve.  
Then, a horizontal line is drawn to connect the y-axis to the point of the 




Once again, the gray squares represent the solution to this problem.  
Then, using interpolation: 
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Now, assuming that the density of this solution is the same as water, 
the volume of solution is: 
                   
 
  






























So on a 1 liter basis, 40 grams of crystals are precipitated out.  Using 
the volume of 100 L, we get 4000 grams, or 4 kg, precipitated out. 
b. Now, say this cooled solution is sent to a filter.  The filter is 
considered 100% effective at removing the crystals.  If the 
composition of the cake is 80% crystal by mass, calculate the mass 
of saturated solution that has been separated from the crystals. 
ANS. If the filter is 100% effective at removing the crystals, then we 
know 40 grams of crystals makes up the cake, then, using the 
definition of mass percent: 
 
           
         
                 
       
    
            
      
 
             
c. If the dryer only allows the water to evaporate, what is the overall 
mass of crystals that was collected?  If compared to the original 
amount of crystals in solution, what is the overall yield of this 
process? 
ANS. If 1 kg of solution is with the crystals, there is 1 L of saturated 
solution.  If the dryer only evaporates water, and the solution had a 
concentration of 90 grams of DXM per liter, then 90 grams, or 0.09 kg, 
of crystals is left after drying.  This gives: 
                                                                 
         
 
The original amount of crystals is: 
                
     
 
                 
  
     
       
The yield is: 
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B.7 Creation of Dissolvable Strips Lab 
Creation of Dissolvable Strips – Instructor’s Version 
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der Wielen, Rowan University, Department of Chemical Engineering 
Edited by:  C. Stewart Slater and Mariano J. Savelski, Rowan University, 
Department of Chemical Engineering 
Date of Experiment: 
 
OBJECTIVES 
 Students will learn about the commonly used processes for industrial thin 
film production 
 Students will learn and use basic quality control testing methods 
 Students will gain insight into energy requirements for drying thin films 
 
INTRODUCTION 
Dissolvable strips have become an important mechanism for drug delivery.  
Orginially created as candy, dissolvable strips fill a niche role, providing rapid-
release drug delivery.  Due to the drug being dissolved directly into the blood 
stream through the tounge, it bypasses the metabolism of the body, which can 
cause drugs to lose some of their bioavaliability (the amount of drug that will 
circulate through the body).  Other advantages of using thin films include not 
having to take the drug with water, no risk of choking, and reduced dose size 
because the drug is more bioavailable sublingually (tissues under the tounge).1 
 The ingredients of a dissolvable strip will vary, depending on the desired drug 
release rate, the sensitivity of the drug, and several other factors.  However, all 
strips will contain the following ingredients; an active pharmaceutical ingredient 
(API), polymers, placticzers, and sweetners/flavoring.2  A polymer is often 
determined based on its reactions with water.  The more hydrophilic (attraction to 
water) the polymer is, the faster the film will dissolve and release the API.  The 
plasticzer helps improve flexibilty and prevent brittleness in the strip, while the 
sweetners and flavorings help to improve palatability and increases patient 
compliance. 
On an industrial level, dissolvable strips are primarily made with either a solvent-
casting film system or a film extrustion system.  Solvent-casting systems are the 
most common process, as they do not require heat, which could damage an API, 
and are relatively inexpensive to construct.  A typical setup for a solvent-casting 
system can be seen on the next page.3  The drawbacks to solvent-casting 





Alternatively, hot melt extrusion 
is also used to create strips.  
The advantages to extrusion 
are a simpler design and the 
lack of water needed to run the 
process, but the materials used 
in the dissolvable strip must be 
heat resistant and be able to 
flow as a dry powder.  A sample 
of both of these systems can be 
seen in Figures 1 and 2.   
In this lab, you will be creating your own dissolvable strips.  This procedure is 
based on the solvent casting method described above.  Through this lab, you will 
have a better understanding of the way that dissolvable strips are created, and 
some of the engineering principles behind the process. 
INSTRUCTOR’S NOTE 
In this experiment, no API is added to the dissolvable strips, as no drug modeling 
is being analyzed.  If you wish to use an API, that is acceptable, and caffeine is 
recommended as an inexpensive API.  In addition, it is possible to obtain food-
grade versions of each of these chemicals.  If possible, you may wish to do this 
in a food-safe area, and allow the students to try their strips once they are done 
the experiment.  Lastly, the apparatus used in this experiment is a Teflon sheet 
Figure 1. A diagram of a solvent-casting system as adapted from Particle Sciences.
3
 
Figure 2. Screw-forced extrusion of dry feedstock 











These thickness guides have dimensions as follows:  Length of 31 cm, a height 
of 2.7 cm, and a thickness of 0.06 cm.  The thickness guides were made from 
aluminum metal sheets.  Note that the thickness guides are adhered to the 
surface.  This was done through silicone adhesive caulk.  The adhesive caulk 
takes time to dry (48-72 hours), so it is suggested to have these sheets prepared 
ahead of time for the experiment. 
SAFETY CONSIDERATIONS 
Make sure to wear safety goggles at all time.  Laboratory safety gloves should 
also be worn. 
  
  





MATERIALS NEEDED  
 
PROCEDURE 
Table 6: Recipe for CMC preparation 
Species* Weight (g) Weight % 
CMC 7.7 1.6 
Glycerol 2.6 0.6 
Peppermint oil 0.5 0.1 




Sucrose 1.5 0.3 
Water 500 97 
TOTAL 514.3 100 
* Instructor’s Note: All chemicals can be 
obtained from Fisher Scientific.  Peppermint 
oil can be found in specialty food stores or 
online. 
 
1. Weigh out the appropriate amounts of all powdered ingredients. 
2. Add the required amount of deionized water to the large beaker.  
Reminder:  density of water = 1 g/mL. 
3. Place the beaker on the hot plate and add the stir bar.  Set the heat to the 




Figure 4. Funnel and screen 
setup for pouring into flask. 
 
Figure 5. The setup that should 
be used when using the 
vacuum. 
 
4. Add the CMC to the water at a very slow 
rate, dusting the powder over the surface 
of the water and waiting for it to be 
absorbed.  Once most of it is mixed in, the 
solution will become very viscous and trap 
air bubbles.  Once the viscosity increases, 
you will need to increase the stirring 
intensity.  Do this slowly. 
5. Add the glycerol to the solution with the 3 
mL syringe.  You will need approximately 2 
mL of glycerol to correspond to the weight 
shown in Table 1. 
6. Add the remaining components to the 
solution similarly to how the CMC was 
added.  At this point, the solution should 
be extremely viscous and appear opaque 
white. 
7. Add three drops of peppermint oil 
to the solution.  
8. Add one drop of blue food dye.  
The mixture should now be a light 
blue color. 
9. Transfer the solution into the 
vacuum flask with the mesh and 
funnel, pouring through the mesh, 
to catch any large clumps of 
solidified product and the stir bar.  
Discard the solidified product. 
10. We will now make a vacuum 
filtration system.  The purpose of 
this is to de-aerate the mixture.  
This minimizes the bubbles in the solution.  Hook the vacuum flask up to a 
tube and place a rubber stopper in the top of the flask.  Then, connect the 
tube to the other vacuum flask.  Next, place a stopper with an attachment 
into the top of the other flask and connect this to the vacuum source.  See 
Figure 5 for the appropriate setup.  This second beaker will stop any foam 
from entering the vacuum. 
11. Turn on the vacuum and wait approximately 30 minutes for the gas to 
leave the solution.  The solution should slowly turn clear and may get 




Figure 6. Strips being cut 
12. Turn off the vacuum and disconnect the 
tubing from the vacuum source.  Then, 
remove the beaker with solution from the 
setup. 
13. Carefully pour some of the solution into a 
500 mL graduated cylinder.  This will make 
it easier to transfer the solution to the 
Teflon sheet or petri dish. 
14. Take a petri dish and weigh it. Record this 
weight. 
15. Prepare a sample of the film in the petri dish 
by adding 10 mL to the dish.  Do this by 
using a small graduated cylinder (10 to 25 mL).  If any bubbles remain on 
top of the solution, be sure to draw solution from under the surface.  
16. Weigh the wet petri dish and record this weight. 
17. Pour out 400 mL of the remaining solution onto the sheet using the 500 
mL graduated cylinder. 
18.  Allow 1-2 days for the samples to dry.  The batch should appear much 
thinner and have a glossy finish on its surface.  Take a final weight of the 
petri dish sample and record its weight.  
QUALITY ANALYSIS 
How uniform is your batch?  In industry, this is done 
by sampling a batch and testing it in several ways to 
ensure that specifications are met.  Several samples 
are taken and their results are averaged.  Quality 
analysis is critical to the success of a company, so 
that deviations can be caught and fixed before they 
become a costly problem. 
Sample Creation 
1. Carefully peel the strip out of the mold with a 
spatula. 
2. Take a ruler and measure 4 samples with 
dimensions of 1” x 1.5”.  Try to find room for samples from each of the four 
corners so that the samples are representative of the entire batch. 
3. Using a scalpel carefully cut out the four samples. 
Thickness Measurements  
1. Using a caliper, take each sample and place it in the jaws of the caliper. 
Figure 7. How to use the 





2. Adjust the jaws so that the sample fits snugly between them.  Do not over 
tighten the caliper so that the sample tears.  The sample should be 
pinched, but also be able to slide out from between the jaws when a small 
force is applied to it.  
3. Record your results and repeat for all samples. 
Folding endurance 
1. Take a sample and fold it in half along the 1.5” 
face (At the 0.75” mark). Pinch the folding point 
with your fingers so that a distinct crease is 
formed.  
2. Unfold the strip and flip it over.  Carefully fold the 
strip in the opposite direction, along the same 
crease and pinch.  This has now been 2 folds. 
3. Repeat steps 1 and 2, counting the number of 
folds that you perform. 
4. Record the final number of folds, and repeat for 
the rest of the samples. 
Surface pH 
1. Using one of the halves from each sample, use a pipette to drop a small 
quantity of DI water on the strip. 
2. Place a broad-range litmus paper strip in the drop. 
3. Compare the color of the strip to the package to determine the pH of the 
sample. 
4. Record your results and repeat for the rest of the samples.  Again, you 
only need to measure the pH from one half of each sample. 
Analysis 
1. Average the results from each test. 
2. Find the range of results for all tests.  Was there significant variance in the 
data you collected? 
3. Do you think that the average pH of the samples would be dangerous to 
ingest?  What about the highest/lowest pH sample? 
4. The average number of folds it takes to break a Sheets® brand strip was 
found to be in the range of 15-20 folds.  Does your average fall in this 
range?  If not, why do you think it didn’t? 
5. What could be a dangerous consequence from a lot of variance in the 




Figure 8. Ensure a good 





Moisture Content Analysis 
In this section, you will use the initial and final weights of the petri dish sample, 
as well as an introductory energy balance, to find the energy required to dry the 
sample and the amount of water remaining in the sample. 
1. Find the change in mass of the sample.  Assume that the mass that 
evaporated was 100% water.   
2. Find the moisture content with the following equation: 
 
          [   (
     
  
)]      
Where, 
   = final weight of the sample 
   = initial weight of the sample 
3. You will now calculate the amount of energy required to evaporate all of 
the water that was lost.  This energy was transferred into the sample from 
its surroundings, so the balance of energy transferred appears as such: 
 
           
     
Where, 
  = energy required to dry the sample 
      = mass of water vaporized, (     ) 
     
    = Latent heat of vaporization for water, 2260 kJ/kg 
Make sure to watch your units! 
4. Where do you think this energy came from? 
INSTRUCTOR’S NOTE: For an in-class exercise, the averages from each group 
can be compiled on the board, and then used to create a control chart.  Was the 
“process” of the student’s lab activity in control or out of control?  This can be 
used as an introduction to control charts, Western Electric rules, and Six-Sigma 
manufacturing.4   
QUESTIONS 
1. For the following APIs, research the drug’s therapeutic use and determine 
if a hydrophilic or hydrophobic polymer matrix would be best suited for 
drug delivery: 
a) Salbutamol 
b) Zolpidem tartrate 
c) Ondansetron 




2. Your boss approaches you with a new design project.  The 
pharmaceutical company you work for has recently signed a contract with 
a client, requiring that you produce 800,000 dissolvable strips/year of a 
new API designed to treat the common cold.  The API, referred to as DK-
12, is potent in very small doses, but degrades rapidly when it hits 
stomach acid.  Therefore, a dissolvable strip is the perfect method for 
introducing the drug into the body.  The film must be fast-dissolving.   
a) Before any equipment can be decided upon, you must create the 
formulation.  The required ingredients are: 
 DK-12 (10% w/w) 
 Water soluble polymer (40-50% w/w) 
 Plasticizers (0-20% w/w) 
 Sweetening agent (3-6% w/w) 
 Saliva stimulating agent (2-6% w/w)  
 Colors and flavors (1-10% w/w) 
Find a suitable chemical for each of these components and compile 
a list for your boss. 
b) Now that you’ve selected the ingredients for the strip film, you have 
to select whether you are going to use a hot-melt extruder or a 
solvent casting system.  The material dissolves easily in water and 
polar solvents, and is not friable (does not degrade from heat).  It 
must be noted that since DK-12 is new, it is very expensive, and 











1 0.08 32 5.0 
2 0.10 28 5.5 
3 0.12 39 5.5 
4 0.07 23 6.0 







The following data was for the petri dish portion of the experiment: 




1. Average the results from each test. 
ANS: See the above table. 
2. Find the range of results for all tests.  Was there significant variance in the 
data you collected? 
ANS: “Significant” is used loosely here.  This does not mean statistical 
significance, but the student should be able to relatively compare the 
ranges of the three tests against each other. For example, the ranges 
above are 0.05 mm, 16 folds, and 1 pH.  A student should realize that 
the folding test generated inconsistent results. 
3. Do you think that the average pH of the samples would be dangerous to 
ingest?  What about the highest/lowest pH sample? 
ANS: For this set of data, the strips would be safe to ingest.  Humans 
can ingest foods such as lemon juice, which has a pH of 2.  However, 
stomach discomfort or heartburn may result from ingesting something 
this acidic.  A student thinking critically will realize the potential side 
effects.  
4. The average number of folds it takes to break a Sheets® brand strip was 
found to be in the range of 15-20 folds.  Does your average fall in this 
range?  If not, why do you think it didn’t? 
ANS: The strips in this mock scenario do not.  The folding endurance 
study was found to be highly dependent on the humidity of the room.  
In very dry air, the strips will become brittle and shatter after 1 or 2 
folds.  In humid air, the strips can be folded a near-indefinite amount of 
times with little fatigue.  Commercial strips are packaged in controlled 
climates so they always have ideal properties.  Opening a commercial 
strip package and leaving the strip out to reach equilibrium with the 
surroundings should yield similar fold endurance to the experimental 
strips.  
5. What could be a dangerous consequence from a lot of variance in the 





ANS:  Large variance means concentrated areas of API, and areas 
with little API.  The highly-dosed strips could lead to an overdose, and 
the under-dosed strips could lead to diminished therapeutic value.  
Obviously, these strips would not be sold commercially.  This question 
segues nicely into the importance of process control.  
Moisture Content Analysis 
1. Find the change in mass of the sample.  Assume that the mass that 
evaporated was 100% water.   
ANS: The Δm = 20.315 g.     
2. Find the moisture content with the following equation: 
 
          [   (
     
  
)]      
Where, 
   = final weight of the sample 
   = initial weight of the sample 
ANS:  
          [   (
        
       
)]            
3. You will now calculate the amount of energy required to evaporate all of 
the water that was lost.  This energy was transferred into the sample from 
its surroundings, so the balance of energy transferred appears as such: 
 
           
     
Where, 
  = energy required to dry the sample 
      = mass of water vaporized, (     ) 
 
     
    = Latent heat of vaporization for water, 2260 kJ/kg 
Make sure to watch your units! 
ANS: 
  
(               )
         
     
  
  
          
4. Where do you think this energy came from? 
ANS:  This energy was transferred into the liquid from the natural 




Questions    
1. For the following APIs, research the drug’s therapeutic value and 
determine if a hydrophilic or hydrophobic polymer matrix would be best 
suited for drug delivery: 
a) Salbutamol 
ANS: Because salbutamol is used for immediate relief of an 
asthma attack5, a fast dissolving hydrophilic polymer would be 
best suited for this application. 
b) Zolpidem tartrate 
ANS: Zolpidem tartrate has only been shown to induce sleep, 
but not maintain it, unless it is in a controlled release form.6 
Therefore, a hydrophobic polymer would be best suited for this 
application.  The strip would most likely be applied sublingually 
or to the cheek. 
c) Ondansetron 
ANS: Again, ondansetron is used primarily for immediate relief 
of nausea in chemotherapy patients.7 Therefore, a hydrophilic 
polymer would be best in this application. 
d) Fentanyl citrate 
ANS: Being a highly potent opioid analgesic that is used for 
moderate to severe pain relief,8 it can be found in both 
hydrophilic and hydrophobic polymer matrices.  It may even be 
found in a layered strip that uses both types of polymer. 
2. Your boss approaches you with a new design project.  The 
pharmaceutical company you work for has recently signed a contract with 
a client, requiring that you produce 800,000 dissolvable strips/year of a 
new API designed to treat the common cold.  The API, referred to as DK-
12, is potent in very small doses, but degrades rapidly when it hits 
stomach acid.  Therefore, a dissolvable strip is the perfect method for 
introducing the drug into the body.  The film must be fast-dissolving.   
a) Before any equipment can be decided upon, you must create the 
formulation.  The required ingredients are: 
 DK-12 (10% w/w) 
 Water soluble polymer (40-50% w/w) 
 Plasticizers (0-20% w/w) 
 Sweetening agent (3-6% w/w) 




 Colors and flavors (1-10% w/w) 
Find a suitable chemical for each of these components and compile 
a list for your boss. 
ANS: Make sure the ingredient is safe for consumption! 
 DK-12 (10%) 
 Pectin, HPMC, hypromellose, etc. (40-50%) 
 Glycerol, etc. (0-20%) 
 Sucrose, dextrose, aspartame, etc. (3-6%) 
 Ascorbic acid, malic acid, citric acid (2-6%) 
 Peppermint oil, various esters, Red No.40, etc. (1-
10%) 
 
b) Now that you’ve selected the ingredients for the strip film, you have 
to select whether you are going to use a hot-melt extruder or a 
solvent casting system.  The material dissolves easily in water and 
polar solvents, and is not friable (does not degrade from heat).  It 
must be noted that since DK-12 is new, it is very expensive, and 
therefore it is important to minimize wasted API.  Explain your 
reasoning.  
ANS: Hot melt extrusion would be the best operation for 
creating the strips.  They do not degrade from heat, and 
extrusion minimizes product lost.  While a more expensive 
process, it is worth it if a contract has been made with a 
client.  
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Test and Survey for the Advil Statistical Analysis Lab  
Rowan University – Freshman Clinic 
Fall/Spring Semester 
 
Please answer the following questions as best you can: 
 
1. What does API stand for? 
o Active Pharmaceutical Ingredient 
o Appropriate Pharmaceutical Ingredient 
o Abridged Pharmaceutical Inspection 
o Altered Pharmaceutical Ingredient 
 
2. What is the purpose of an API? 
o To test the production process 
o To make sure that you are meeting safety regulations 
o To perform the treatment of the patient 
o To keep the pill intact until swallowed 
 






4. A binder is: 
o A substance to ensure the drug is fully dissolved in the body 
o A substance that makes components in the drug stick together 
o A piece of equipment that makes tablets stick to each other 
o A device that keeps two pieces of equipment attached to each other 
 
5. The substance used in a tablet to take up space in a pharmaceutical product is: 
o A filler 
o A settler 
o A spacer 





6. The purpose of an F-test is to: 
o To compare a sample to a known value 
o To compare a sample to an unknown value 
o To compare a set of data to a known value 
o To compare two sets of data with one another 
 
7.  The purpose of a t-test is to: 
o To compare two sets of data to one another 
o To compare a sample to a known value 
o To compare averages of two sets of data 
o To compare a known value to an unknown value 
 
8. What is the purpose of a flow diagram? 
o To model the flow of material for a process 
o To determine the curvature in a model 
o To compare a material balance to an energy balance 
o To determine the costs of utilities 
 
9. What is the definition of variance? 
o The  dispersion of data from the mean 
o The probability of a number being the mean 
o The average of the squared difference of the mean 
o The mean of the data 
 
10. What is the purpose of a box-and-whisker plot? 
o To determine the cost of utilities 
o To determine if any outliers exist in a set of data 
o To determine the variance of a set of data 





This survey is in regards to the laboratory experiment:  Tablet Statistical Analysis Lab.  
Please fill in the column that most closely resembles your opinion with the statement to 
the left.  This survey in no way affects your grade for this class.  Please be honest with 
your answers.  If you fell a specific statement does not pertain to the lab, please fill in the 
N/A column for that question.  If you were absent from lab, please fill in the N/A column 















 Statement 1 2 3 4 5 6 
1 
The experiment introduced 
a concept of 
pharmaceutical 
engineering 
      
2 




      
3 
I wish to pursue more 
studies in the field of 
pharmaceutical 
engineering 
      
4 
The experiment helped me 
understand the application 
of statistics to 
pharmaceutical product 
quality control 
      
5 
I can apply the statistical 
principles I learned in this 
lab to other engineering 
problems 
      
6 
I had to appropriately use 
laboratory equipment 
(scales, etc.) for 
measurements 
      
7 
I felt I could complete the 
experiment in the time 
given 
      
8  
I knew exactly what was 
expected of me from the 
write-up given 
      
9 
I felt challenged by the 
experiment 
      
10 
I felt safe in the laboratory 
while under the 
supervision of faculty 










Tablet Statistical Analysis Test and Survey Data 
 
For this raw data, the questions were the same as those presented in Appendix C.  
Students remain anonymous for this, but their major is stated.  For the “Test” portion of 
this data, a “C” represents a correct response, while an “I” represents an incorrect one. 
Pre-Lab Test Results 
Student NO. Major Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 
1 Mechanical Engineering I I I C C I I C I C 
2 Chemical Engineering C I C C C I I C I I 
3 Chemical Engineering I C C C C I I C C C 
4 Chemical Engineering C C I I C C C C I C 
5 Chemical Engineering C I I C I I I I C C 
6 Chemical Engineering I C I C C I I C C I 
7 Chemical Engineering C C I C C C C C I C 
 
Number of Incorrect 3 3 5 1 1 5 5 1 4 2 
 















Post-Lab Test Results 
































0 0 0 0 0 0 0 0 2 0 
 





The results of the survey are shown below.  Again, student names are kept confidential, 
and only the student’s majors will be shown.  Responses are numbered 1 to 6, 1 being “I 
strongly disagree with the statement” and 6 being “I strongly agree to the statement.”  
The statement numbers coincide with those shown in Appendix C. 
 
Post-Lab Survey Responses 
Student 
NO. 
































4 4 4 4 5 5 5 4 2 4 
 
